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Antibacterial agent delivery is of great importance in medicine and dentistry since the bacterial 
infections are still one of the major reasons for hospitalization and mortality. Despite of the 
development of technique and pharmacy, more antimicrobial agents are optimized and utilized 
to treat infections, and their action of principal is better understood which lay a foundation for 
developing strategies for infection treatment. Over the last decades, many delivery systems 
have been established to deliver bacterial agents and maintain a sustained activity against them. 
However, the bacteria are always developing and finding a way to defend themselves. A more 
responsive antibacterial agent delivery system, which can release the active substances on 
demand to match the stages of diseases, is highly desirable.  
Therefore, it motivates us to carry out the work to develop a multifunctional delivery system 
for antibacterial particle formulation and encapsulation based on the layer-by-layer self-
assembly technique and electrospinning, to manipulate the release with external triggers, such 
as near-infrared (NIR) light and alternating magnetic field (AMF). Strategically, two different 
kinds of antibacterial agents, chlorhexidine and doxycycline, were studied. Chlorhexidine was 
fabricated into spherical particles and functionalized with both gold and magnetite 
nanoparticles, and doxycycline was encapsulated within microcapsules which were also 
functionalized with magnetite nanoparticles. Their release kinetics and possibilities to trigger 
the release with either a NIR light or AMF was explored.  
The first two chapters of the thesis give a general introduction and literature review on the 
current use of antibacterial agents and the problems concerned, strategies already developed 
for antibacterial agent delivery, and the potential triggers to induce a smart release. In chapter 
3, a brief description of materials and methods, and instruments is presented. Chapter 4 is about 
chlorhexidine particle formulation. Firstly, particulation of chlorhexidine and mechanism of 
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spherical interconnected structure formation was explored, and then the chlorhexidine particles 
are encapsulated either by LbL assembly or spray-drying. The chlorhexidine spheres were also 
functionalized with gold nanorods and Fe3O4 nanoparticles to achieve NIR light and magnetic 
field manipulated release, and the effect of nanoparticles on the formation of chlorhexidine 
spheres was also studied. When the chlorhexidine particles were incorporated into electrospun 
fibers, a sustained antibacterial activity was demonstrated. Chapter 5 is about the delivery of 
doxycycline to cells with microcapsules and the sustained intracellular doxycycline activity 
was demonstrated via EGFP expression when the cells were engineered with a tetracycline 
regulated gene expression system. Intracellular triggered release and upregulation of EGFP 
expression was achieved by an AMF. The results successfully demonstrated the possibility of 
chlorhexidine and doxycycline delivery and NIR light/AMF triggered release, which is 
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1.  Introduction 
We are sharing the world with numerous forms of life, animals, plants, and microorganisms, a 
harmonious living together of which ensures us a happy and high quality life. Microorganisms, 
or more specific bacteria, are more directly contacted with us every day. Some of them are 
good and essential for our health, while the others may cause us troubles. When harmful 
bacteria invade and reproduce in our body, we may suffer from infections or even death. So 
actually, the immune system of human body is fighting with these harmful bacteria every 
seconds. However, sometimes our body still fails to defend the invasion of harmful bacteria 
and has infection diseases, ranging from cutaneous infections to deep-seated life threatening 
infections such as pneumonia, endocarditis, septicemia, osteomyelitis, and other metastatic 
complications.1 Therefore, some treatments are needed to help to get rid of these bacteria.  
Various antibacterial agents are developed and used for infection treatment, ensuring a happier 
and healthier life. Nevertheless, the battle is never ended. We still face huge challenges to fight 
with the bacterial infections, such as bacterial resistance, intracellular infections, and formation 
of biofilms.2 The direct application of antibacterial agents cannot ensure a depletion of bacteria, 
so in this case, some delivery systems which can facilitate a local sustained activity of 
antibacterial agents are needed to enhance their performance.1, 3  
Local and sustained delivery of antibacterial agents is a novel concept for the treatment of 
recurrent and chronic infections, as an increased drug concentration at the site of infection 
could reduce the need for systemic drug administration, and avoid side effects.4-5 A high local 
drug concentration is essential to eliminate bacteria initially and with a sustained drug release 
in the long term to prevent secondary infection.6 Many delivery systems, such as microparticles, 
nanogels, foams, films and nanofibers have been developed to deliver antibacterial agents.7-10  
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Polyelectrolyte microcapsules generated on a dissolvable matrix core using the layer-by-layer 
(LbL) assembly method are good candidates for antibacterial agents delivery.11 Their 
construction utilizes electrostatic interactions between oppositely charged polyelectrolytes to 
add layers to the core. Assembly is performed under native conditions which permit the 
inclusion of various molecules within the structure, the positioning of these, influences activity 
in intact capsules as well as stability and release kinetics.12-13 Microcapsules have been 
extensively studied in isolation and have been successfully employed for the delivery of drugs 
to cells, which is potentially beneficial for intracellular infections. Their fate within cells 
depends upon their chemical composition that those composed of biodegradable polymers will 
be broken down and release their contents whilst those assembled with synthetic polymers can 
potentially remain intact. On the other hand, nano-/micro- fibers are advantageous for drug 
delivery because of their small diameter, high specific surface area and easy of surface 
functionalities.14-15 The fibers are commonly produced by electrospinning and there are various 
approaches to load the fibers with antibacterial agents. They are especially attractive to be used 
as wound dressings.16  
On the other aspect, how to target delivery of the antimicrobial agents and tailor the release in 
a desired manner is of great interest for a more effective and responsive treatment of infections. 
It can be achieved by carriers functionzalization. For example, the inclusion of metal 
nanoparticles (gold or magnetite) into carriers may facilitate a near-infrared light or magnetic 
field responsive properties, the exposure to which can thus induce a triggered release of cargos. 
The inclusion of gold nanoparticles and magnetite nanoparticles as a charged species in 
microcapsule layers is already extensively studied.17-19 With magnetic nanoparticles 
encapsulated, movement of carriers can be navigated with an external magnetic field20 and the 
specific targeted delivery of drug can greatly improve the efficiency and reduce dosage used, 
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which is important for infection treatment. The in situ release of cargo is also reported with 
either NIR light or an alternating magnetic field.21-23  
According to all mentioned above, this thesis describes experiments on delivery of antibacterial 
agents (chlorhexidine and doxycycline). For chlorhexidine part, a novel formulation of 
chlorhexidine spherical particles was produced and functionalized with gold nanorods and iron 
oxide nanoparticles. The possibility to achieve a more sustained activity by incorporating them 
into polymer films and electrospinning fibers, and a triggered release by NIR light or magnetid 
field was studied. Doxycycline, on the other hand, was encapsulated into LbL microcapsules 
and sustained effect in cells was evaluated via the tet-on system. When the microcapsules were 
functionalized with magnetic particles, targeted doxycycline delivery to cells and alternating 




2.  Literature Review 
2.1 Antimicrobial agents 
Bacteria are the most common life forms which we contact with every day, and even many of 
the normal functions of human body are relied on some of the bacteria. However, despite the 
improvement of medicine, infection by the harmful bacteria is one other leading causes of 
diseases nowadays.1 There is a wide variety of agents which have an antibacterial activity, 
including metal ions (e. g. zinc, silver), nanoparticles, antibiotics, chlorhexidine, and other 
agents such as chitosan and quaternary ammonium compounds, also demonstrate a good 
antimicrobial capability.24-26 The review here mainly focuses on the application of 
chlorhexidine and doxycycline.   
2.1.1  Chlorhexidine 
2.1.1.1 Chlorhexidine and its compounds 
Chlorhexidine is a broad spectrum antimicrobial agent, which is effective against both the 
gram-positive and gram-negative microbes.27 The molecular structure of chlorhexidine is given 
in Figure 2.1.  The antimicrobial properties of chlorhexidine are assumed to be that the 
guanidium groups from its structure have strong coordinating ability, which enables binding to 
bacteria cell membranes to cause cell function disruption.28 At a low concentration, the action 
of chlorhexidine is bacteriostatic while at a higher concentration, its action is bactericidal.29 
Chlorhexidine has a very solubility, so it is normally used in the form of salts, such as 
chlorhexidine diacetate, chlorhexidine digluconate, and chlorhexidine dihydrochloride. The 
solubility properties of the chlorhexidine as a function of salts type and concentration are well 




Figure 2.1  The chemical structure of chlorhexidine. 
 
The biguanide groups of chlorhexidine have remarkable coordination ability, which are utilized 
to produce other formulation of chlorhexidine compounds.31 For example, new copper (II) 
complex compounds have been reported, which utilized the biguanidine of chlorhexidine to 
coordinate with Cu2+, and the structure of proposed interaction between copper ions and 
chlorhexidine is showed in Figure 2.2.28-29 Moreover, the incorporated Cu2+ ions, or other ions 
such as Zn2+, Sn2+, and Ag+ can enhance the antimicrobial activities.29 Another study also used 
chlorhexidine digluconate to precipitate with sodium hexametaphosphate, and produced a new 
formulation of chlorhexidine nanoparticles.32  
 
Figure 2.2 Proposed coordination mode for the chlorhexidine and copper complexes. 28 
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2.1.1.2 Application of chlorhexidine in dentistry 
Chlorhexidine is widely used in our everyday life to disinfect of our skin and hand. It also has 
broad applications in dentistry, which is used in the toothpaste, mouthwashes and other 
products to control dental plaque and to treat gingivitis and endodontic disease.6, 33-34 The 
problem concerned with its oral performance nevertheless is always sustained function against 
microbes, and a lack of long term effect, which can lead to repetitive infection or failure for 
implants. For example, chlorhexidine contained in mouth rinse is effective for general oral 
bacteria but for those bacteria in periodontal pockets, a longer and sustained activity is 
required.35 A delivery system which allows a sustained release of chlorhexidine (2% aqueous 
solution) may be useful in the treatment of endodontic infections,6 and to reduce the prevalence 
of dental infections. A commercially available product now for the treatment of periodontal 
(gum) disease is known as PerioChip, which combines chlorhexidine digluconate with cross-
linked gelatine. The problems with these kinds of carriers however, are low drug loading 
capacity and release of the preloaded drug is dependent on polymer degradation rate. Many 
delivery systems have been developed for sustained chlorhexidine delivery and most of those 
are based on biodegradable polymeric carriers, nano/micro particles or gels.7, 36-38 Interestingly, 
β-cyclodextrin was also reported to form reversible complexes with chlorhexidine to promote 
drug loading and sustained release.35  
For restoration, chlorhexine is also incorporated into resins and other resin based dental 
composites.39-41The functionalization of the restoration materials with chlorhexidine is 
beneficial to reduce secondary caries and inhibit cariogenic biofilms. To achieve a sustained 
antimicrobial activity, inorganic particles such as mesoporous silica nanoparticles (MSNs) are 
used for chlorhexidine loading, since MSNs have porous surface structure. Moreover, this 






Antibiotics are another category of antibacterial agents, which can either stop microbes 
growing or kill them outright.43 The mechanism of their action against bacteria is more 
complicated than chlorhexidine and varies from different type of antibiotics. They can either 
interfere with the cell wall synthesis (e.g. β-lactams and glycopeptides) or nuclei acid synthesis 
(e.g. fluoroquinolones and rifampin), or inhibit protein synthesis (e.g. macrolides, 
aminoglycosides, tetracycline and oxazolidinones), or inhibit a metabolic pathway (e.g. 
sulfonamides and folic acid analogs), or just interrupt the bacteria membrane (e.g. polymysins 
and dapomcin).1, 43  
Tetracycline is a kind of broad spectrum antibiotics which is effective against both gram-
positive and gram-negative bacteria. They are named according to the chemical structure, four 
(tetra) hydrocarbon rings (cycl). Doxycycline is one derivative from the tetracycline family, 
and its chemical structure is given in Figure 2.3.  
 





2.1.2.2 Application of doxycycline 
Doxycycline is a widely used antibiotic in the treatment of infections in humans. At low 
concentrations below those required for antimicrobial effects doxycycline also exerts anti-
inflammatory effects due to inhibition of matrix metalloproteinases44 so has potential use in 
treatment of inflammatory conditions.45 Doxycycline is typically administered orally as tablets 
or suspensions and also topically in creams. Doxycycline has been incorporated into both nano 
and microstructures however sustained biological activity of the antibiotic has not been 
explored in these studies.46-47 Take the commercially available product containing doxycycline, 
Atridox™ as an example (Figure 2.4). Atridox™ is a subgingival controlled release product 
composed of bioabsorbable, flowable polymeric formulation, poly(DL-lactide) (PLA) 
dissolved in N-methyl-2-pyrrolidone (NMP), and doxycycline hyclate. The constituted product 
is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. 
Upon contact with the crevicular fluid, the liquid product solidifies and then allows for 
controlled release of drug for a period of 7 days. 
 
 




Besides, doxycycline can also be used for gene regulation based on the tet-on system. The tet-
on system is the most efficient and broadly used one among all of the gene regulatory systems, 
and it is optimized in various ways to promote sensitivity and robust induction by tetracycline 
or its derivatives48-50. Tet-on system is based on the specific and affinity binding between 
reverse Tet repressor protein (rtTA) and operator DNA sequence (tetO), which at the present 
of tetracycline, the binding would be enhanced and transgene switch is kept on51. Doxycycline, 
is more routinely used for its penetration of cell and nuclear membranes52. Based on 
doxycycline, light and pH regulated gene expression system could be established by chemically 
modifying the molecule with photoactivatable cage 53-54 or conjugating it to dendritic polymers 
via pH-sensitive binding55.  
 
 
2.2 Various polymers-based drug delivery system 
2.2.1 Resin composites 
Since being introduced to dentistry in the 1950s, dental composites have undergone 
considerable changes; the modification of fillers to enhance the mechanical properties and the 
optimisation of the polymeric matrix to improve their biocompatibility 56. Resin composites 
are used extensively in dentistry as restorative materials, cavity liners, cores and buildups, 
crowns, inlays, sealants and cements for tooth prostheses.57 According to different applications, 
the resin composites can be distinguished, but they are normally made of polymeric matrix, 
reinforcing fillers, silane coupling agents to bind the filler to the matrix, and chemicals that 
promote or modulate the polymerization reaction. The most commonly used base monomers 
in the resin composites are bis-GMA, which is usually mixed with other dimethacrylates, such 
as TEGDMA, UDMA or other monomers.58 Currently available dental composites have 
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exceptional aesthetics and comparable mechanical properties (flexural strength, fracture 
toughness and tensile strength) when compared with porcelain and amalgam, and superior to 
that of glass ionomers57. This allows their wide use for anterior and posterior tooth restorations, 
as well as pit and fissure sealants 59. Most composites are light-activated, and the most common 
photoinitiator system is camphoroquinone, accelerated by a tertiary amine. When dental 
composites are cured by light and chemically initiated by free radical polymerization, there 
will be 2-5.63 vol. % shrinkage of the material 60. This can lead to the formation of gaps 
between the restoration and the tooth 61. Bacterial microleakage through these gaps can cause 
marginal discolouration, sensitivity, inflammation, recurrent caries and apical periodontitis 62. 
Furthermore, accumulation of bacterial biofilms on the surface of dental composites can lead 
to degradation of the polymer matrix, resulting in the weakening of the restoration. Dental 
composites with antimicrobial properties are therefore highly desirable to overcome these 
problems.  
Chlorhexidine has been incorporated in a variety of resin composites 40, 63-64. Chlorhexdidne 
also stabilizes the resin-dentine bond by inhibiting matrix metalloproteinases (MMP) which 
are responsible for the breakdown of the bond at the dentine-restoration interface 65.  Inclusion 
of chlorhexidine into dental composites has been achieved by mixing the chlorhexidine 
diacetate with monomers 42, 66-67. This composite however suffers from an uncontrollable 
release of chlorhexidine, due to its rapid diffusion from the methacrylate based resin. To 
overcome these drawbacks efforts have been made to develop new chlorhexidine formulations 
28, 32, 68-69 and investigate novel drug carriers 70-71. Interestingly, a recent study used the 
mesoporous silica nanoparticles as carriers for chlorhexidine loading, which were further 
incorporated into resin composites. The chlorhexidine release of which was more controllable 





Figure 2.5 CHX release and recharge. (a) CHX release profiles from composites containing 
directly mixed CHX or CHX@MSN. (The insert is the release rate (µmol/cm2/hr) during the 
first 72 hr.) (b) Cumulative CHX release as the weight percentage of the total loaded CHX. (c) 
CHX recharge profile in 3 repeated recharges. (d) Cumulative CHX release over 3 days after 
recharge. 42 
 
2.2.2 Spray dry particles  
A more straightforward and simpler approach to produce drug crystals or drug loaded 
polymeric spheres is spray-drying.72-74 Particles fabrication by spray-drying is mainly based on 
the atomization of fluid in a hot drying gas stream, which will transform the liquid droplets 
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into solid dry powders. The spry-drying process is schematically demonstrated in Figure 2.6. 
Briefly, it consists of four main steps, firstly, liquid feed is pumped into the drying chamber 
through an atomizer or nozzle to form atomization; then solvent will evaporate in the hot gas 
stream and the small droplets will transfer into dry particles; finally, the resulting dry particles 
will be separated from the dry gas and collected via a cyclone.72 
 
Figure 2.6 Diagram of the equipment and process of conventional spray-drying. 72 
 
The flow of drying gas can be in the same direction (co-current flow) or in the opposite 
direction (counter-current flow) as that of liquid atomization. For the co-current flow method, 
solvent is evaporated quickly at the beginning and the final dried particles are contacted with 
the coolest air, which is preferred for the heat sensitive materials. While for the counter-current 
flow method, though is not good for heat sensitive materials, the thermal efficiency is higher. 
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The fluid feeds which are used for spay-drying vary from solutions, suspension, emulsions, 
melts, or pastes, and the gas used for drying can also be air or other inert gas.72, 75 
All the parameters involved in the four steps of spray-drying process will affect the final 
particles. First of all, the concentration of liquid feeds, viscosity, and the boiling point of 
solvent will have a profound influence on the particle size and morphology. A high 
concentration and viscosity of liquid feeds will result in large particles and a fast solvent 
evaporating rate will lead to porous morphology of particles. Besides, flow rate of liquid feeds 
and the diameter of nozzle will affect the atomization process, which also have fundamental 
effect on the dry particles. Other factors, such as temperature of flow gas, type of gas and its 
flowing direction also matter for particles fabrication.72, 75    
Spray-drying has many advantages over other methods to produce particles and for drug 
encapsulation.76-77 The process of spray-drying is simple, rapid, continuous, and reproducible, 
therefore, it is easy to scale up, which is attractive for industrial production. In fact, the spray-
drying technique is already widely used in pharmaceutical, chemical, materials, cosmetic and 
food industries.72   
As for drug encapsulation, spray-drying also has remarkable advantages.78 A variety of 
substances can be dried via this method, and since the evaporation of atomized droplets is so 
fast, the detrimental effects to heat sensitive compounds can be reduced to the minimum. 
Similar to the ultrasonication approach to produce pure drug particles, spray-drying can also 
be used, which is simpler and faster, and the yield is higher. Drugs can also be mixed together 
with polymers, and spray-dried to encapsulate them into polymeric particles. Compared to the 
emulsion/solvent evaporation method, spray-drying has less limitations on the solubility of 
drugs and polymers. The fabricated particles are stable and can be re-dispersed into aqueous 
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solutions without size changing of particles. Besides, the drug encapsulation rate is also higher 
than the other methods.  
The biggest advantage to used spray-drying for encapsulation is that the activity of biological 
agents can be protected.76-77 For instance, proteins and genes are sensitive to harsh conditions, 
which may reduce or lose their activity during the other encapsulation process, such as 
ultrasonication in the emulsion/solvent evaporation approach. When siRNA was encapsulated 
into spry-dried PLGA nanoparticles, their activity was not affected by comparing to the free 
siRNA control in the cell transfection assay.77 In addition, for antigen delivery, particulation 
of which can protect the immunity against intracellular pathogens, and thus enhance 
intracellular immune response. Encapsulation of antigens into polyelectrolytes and mannitol 
by spray-drying produced porous particles, which promoted enzymatic processing of antigens 











Figure 2.7 Encapsulation of antigens into polyelectrolytes and mannitol by spray-drying. (A) 
Microparticle recovery expressed as the weight percentage of the microparticles collected in 
the recipient after the cyclone to the original dry weight of the formulation prior to spray drying. 
(B) Scanning electron microscopy image of the spray dried microparticles before resuspension 
in aqueous medium. (C) Size distribution measured by laser diffraction of the microparticles 
redispersed in water. (B) and (C) were recorded from microparticles produced at optimal 
formulation and processing conditions. (D) Transmission electron microscopy images of 
epoxy-embedded and ultramicrotomed porous microparticles obtained after resuspension in 




2.2.3 Electrospun fibers  
Micro- and nano-fibers are another category of carriers for drug delivery.14-15 Different from 
the microcapsules, polymeric spheres, the fibers are in two dimensions, with continues 
structure and flexible shapes. They are advantageous for drug delivery because of their small 
diameter, high specific surface area and surface functionalities.10, 14 Many polymers, such as 
PCL, PLGA, and PLA, are fabricated into fibers. PLA is particularly attractive to produce 
fibers due to its good mechanical strength, excellent biocompatibility and biodegradability and 
is currently used in biomedical applications.80  
The fibers are commonly produced by a method named electrospinning, which polymers in 
solution or melt polymers are fabricated into fibrous structure. Basically, to produce 
electrospun fibers, three major components are needed, high voltage source, syringe pump and 
collector (Figure 2.8).15 Briefly, the polymer solution or melt is loaded into the syringe and 
pumped with a very low rate (normally a few ml per hour). The liquid drop comes out from the 
tip of needle will be electrified in the applied high voltage (1- 30kv). The induced charges will 
distribute over the pendant drop surface evenly and deformed it into a conical shape which is 
called Taylor cone. When the threshold is reached, electric force will overcome the surface 
tension of droplets, and charged jets of solution will eject from the tip and reach the collector, 







 Figure 2.8 Schematic illustration of the basic setup for electrospinning. 15 
 
The properties of electrospinning polymer solutions play a dominant role in fibers formation, 
such as concentration, viscosity, conductivity, surface tension and homogeneity.81 Polymer 
solutions with a too high concentration will result in a high viscosity, which is not beneficial 
for fiber formation. It is reported that viscosities range from 1 to 20 P is suitable for fiber 
fabrication, which viscosity above 20 P will result an instable flow and viscosity below 1 P 
will lead to formation of droplets.15 A homogeneous polymer suspension is also key to produce 
continuous fibers. Other process factors, such as applied voltage, pump speed of solution, 
humidity and temperature, distance between needle and collector, will also determine the 
formation of fibers. For example, humidity less than 35% is good for electrospinning and 
higher than that will result a non-continuous jet. Therefore, it is better to record every parameter 
during electrospinning to ensure reproducible of fibers.  
Electrospinning fibers are especially advantageous to be used as wound dressing materials and 
for postoperative local therapy.82-84 There are various approaches to load the fibers with 
antibacterial agents. The most straightforward method is directly mixing the drug in the 
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electrospinning solution. The antimicrobial effect of fibers made using this approach is not 
durable, as the release cannot be controlled.85-86 Chemically binding of antibacterial agents to 
fibers can however improve the controllability of release. For instance, cyclodextrins were 
utilized in fibers to complex with chlorhexidine digluconate,35 and chitosan fibers were 
functionalized with thiol groups to covalently bind with gentamicin-loaded liposomes.10 Other 
drug carriers, such as mesoporous silica nanoparticles,87 Ca-alginate microspheres,88 chitosan 
nanoparticles89 and clay nanotubes,90 can also be combined with electrospinning fibers, which  
facilitate a more controllable drug release.91 For instance, the halloysite clay nanotube doped 
microfibers can extend the drug release to over 20 days, compared to just 4 days for fibers with 
drugs mixed directly.90 The drug loading ratio is however always a concern with these methods, 
as is vital to achieve a high local drug concentration to avoid reapplication of the treatment.  
The development of electrospinning also brings new strategies for drug loading and controlled 
release. Coaxial electrospinning, for example, produce fibers with a core-shell structure, which 
is beneficial for a programmed drug delivery. Different for the normal electrospinning setup, 
for coaxial electrospinning, a concentric spinneret with different diameters is used, which are 
connected to different syringes and pumps. The pumping of different polymer solutions at the 
same time through the core-shell nozzle will result core-shell fibers. Moreover, this method 
greatly broad the materials which can be used for electrospinning, as the core materials cannot 
necessary be able to form fibers by themselves. This coaxial structure of fibers provides 
different release profiles, as the drug loaded in the core is better isolated from outside thus a 
sustained release is ensured, but the drug in the sheath layer will has a burst release. This 






Figure 2.9 Comparison of drug release behaviors from different type of fiber mats. (a) KAB 
release from PVP core of coaxial/triaxial fiber mats; (b) KAU release from PCL sheath of 
coaxial/triaxial fiber mats or single fiber mat (S1). Inserts: Cross-sections of fibers are 
illustrated with indication of dye loading. 92 
 
2.2.4 Polyelectrolyte microcapsules 
2.2.4.1 Polyelectrolytes 
Polyelectrolytes refer to a category of polymers which consist of charged or ionizable 
monomers and the counterpart ions. When the polyelectrolytes are dissolved in aqueous 
solution, the solution will also have a charge. According to the charge of solutions, either 
positive or negative, the polyelectrolytes can be classified into polycations and polyanions. 
Some of the them, which can dissociate completely in solution, are known as strong 
polyelectrolytes, while others can only partly dissociate are called weak polyelectrolytes. Many 
of the natural polymers are polyelectrolytes, such as polypeptides and DNA. Therefore, to 
further understand their dissociating behavior and interaction is important.  
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When dissolved in water, the polyelectrolyte ion pair will reversibly dissociate as indicated by 
the following equation:  
The dissociation behavior can be described by dissociation constant Kα, which is given as the 
following equation (brackets represent the concentration of each species): 
The Henderson-Hasselbalch equation will be showed as below when logarithm is taken for the 
dissociation equation:  
 
Where pK  represents the acid dissociation constant, n is the charge density along the polymer 
chains, α is the protonation degree. 
From the equation (2.3), we can see that pH has a dominating influence on the charge density 
along the polyelectrolyte chains, and thus affects the interaction between polyelectrolytes. 
Polyelectrolyte complexes (PEC) will form when oppositely charged polyions are mixed 
together. The polycations and polyanions will attract and bind to each other via the force of 
Coulombic and hydrophobic interactions. It is supposed that the entropy will increase when the 
counter-ions are released into the solutions. Therefore, the change of charges of 
polyelectrolytes will affect their interaction and PEC formation. For example, the presence of 
salts in the polyelectrolyte solutions will have a profound influence on the PEC formation, 
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with a small amount of salt, the polyelectrolytes will rearrange, and the reaction will shift to 
the thermodynamic equilibrium, resulting in a uniform distribution of short chain components. 
Further increasing the salt in solution will lead to polyelectrolyte molecule chains shrinkage, 
as the changes of the polymers will be shielded, and at a critical salt concentration, 
disproportionation will happen, leading to a completely complexed and precipitation. With a 
higher salt concentration, the PEC will completely dissociate, with free polyelectrolyte chains 
in solution. Theory about the PEC structure and the conformation is well studied and 
demonstrated schematically in Figure 2.10.203  
For strong polyelectrolytes, they are highly aggregated and the addition of small amount of salt 
will help to reduce the aggregation, however, a higher salt concentration will lead to 
macroscopic flocculation and precipitation.  
 
Figure 2.10 Effect of salt concentration on polyelectrolytes in solution 
 
2.2.4.2 Layer-by-layer assembly and microcapsules 
Layer-by-layer (LbL) assembly refers to a technique which builds multilayers by alternately 
absorbing oppositely charged macromolecules on the surface of substrates. Briefly, this process 
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can be demonstrated schematically in Figure 2.11.93 Firstly, when a charged surface is placed 
into an oppositely charged polyelectrolyte solution, and kept immersed for a specific duration, 
the polyelectrolytes in solution will travel towards the substrate and adhere on the surface, and 
thus change the surface to an opposite electrical charge. By rinsing the surface with 
polyelectrolyte-free solvent, excess polyelectrolytes are removed. Then introducing the surface 
to another oppositely charged polyelectrolyte solution, a second layer will be deposited. By 
repeating these procedures, multilayers can be built to as many layers as desired.  
Figure 2.11 Polyelectrolyte multilayer assembly process. 93 
 
The main driving force for the multilayer assembly is the electrostatic interaction, which the 
absorption of polyelectrolytes will decrease the free energy of whole system. Besides, non-
electrostatic interactions such as hydrogen bonding, van der Waal force and hydrophobic 
interactions also help to form LbL multilayers. There are various factors which will have an 
influence on the finally multilayers formed (e.g. thickness, permeability). First of all, since the 
assembly is dominated by electrostatic interactions, the charge density of polyelectrolytes and 
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configuration of polymers will have profound effect on the layers. When the charge of surface 
is high, and the ratio to the charge of polyelectrolytes is 1:1, a flat conformation will be formed. 
But when the surface charge is not at 1:1 stoichiometric ratio to that of polyelectrolyte, a loose 
conformation will be deposited. In addition, presence of salts in the polyelectrolyte solutions 
will also affect the interaction between polymers and charged interfaces. When the salt 
concentration is low, the polyelectrolytes are better stretched and the layer formed will be thin. 
However, when the concentration of salts in solutions is high, the polyelectrolytes will shrink 
and coil, so the absorption in this form will lead to a thicker layer with polymer tails and loops. 
The type of ions in the solutions will also affect the multilayer assembly. It is reported that 
small ions have more fundamental influence than the large ions due to the small polarizability.  
Basically, quartz crystal microbalance (QCM) and zeta-potential measurement are two 
common ways to study the kinetics of the multilayer assembly. Theoretically, the QCM 
measurement is based on the oscillator resonant frequency change during the deposition of 
each layer. The resonance frequency is related with the oscillating mass, that when the 
deposited layer numbers increase, the mass will increase, leading to the change of resonance 
frequency. According to the Sauerbrey equation below:  
 
In which, M  refers to the mass change, K  is the coefficient, and F  is the resonance 
frequency change. Therefore, there is a linear relationship between change of mass and 
resonance frequency.  
Zeta-potential measurement is another technique to evaluate the surface charge changes during 
LbL assembly. But because the measurement is based on the movement of particles in the 
electrical field, it is normally used for investigate deposition on small templates.  
M K F    (2.4)
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LbL process can be carried out on particulate templates and when the templates are removed, 
hollow polymeric shells are remained, which are well known as microcapsules. The process of 
producing microcapsules is similar to that of making LbL multilayers, which is shown 
schematically in Figure 2.12.94 Briefly, various particles, regardless the size and shape, are 
employed as colloidal templates, and then first layer of oppositely charged polyelectrolytes is 
deposited and incubated for a period. Wash steps are also needed to remove the excess non-
absorbed polymers by either centrifugation or micro-filtration. Then the second layer of 
polymers is assembled with the same procedure. Subsequently assembly of polycations and 
polyanions leads to colloids with multilayers coated. At the end, the colloidal templates are 
removed and hollow microcapsules are formed.  
 




Many particles can be used as templates, including organic, inorganic particles, metal 
nanoparticles, oil emulsions, microbubbles and even living cells. The most commonly used 
organic templates are crosslinked melamine formaldehyde (MF) particles. The MF particles 
are stable at neutral pH and once encapsulated with multilayers, they can be dissolved with 0.1 
M HCl or solvents such as N, N-dimethylformamide (DMF) and tetrahydrofurane (THF). The 
problem with MF templates is that the remained oligomers from dissolution are hard to diffuse 
out from the multilayer shells, which will tend to damage or rupture the capsules. Also the 
positively charged MF oligomers can stick to the negatively charged layers, bringing 
challenges to completely get rid of the cores. Polystyrene particles (PS) are also used as 
templates for LbL assembly, but the same problems remain as the same as MF templates.  
Inorganic particles, on the other hand, are advantageous for using as templates, because they 
can easily be dissolved and removed from the shells and no large oligomers will be remained 
in capsules. CaCO3 particles are the most frequently used inorganic templates, as they are easy 
to produce and dissolve with EDTA or HCl solutions. The calcium ions or CO2 are easy to get 
rid of. Moreover, the porous structure of CaCO3 particles can act as excellent reservoirs for 
cargos, such as large molecular drugs, proteins and DNA. After removing the core, these cargo 
molecules will be trapped within the cavity of capsules, which provides a good strategy for 
encapsulation. Silica (SiO2) particles are another kind of good inorganic templates. They are 
monodispersed and not porous, and with addition of hydrofluoric acid (HF), they can be 
quickly dissolved. But attention must be paid to during the silica dissolution as the HF is 
dangerous to handle. Other inorganic particles, such as cadmium carbonate (CdCO3) and 
manganese carbonate (MnCO3) are also reported.  
Any charged polymers can be used to construct microcapsules, either synthetic polymers or 
natural biodegradable polymers, peptides, proteins, even DNA. The most commonly used 
synthetic polyelectrolytes are poly(allylamine hydrochloride) (PAH) and poly(sodium 4-
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styrenesulfonate) (PSS). Other biodegradable polymers such as chitosan, poly-L-arginine, 
dextran sulfate sodium salts, are also widely used for LbL assembly. The main advantage of 
using biodegradable polymers for LbL is that they can be decomposed inside living cells, and 
encapsulated cargos can thus be released intracellularly. This is clearly demonstrated by 
encapsulating a fluorogenic protein, DQ-OVA, into both synthetic and biodegradable capsules, 
which is self-quenched (red fluorescence) and only when enzymatic cleavage into single dye-
labelled peptides, a bright green fluorescence will appear (as shown in Figure 2.13). 95       
 
Figure 2.13 Enzymatic cleavage of protein cargo. Embryonic NIH/3T3 fibroblasts were 
incubated with (a) nondegradable PSS/PAH or (b) degradable DEXS/pARG capsules filled 
with the fluorogenic protein cargo, DQ-OVA. Images were taken immediately after addition 
of the capsules (t = 0h) over time up to 120 h with a confocal microscope in different channels, 




Metal nanoparticles, such as gold, silver and magnetite nanoparticles, can also be incorporated 
into the polyelectrolyte shell of microcapsules by electrostatic interaction. The imbedding of 
nanoparticles into microcapsules facilitates mult-functionalities. For instance, the gold 
encapsulated capsules have a near infrared absorption, thus a site specific rupture of capsules 
and cargo release can be achieved by laser irradiation. Microcapsules with magnetite 
nanoparticles can be used for targeted delivery and alternating magnetic field triggered release, 
since the nanoparticles are magnetic responsive. Detailed application of triggered release will 
be discussed in Section 2.3.  
 
2.2.4.3 Drug encapsulation 
Large molecular weight drugs, and bioactive molecules can be directly encapsulated into 
microcapsule, as the polyelectrolyte shells are not permeable to molecules larger than 5 kDa.96 
These large molecular cargos can be co-precipitated with the templates, calcium carbonate for 
example. The resulting hybrid particles are used commonly for LbL assembly. After that, 
templates are removed, and the desired substances will be trapped inside the cavity of capsules. 
This is the simplest method for encapsulation, and the encapsulation rate is always high. This 
encapsulating method is affected by their solubility, molecular weight, as well as the affinity 
to the template (CaCO3). Proteins, DNA, and other bioactive molecules are usually 
encapsulated in this way, as the precipitation inside calcium carbonate can very well preserve 
their activity during LbL process, and the dissolution with EDTA is also mild. Besides, they 
can also be encapsulated as a layer of capsules shells via an electrostatic interaction. In previous 
study by our group, luciferases are encapsulated into to microcapsules at different locations, in 
the cavity by co-precipitation with CaCO3, in the middle of polyelectrolyte layers, and at the 
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out most layer of microcapsules. Activities of luciferase at the different locations are proved to 
be different, that luciferase in the cavity and at the surface of capsules are more active that 
these within the shells (Figure 2.14). 13, 97  
 
Figure 2.14 Schematically showing the locations of luciferases encapsulated in microcapsules. 
13 
Another method to load the microcapsules with desired substances is by diffusing. Briefly, the 
fabricated hollow microcapsules are incubated with the solutions of molecules of interest, and 
they will then diffuse into the microcapsules, driven by either electrical interaction or 
concentration gradient between the bulk solution and the interior of capsules. For example, 
bovine serum albumin (BSA) was co-precipitated with CaCO3 to produce hybrid particles, and 
after core dissolving, a charged network remained in the capsules, which can attract the 
oppositely charged doxorubicin molecules. Moreover, since the charge of BSA can be tuned 
by adjusting the pH, a pH controlled drug release cab be achieved.98-99 However, the 
disadvantage of this method is that the encapsulation efficiency is low (encapsulated amount 
compared to the high concentration bulk solution added).  
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Since it is always easy for the small molecular drugs to diffuse out from the microcapsules, 
many methods are developed to seal the microcapsules after drug loading. Basically, the 
problem is how to reduce the permeability of polyelectrolyte shells.  
Heat treating the microcapsules is the simplest way. It is proved that with an increase in the 
temperature, the capsules will shrink, which is due to the change of building block polymers 
from two-dimensional arrangement to a more coiled arrangement. With an elevated 
temperature, the microcapsules will shrink, resulting a decrease in size and increase in shell 
thickness, and the permeability is thus reduced (Figure 2.15). 100-101   
 
Figure 2.15 Schematic illustration (a) and SEM (b) images of heat shrinkage. (a) 
Configurational arrangements of the (PSS/PAH)5 capsules before and after heating. The 
reduction of the capsule diameter is accompanied by an increase of the thickness of the layer. 
(b) SEM images of (PDADMAC/PSS)4 capsules shrunk to different sizes as a function of 
diameter after temperature treatment. The first image shows an initial capsule with a diameter 




Coating the microcapsules with a hydrophobic layer is another method to reduce the 
permeability and enhance the encapsulation efficiency. Phospholipid, for example, is a good 
candidate for capsule sealing. The lipids are hydrophobic, and the their absorption on the 
surface of capsules can effectively reduce the permeability to small hydrophilic molecules. 
Besides, polypyrrole (PPy) also exhibited outstanding low permeability, due to the π electron 
delocalization along the polymer chains and their high rigidity. Depositing a PPy layer on 
microcapsule surface was proved to be efficient to entrap low molecular weight compounds.102 
Crosslinking the microcapsule building block polymers is also utilized to encapsulate low 
molecules weight cargos. Chemical crosslinker can be used to bind the related functional 
groups of polyelectrolytes, or it can also be externally triggered, such as by UV light. Polymers 
containing a photoactive diazonium groups are normally utilized. In previous study by our 
group, a novel microcapsule system consisting of diazoresion and Nafion was produced, which 
upon UV illumination, the diazonium groups and the sulfonate groups reacted and sealed the 
microcapsules (Figure 2.16). 103  
 
 




The low soluble drug crystals, on the other hand, can be directly used as cores for LbL assembly 
and producing capsules with a high drug loading capability. This approach was first reported 
to encapsulate fluorescein particles. At normal aqueous solutions, fluorescein crystals are very 
easy to dissolve, so the LbL encapsulation was carried out at pH 2 hydrochloric acid solution 
to prevent the preliminary core decomposition. The number of polyelectrolyte layers sufficient 
to sustain fluorescein release was found to be 8-10, and with increasing layers, the release time 
was also prolonged.104 Other water soluble drugs, such as ibuprofen, furosemide, nifedipine, 
and insulin, are also successfully encapsulated by tuning the LbL assembly conditions 
carefully.105 Poorly soluble drug crystals, including paclitaxel, tamoxifen, curcumin, resveratol, 
are also encapsulated by LbL assembly.106 However, for those poorly soluble drug crystals, 
ultrasound is usually applied to ensure a better dispersion of crystal size, and the ultrasonication 
formation of drug cores is accompanied by simultaneous polyelectrolytes coating. According 
to the difference of sonication process, it can be classified as top-down and bottom-up 
approaches. In the top-down approach, the drug powder is added into water and sonicated to 
break the big crystals into smaller one, and re-aggregation is prevented by absorption of 
polyelectrolytes. While for the bottom-up approach, drug crystals are completely dissolved in 
water/organic solvent mixture and ultrasonication with polyelectrolytes at presence will 
evaporate the organic solvent and precipitate fine drug crystals (Figure 2.17).107 Therefore, the 
bottom-up method is more efficient to produce smaller capsules compared to the top-down 
method. The traditional LbL technique to produce encapsulated drug crystals always need 
intermediate washings to remove excess polyelectrolytes, which is time and polymer 
consuming, and dissolution of drug crystals is not avoided. More recently, an optimized method 
by carrying out the assembly in equilibrium or reduced concentrated polyelectrolyte solutions 




Figure 2.17 Schematic representation of ultrasonication assisted layer-by-layer assembly using 





2.3 Triggered release 
Methods to trigger the release are one of the main tasks, since a desired release kinetic is 
beneficial for not only a safe performance but also an enhanced activity of encapsulated 
substances.19, 109 For the delivery of antibacterial agents, it is even more important to have a 
precise control of the release kinetics.  A smart and on demand release will be essential to treat 
chronic infections and eliminate the bacteria.  
There are various methods which can control the release from carriers. Basically, these triggers 
can be divided into physical, chemical and biological approaches.110 Here the physical way to 
induce encapsulated cargo release is presented, including ultrasound, NIR light and alternative 
magnetic field (AMF). 
2.3.1 Ultrasound  
Ultrasound is a kind of sound wave with a high frequency (20 kHz and above) which is beyond 
human’s hearing limit. It is usually generated by piezoelectric transducers which can transfer 
the voltage into mechanical displacement surface, and mediums such as water and gel, then 
transmit the ultrasonic waves.111 Ultrasound is widely used in our everyday life, such as 
detecting object and distance. As a non-invasive and no surgery method, it also has useful 
applications in medicine, for example, ultrasound imaging, and its ability to be focused at 
specific site in human body make it attractive for diseases treatment.112 In dentistry, ultrasound 
is mainly used for mechanical removal of hard tissues, debris, apical root structure, plaques 
and biofilms, and more interestingly ultrasound was proved to be beneficial for tooth growth.113  
Ultrasound, with the benefits of improving cell membrane permeability and being focused at 
targeted tissue, has widely been used for controlled drug delivery.111, 114 Ultrasound has the 
potential to control the delivery of antibacterial agents as it was demonstrated in the bone 
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cements that the synergistic effect of ultrasound and antibiotics had enhanced antimicrobial 
efficiency.67, 115 And moreover, a more recent studies have tried to use the high frequency 
ultrasound to delivery antimicrobial chitosan nanoparticles into dentinal tubule, which may 
open up new approaches for root canal infection treatment (Figure 2.18).113, 116 
 
Figure 2.18 Field emission scanning electron micrographs of a sample from the treatment group 
showing the nanoparticles penetration into the dentinal tubules. Penetration up to 1000mm deep 
from the opening of the tubules is seen; however, the distribution of the particles is not uniform. 
(a) The nanoparticles lining inside the tubule (white arrow) and on the side of another tubule. 
(b) Magnified view of the nanoparticles cluster inside the dentinal tubule. (c) Nanoparticles 
penetration at the openings of the dentinal tubules. (d) Nanoparticles aggregates penetrating 
into the tubules. 113 
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When drugs are loaded in various carriers, ultrasound can efficiently trigger the release. 
Basically, ultrasound induced thermal effect can change the phase of polymers which used as 
carrier composition, the phase transition of which will disrupt their original close and ordered 
packing, thus increasing permeability for drug release.117 Another explanation for ultrasound 
enhanced drug release is the intense acoustic streaming field which accelerate the fluids 
exchange. For instance, liposome vesicles with sonication will demonstrate transient pores in 
the membrane, and intra and extra-vesicular substance exchange is promoted.118 The cavitation 
generated by sonication, especially at the presence of microbubbles is proved to be very 
efficient to enhance the drug and gene delivery.119 
In addition, sometimes the mechanic oscillation resulted from sonication is dominant to release 
the encapsulated substances. It is reported that the pressure generated to the vesicles is uniform 
and the pressure gradient is negligible when the vesicles are small compared to the ultrasound 
wavelength. But when their size is comparable to ultrasound wavelength, the pressure is not 
uniform and shear force will be generated.118 On the other hand, by increasing rigidity of 
carriers, the mechanical effect will be more remarkable. Normally, the LbL assembly 
microcapsules are quite stable upon ultrasound irradiation, however, by incorporating 
nanoparticles in the polyelectrolyte shells, ultrasound can easily rupture the microcapsules.111 
More interestingly, recent work by our group revealled that with a layer of SiO2 deposited on 
the surface, the microcapsules are highly sensitive to ultrasound, which 6s of exposure to 




Figure 2.19 Normal and SiO2 coated PAH/PSS capsules upon ultrasound irradiation. 120 
 
2.3.2 NIR light based stimuli 
Near infrared (NIR) light with the advantage of high tissue penetration ability, is widely used 
for medicine, such as cancer therapy and controlled drug delivery.121-122 The NIR light can be 
focused at specific site and functionalize locally, and due to it photothermal effect, NIR light 
is used for cancer therapy, which the cancer cells can be burned to death by the absorbed energy 
from NIR light. For drug delivery, many metal or metal oxide nanoparticles can absorb the 
energy from the light and generate local heating to trigger the release of delivered cargos. It is 
due to the surface plasmon resonance effect of these particles. This no-invasive method for 




2.3.2.1 Gold nanoparticles and nanorods 
Gold nanoparticles and nanorods are the most commonly used laser responsive particles. Gold 
nanoparticles with controlled shape and size are normally synthesized via a seed-mediated 
method (HAuCl4), in which the nucleation and growth of nanoparticles are separated.123 By 
adjusting the synthesis parameters, such as kinds of reduction agents, initial gold salt 
concentration, temperature, solvent, the size of gold nanoparticles can be ranged from a few 
nanometers to hundreds of nanometers. To further control the morphology of gold 
nanoparticles, for example to get gold nanorods, the cetyl-trimethylammonium bromide 
(CTAB) can be used to navigate the growth of gold particles.124-125 The gold nanorods are also 
synthesized via a seed-mediated growth method, which the gold seeds are synthesized first and 
further grow in an anisotropic CTAB solution. Interestingly, the axial ratios of gold nanorods 
can be tuned by changing the concentration of reagents, which even rods with 200 nm in length 
and 100 nm in width can be produced. More recently, by using a mixing competitors of CTAB 
and cuprous ions to guide the growth of nanorods, single-crystalline gold nanorods with various 














Figure 2.20 SEM and TEM images of Au (A) ETHH, (B) ETOH, (C) CCB, (D) QCB, (E) 
TCB, and (F) EOH NPs. The SEM images and TEM images are shown in the left and right 
columns, respectively. The insets show the geometric models of individual NPs. All the SEM 
and TEM images share the same scale bars in panel A. (G) Extinction spectra of colloidal Au 
ETHH, ETOH, CCB, QCB, TCB, and EOH NPs. The particle concentration was ∼1.0 × 1011 
particles mL−1 for all the samples. 126 
 
Basically, due to the surface resonance effect, the gold nanoparticles have absorbance peak 
ranging from 400 nm to 800 nm, the position of maximum absorption is predominately 
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determined by the size and shape of nanoparticles. By increasing the diameter of gold 
nanoparticles, the absorption peak will shift to longer wavelength, which is known as red shift. 
Gold nanoparticles with an average size of 10 nm show a peak at 520 nm, however, for 109 
nm gold nanoparticles, the main resonance band will peak at 574.5 nm and the shape of which 
will also broaden.123  The aggregating state of gold nanoparticles will also affect the absorbance 
band. Take advantage of the surface charge of gold nanoparticles, they can be aggregated by 
introducing oppositely charged molecules or NaCl solution in the suspension. By forming large 
clusters, their absorption band can be shifted to the NIR light region due to the plasmon 
coupling effect between particles, which enables promising biological uses. Moreover, the light 
absorption efficiency of gold clusters is also proved to be dramatically improved. Coating the 
gold nanoparticle surface with other components is another way to shift the absorption position 
of gold nanoparticles.  
For gold nanorods, due to their geometry, there are usually two absorption bands at the 
spectrum, one transverse band around 520 nm which is similar to that of gold nanoparticles, 
and the other longitudinal band which is determined by the aspect ratio of nanorods. The 
absorption band of gold nanorods can be tuned from 550 nm to infrared spectral region by 
simply adapting their length or axial ratio. As the axial ratio increases, their absorption red shift 
and the oscillation strength is also turned out to be enhanced. Their shapes and facets will also 





Local heating of gold particles induced by NIR light irradiation is an important property which 
is used for triggered release. Many studies have been carried out to investigate the mechanisms 
of heat generation and how it transfers to the surroundings. Basically, the temperature 
distribution from the gold particles can be given by the following equation128:  
 
In which, 0k  is the thermal conductivity of surrounding substances, r  is the distance to center 
of the gold particle, and the Q  is heat dissipation rate which is depend on the induced electric 
field inside gold particles.  
Gold is highly thermally conductive, so that upon NIR light irradiation, instantaneous and 
homogeneous heat will generate around the particles within nanoseconds. The temperature 
around the gold particles drops as a function of increased distance from their surface as 
indicated by the equation. It is reported that with a 2 mW laser illumination, 80 nm gold 
nanoparticle can be instantly heated up to 340 °C, and temperature decreases dramatically to 
78.9 °C with a distance of 80 nm away from the particle surface (Figure 2.21).129 So an intimate 
contact with the gold particles is essential to make the most of heat generated. A good example 
is encapsulating gold nanoparticles into LbL assembled microcapsule shells, which can rupture 


















Figure 2.21 Simulation of the heat distribution of an 82 nm gold nanoparticle irradiated with a 
laser beam at a laser power density of 378 kW/cm2 (∼2 mW). 129   
 
The thermal effect of gold particles can be enhanced by assemblying them into clusters, as the 
heat fluxes from each individual particle cumulate. Simply, individual gold particles can be 
aggregated by mixing with oppositely charged components. The gold clusters showed five 
times increase in absorption coefficient than the single ones.130 Also, nanowires assembled by 
gold nanoparticles in cylindrical complexes were reported, in which gold nanoparticles acted 






2.3.2.2 NIR light triggered release 
Gold nanoparticles and nanorod based carriers are extensively used for drug delivery and 
photothermal therapy due to their facile surface modification and intrinsic plasmonic 
properties.132-134 Upon near infrared (NIR) light irradiation, the gold particles can efficiently 
convert the energy into heat, inducing release of loaded cargos. The general approach is to 
attach drug molecules or therapeutic agents, such as DNA and RNA, to their surface and then 
selective release can be achieved via photothermal treatment.135-136 They are also incorporated 
into carriers such as micelles,137 liposomes,138 polyelectrolyte microcapsules,139 and 
nanogels140 to facilitate stimuli responsive drug release. Previously a NIR mediated tumor cell 
apoptosis was achieved with gold nanorod based carriers in  vivo.136 Hollow vesicles consisting 
of gold nanoparticles and gold nanocages were also reported, which were supposed to be more 
sensitive to NIR light because of the high gold content.141-142 Moreover, their hollow structure 
was also advantageous over the other carriers due to the drug loading capability.  The advantage 
of NIR light induced release is high specific and that drug release pattern can be precisely 
controlled.143 A specific and sequential intracellular release of cargo triggered by light 
irradiation was demonstrated by Carregal-Romero et al., with a 3.8 mW/µm2 laser spot and less 
than 2s exposure.144 The gold nanoparticles embedded ruptured the microcapsule shells upon 
laser irradiation, releasing the encapsulated cascade blue labelled dextran intracellularly and 
one hour after, by irradiating another TRITC-dextran encapsulated capsule in the same cell, 
sequential cargo release was achieved (Figure 2.22).144 This observation shows potential for 






Figure 2.22 Sequential release in A549 cells. (a) before, (b) after the opening of 
(PSS/PAH)2 Auagg (PSS/PAH)2 capsules loaded with 10 kDa Cascade Blue-dextran, and (c) 
after the opening of capsules loaded with dextran-Tetramethylrhodamine.144  
61 
 
Another approach is to make the most of the photothermal properties of gold nanoparticles and 
nanorods for drug delivery, by directly constructing a drug on top of the particles. For instance 
mesoporous silica shells were deposited on the surface of gold particles to produce core-shell 
nanocomposites.145-146 Since this was first reported by Liz-Marzan et al., (1996),147 these 
gold/silica composites have attracted great attention for usage in controlled drug delivery. This 
is due to the porous silica shells acting as a good drug container and the gold core serving as 
an efficient photothermal convertor. The release kinetics of the payload from such composites 
can be easily tuned by NIR light illumination and with targeted delivery realised via 
modification of the silica surface.132, 136 The mechanism of formation of these core/shell 
structures consists of two stages: hydrolysis to form silica oligomers and mesoporous silica 
growth on the surface of the gold seeds via Ostwald ripening.148 Because gold has little affinity 
for silica, silane coupling agents are usually used as surface primers.145, 147 Since most of the 
payload molecules are physically entrapped in silica cavities, gating moieties on the composite 
particle surface are usually needed to regulate the release behavior.149  
 
2.3.3 Magnetic field based stimuli 
Efficient delivery of therapeutic agents to the specific target site is of great interest in disease 
treatment since the capability of concentrating a drug locally can reduce the overall dose and 
adverse effect of off-targeted molecules to normal cells or tissue.150-151 The requirement of 
targeted delivery has motivated people to design various carriers in recent decades. Basically, 
the idea is how to navigate the drug loaded carriers in a programmed route. Magnetic 
nanoparticles which can respond to magnetic field, provide a good approach to achieve it. 
Carriers, such as micelles, liposomes, emulsions and microcapsules, can be functionalized with 
magnetic nanoparticles and directed to the targeted tissue with a magnetic field.17-18, 152 
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Moreover, the release of loaded cargos can be triggered by an external alternating magnetic 
field, which is a promising method for remote controllable release. 
2.3.3.1 Magnetic particles 
Magnetite (Fe3O4) nanoparticles and the other forms of iron oxide nanoparticles have been 
highlighted for targeting drug delivery and other biomedical applications. There are many 
chemical approaches developed during the past decades to synthesize magnetite nanoparticles 
with various size and morphology.153-155 The basic method is well known Massart’s co-
precipitation method, where the particles were stabilized with citric acid into the aqueous 
solution.156 The ratio of Fe3+ and Fe2+ has to be tuned to 2 to 1 and the reaction has to be carried 
out in the atmosphere of nitrogen to avoid oxidation. Other methods such as reverse micelle 
method, sol-gel techniques, hydrothermal or solvothermal reactions are also used to 
synthesized magnetic nanoparticles. The properties of synthesized magnetic nanoparticles 
depend not only on their composition, but also their structure, shape, size and size 
distribution.157 Normally, without any templates or external forces, the synthesized magnetic 
nanoparticles have a spherical shape, and the size of which are largely depended on the reaction 
conditions (e.g. temperature, time). Magnetic nanoparticle with other shapes are also 
synthesized to enhance their performances. For example, iron oxide nanocubes have been 
demonstrated with better specific absorption rate (SAR) and magnetic properties. They are 
synthesized by using dibenzyl ether as the solvent, the decomposition product of which can 
control the nucleation and size of the nano cubes. By adding different amount of squalene to 
the reaction mixture, the size of nanocubes can be tuned (Figure 2.23).158 By using other 
template, such as polyethylene glycol, magnetite nanoparticles with spherical, cubic, rod-like 
and dendritic morphologies can be produced, which the concentration of Fe3+, Fe2+, and the 
molecular weight of polyethylene glycol are key factors.153 In addition, with the assistance of 
external magnetic field, magnetite nanoparticles with a rod-like structure can also be 
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synthesized via a conventional co-precipitation method.159 More interestingly, magnetic 
nanoparticles with a hollow structure can also be synthesized via a solvethermal reaction at the 
presence of urea or other ammonium salts.160 It is supposed that the urea and ammonium salts 




Figure 2.23 Representative scanning and transmission (inset) electron microscopy images of 
iron oxide nanocubes synthesized by tuning the relative amount of squalane. The total volume 
of solution was equal to 25mLin all syntheses and the volume ratio between DBE and squalene 
was: 23: 2 (A), 7: 18 (B), 4: 21 (C) and 3: 22 (D). These conditions lead to nanocrystal sizes 




2.3.3.2 Alternating magnetic field triggered release 
Magnetic nanoparticles are a good candidate for targeted delivery of a variety of substances, 
including small molecular drugs, biomolecules and DNA. Moreover, the magnetic particles, 
including magnetite, strontium ferrite, manganese ferrite and others, are sensitive to alternating 
magnetic fields, which can be utilized for triggered release.23, 162-163 Basically, under an 
alternating magnetic field, the magnetic nanoparticles will vibrate and generate heat, which 
will lead to change in permeability or carrier breakdown, and enhance the release.23 
Magnetically mediated hyperthermia was employed to induce cancer cells apoptosis, that upon 
antitumor chemotherapy agent delivery, the hyperthermia effect can greatly enhanced the 
performance.164 For instance, magnetite nanoparticles and thermosensitive poly(N-
isopropylacrylamine) (PNIPAM) nanogels were incorporated into the ethyl cellulose 
membrane, and an external oscillating magnetic field was applied to activate the embedded 
magnetic nanoparticles, and the heat generated by which leaded to the shrinkage of PNIPAM 
nanogels and increase of permeability of membrane. The flux of sodium fluorescein through 
the membrane was successfully tuned by an on-off states of magnetic field (Figure 2.24).165-166 
Magnetic nanoparticles are also incorporated into spherical polymer particles together with 
drugs via emulsification to enable a AMF induced release.140, 167 A more straightforward 
method to utilize the heat generated by magnetic nanoparticles is growing mesoporous silica 
on surface of the nanoparticles, which can be used as drug reservoirs, and the release of cargo 
can be further tuned by modifying the surface with some gate moieties.168-169 Other carriers, 




Figure 2.24 Stimulus-responsive membrane triggering in vitro. (a) temperature-triggering, 
comparison of nanogel particle size in suspension (blue data, right y-axis) and differential flux 
of sodium fluorescein through the nanogel-loaded membranes (red data, left y-axis) as a 
function of temperature; (b) magnetic triggering, temperature profile in the sample chamber 
and differential flux of sodium fluorescein out of membrane-capped devices as a function of 
time over four successive on/off cycles of the external magnetic field; (c) schema of the 
proposed mechanism of membrane function.165 
 
The magnetic nanoparticles can also be assembled into the LbL microcapsules. In the 
alternating magnetic field, the magnetic particles will vibrate corresponding to the frequency 
of AMF and lead to relaxing of polyelectrolytes and loose of capsule walls, which increases 
the permeability for encapsulated cargos. Sometimes when the frequency and strength of 
alternating magnetic field is high, the microcapsules can be ruptured. The morphology change 
of microcapsules was recorded by a previous study (Figure 2.25).174 Though, it is reported that 
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the local heating at surface of magnetic particles decays with increasing distance,175  the non-
heating effect produced by low frequency AMF is preferred for delivery bioactive substances 
(e.g. enzymes, DNA) to normal tissues.176-177  In fact, it is known that the low frequency AMF 
(up to 150 Hz) can more efficiently increase the permeability of a polymer matrix.178  
 
Figure 2.25 SEM and CLSM images of (Fe3O4/PAH)4 capsules after HFMF treatment for (a) 
10 min, (b) 15 min, and (c) 30 min. After 10-min stimulus, a certain amount of nanocavities 
50−100 nm in size appeared on the surface of the microcapsules. Upon further increasing the 
HFMF stimulus to 30 min, the microcapsules were ruptured to a large extent. (d) The drug 
release behavior and morphologies of (Fe3O4/PAH)4 capsules under continue HFMF.174 
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2.4 Motivation and Aims 
 
The use of antibacterial agents greatly improves the efficiency to treat infections, but there are 
still many problems concerned with their performance. First of all, they are easy to be excreted 
from the body or metabolized.179 Increasing the administration amount of drug can rapidly 
improve the effective drug concentration in the whole body, but the overuse of which will lead 
to the resistance of bacteria, which are able to survive exposure to one or several antibacterial 
agents.180-181 Resistance of bacteria will bring great challenges to the treatment. For the bacteria 
in the biofilms, it will be harder to kill them since the structure of biofilm retards antibiotics 
from penetration and bacteria there are also more resistance.2, 182 Finally, for the intracellular 
infections, antibiotics also vary greatly on their penetration into cells, and even if they are 
internalized inside cells, they could be impaired intracellularly and be inefficacious against the 
bacteria.183 Therefore, a delivery system which can maintain a high sufficient concentration of 
drug as well as their activity, is highly admired.   
To overcome these problems, approaches can be taken by either developing new formulation 
of antibacterial agents or using other carriers to enhance their delivery. For the first method, 
modification to the current form of drug would improve its performance, as the examples listed 
previously for chlorhexidine. For the carriers assisted delivery, it is more straightforward 
because antibacterial agents encapsulated in the carriers or polymer matrixes are well protected 
and the drug concentration can be maintained at a high level. Since some of the antibacterial 
agents have trouble to penetrate biological barriers, the polymeric carriers will also facilitate 
their transport across the critical and specific barriers. A sustained activity of which can ensure 
an efficient activity against bacteria locally. 
For these reasons, the motivation of the thesis is to develop new formulation of antibacterial 
agents, which can not only have a sustain activity against bacteria but also demonstrate external 
68 
 
stimuli responsive properties. Rare studies were reported for controlled antibacterial agent 
delivery and external triggered release. In fact, the lack of controllable release of antibacterial 
drug is always the main reason leads to secondary infections. For the less water soluble 
chlorhexidine, it is easy to precipitate it with various of salts, but to get homogeneous 
chlorhexidine particles is a challenge. So parameters such as type of salts, concentration, 
temperature, needed to be investigated. The benefit to produce drug crystals with uniform size 
and morphology is that they can be easily encapsulated or incorporated into other polymeric 
systems. Besides, the size of drug crystals also has a fundamental effect on its release kinetics. 
Functionalization the drug delivery system with other triggers responsive components is a way 
to facilitate smart release. If these components could be directly incorporated into drug crystals, 
it may be easier to manipulate the release kinetics. So precipitation was explored to produce 
chlorhexidine particles, and incorporation of which into various polymer systems to investigate 
the sustained activity. The possibility of external triggered release (ultrasound, NIR light, 
magnetic field) was investigated. 
For   doxycycline, with a very good solubility, the encapsulation could be achieved with LbL 
microcapsules and coating with hydrophobic lipid layer could help to reduce the release. From 
the point of view of targeted delivery, magnetic nanoparticles could be assembled in 
microcapsule shells and even have a AMF triggered release. But most of the reported AMF 
triggered release system were based on high frequency magnetic field, which was not preferred 
to be applied to normal cells or tissues as the hyperthermia effect. Therefore, it was decided to 
deliver doxycycline with microcapsules, and use a low frequency AMF to trigger its release 
intracellularly. By engineering the cells with a tetracycline based gene regulation system, the 
intracellular doxycycline activity could be effectively monitored. 
The ultimate goal of the thesis was to explore the possibility to deliver antibacterial agents 
(chlorhexidine and doxycycline) with various polymer based systems to achieve a sustained 
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activity, and to further facilitate an external triggers responsive release by functionalizing the 
systems with gold or magnetic nanoparticles. Hopefully, the developed antibacterial 
formulations could help to solve the current problems concerned with antibacterial agent 






3.   Materials, Methods and Instruments 
3.1 Materials 
Chlorhexidine diacetate (C6143, Lot: 19H0417), Doxycycline Hydrochloride, Rhodamine B 
(RhB, 283924, lot: 063K3407), Fluorescein isothiocyanate isomer I (FITC, Lot: 020M5305), 
Rhodamine B Isothiocyanate dye (RBITC, 283924), camphorquinone, Calcium Chloride 
(C8106, Lot: SLBF7416V), Boric Acid (B6768, Lot: 119K0067), NH4OH (Sigma, 320145), 
citric acid (Sigma, 27490, Lot: 23405C03), Ethylenediaminetetraacetic Acid disodium salt 
(EDTA), Sodium Carbonate and all other salts were purchased from Sigma-Aldrich. 
FeCl3 (Fluka, 44944, Lot:30607125) and 0.86g FeCl2 (Fluka, 44939, Lot:24606139), Agar 
(Fisher BioReagents) and LB Broth, Miller (Fisher BioReagents) were used for antimicrobial 
studies. 
Poly(allylamine hydrochloride) (PAH, 56 kDa, 283223, Lot: MKBJ4274V), Poly(sodium 4-
styrenesulfonate) (PSS, 70 kDa, 243051, Lot: BCBF6120V), Dextran sulphate sodium salt (DS, 
100 kDa), FITC-Dextran (70 kDa), Poly-L-arginine hydrochloride (Parg, 15-70 kDa), 1,2-
Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),L-α-Phosphatidylcholine (lecithin, from 
egg yolk), hydroxyethyl methacrylate (HEMA), dimethylamino ethyl methacrylate were 
purchased from sigma-aldrich.  
Poly (lactic acid) (PLA, 2002D) was from Nature works. 
2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissaminerhodamine B sulfonyl) 
(ammonium salt) was purchased from Avanti Polar-lipids.  
urethane dimethacrylate (UDMA) (Esschem, UK, Lot: 591-22), 0.08% of N, N-dimethyl-P-
toluidine (Acros Organics)  
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Agar (BP1423, Lot 127054), Tryptone (BPE9726, Lot 21012), Yeast Extract (BCE800, 
Lot4381720) and Sodium chloride (S3160, Lot 1333838) were bought from Fisher 
BioReagents. 
Phosphate buffered Saline (PBS, Lot RNBD7772), DMEM (41966, Lot 1513243) Thiazolyl 
Blue Tetrazolium Bromide (MTT, M5655, Lot 052K5328), Cell Lysis Reagent (CelLytic™ 
M), Protease Inhibitor Cocktail, were all purchased from Sigma-Aldrich. 
Foetal calf serum, penicillin and trypsin were purchased from Lonza Biologics Inc (Newington, 
NH, United States). 
All the reagents were used directly as received without further purification. All the solutions 
were prepared with H2O from hree stage Millipore Milli-Q 185 water purification system 
(Millipore, USA) with a resistivity higher than 18.2 Ω·cm. 
 
3.2 Methods 
3.2.1 Nanoparticles/Nanorods synthesis 
3.2.1.1 Fe3O4 nanoparticles synthesis 
Fe3O4 nanoparticles were synthesized by mixing 2.35g FeCl3 and 0.86g FeCl2 in 40 ml H2O in 
a three-neck flask, which was placed in an oil bath and heated up to 80 ℃ in an argon 
atmosphere. The mixture was next stirred, whilst 5 ml NH4OH was added slowly with a syringe. 
The reaction was maintained at 80 ℃ for 30 mins and then 2ml of 0.5 g/ml citric acid was 
added. The temperature was next raised to 95 ℃ and held for 90 mins. The magnetic 
nanoparticles were dialysed against H2O in a 14 kDa cut-off membrane for one week. The 
Fe3O4 nanoparticles were then characterized with TEM and zeta measurement. 
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3.2.1.2 Gold nanorods synthesis 
Gold nanorods were synthesized according to a reported seed mediated growth protocol. 
Briefly, the seed solution was prepared by mixing 10 mL of 0.1 M CATB and 0.25 mL of 10 
mM of HAuCl4. While stirring, 0.6 mL of ice-cold 0.01 M NaBH4 was added. The mixture was 
kept at 25 ºC. Then 40 mL of 0.1 M CTAB, 0.32 mL of 10 mM AgNO3, 10 mL of 10 mM 
HAuCl4 and 95 mL of deionized water were mixed to produce the growth solution. 0.5 mL of 
0.1 M ascorbic acid was added to the growth solution. 50 µl of the seed solution was finally 
added to the growth solution at 27 ºC and the reaction was kept constant at this temperature for 
6 hours. 
 
3.2.2 Chlorhexidine particles preparation  
Chlorhexidine particles were fabricated by precipitation of chlorhexidine diacetate with CaCl2. 
The chlorhexidine diacetate concentration was fixed at 15mg/ml. CaCl2 solutions with various 
concentrations from 2M, 1M, 0.5M, 0.33M, 0.25M to 0.125M, were mixed with the 
chlorhexidine diacetate solution at 1:1 by volume at room temperature. The mixtures were 
shaken for 1 min, and then centrifuged at 2000 rpm for 1 min (Eppendorf centrifuge 5417C, 
Germany). The precipitates were washed three times with corresponding concentrated CaCl2 
solutions to reduce the dissolution of chlorhexidine compounds. The resulting chlorhexidine 
compounds were characterized using scanning electron microscopy (SEM, FEI inspect-F, USA) 
and the freeze-dried powder was analyzed using Fourier Transform Infrared Spectroscopy 
(FTIR-Bruker, USA). 
To evaluate the influence of temperature on spherical chlorhexidine particle formation, 15 
mg/ml chlorhexidine diacetate and 0.33 M CaCl2 solutions were kept in an ice bath and the 
temperature of the solutions was monitored. At 1, 5, 10, 15, 20 and 25 ℃, specifically, the 
73 
 
solutions were mixed and centrifuged as previous and the precipitations were washed with 
corresponding CaCl2 solutions (three times) and then characterized using SEM. The particle 
size of spherical chlorhexidine compounds prepared at different temperatures was analyzed 
using a particle size analyzer (Nano Measurer, version 1.2). 
Labelled spherical chlorhexidine particle was prepared using the same procedure, but before 
mixing the chlorhexidine diacetate solution with CaCl2 solution, Rhodamine B was added to 
the chlorhexidine diacetate solution. The produced particles were centrifuged, washed and 
freeze dried as described previously. Particles were characterized using confocal microscopy 
(Leica TS confocal scanning system, Germany). 
To functionalize the chlorhexidine spheres with gold, the gold nanorod suspension was pre-
mixed with 0.8 mL of 0.33 M CaCl2, and then the mixture was introduced to 0.8 mL of 15 
mg/mL chlorhexidine diacetate solution. Specifically, a series of gold suspensions, 5, 10, 50, 
100, 200, and 400 µl (0.45 mg/mL), were premixed with CaCl2 solution to determine the 
influence of nano particles on chlorhexidine growth. All the procedures were the same as 
previous described and the gold nanorod functionalized chlorhexidine spheres were also freeze 
dried. The number of particles produced from all the mixtures was counted using a 
hemocytometer. Both Field emission and back scattered SEM were used to characterize the 
synthesized particles, and the size of the gold-chlorhexidine composites were measured using 
a Nano Measure (version 1.2). The gold nanorod functionalized chlorhexidine spheres were 
also characterized using Thermo-gravimetric analysis (TGA, Q50, USA) at 10°C/min under a 
nitrogen atmosphere and over a temperature range of 100-1000 °C.  
Similar here, to functionalize the chlorhexidine spheres with Fe3O4 nanoparticles, 200ul of 
Fe3O4 nanoparticles suspension was premixed with 1 ml of 0.33M CaCl2 (C8106, Lot: 
SLBF7416V). Then the mixture was introduced to 1 ml of 15 mg/ml chlorhexidine diacetate 
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solution (C6143, Lot: 19H0417). The mixtures were shaken for 1 min, and then centrifuged at 
2000 rpm for 1 min (Eppendorf centrifuge 5417C, Germany). To reduce the dissolution of the 
particles, the precipitates were washed three times with 0.33M CaCl2 solutions. All the 
supernatants were collected for UV-vis measurement. The resulting chlorhexidine spheres 
were characterized using a scanning electron microscope (SEM, FEI inspect-F, USA) with 
voltage of 10 kV, working distance of 10 mm and spot of 3.5. The presence of Fe in the spheres 
was confirmed by EDX analysis. The chlorhexidine spheres were freeze dried (ScanVac Cool 
Safe Freeze Drying, Denmark) at -107 oC, 0.009 mBar for 1 day and proportion of 
chlorhexidine in the powders was calculated.   In addition, the freezing dried chlorhexidine 
spheres were analyzed by Thermo-gravimetric analysis (TGA Q50) at 10°C/min under nitrogen 
atmosphere, over a temperature range of 50-800°C.         
Growth of chlorhexidine spheres was also tuned and separated into two stages. The first stage 
involved the slow growth of small chlorhexidine crystals at low temperature and second the 
fast growth of chlorhexidine shells on top of the initial primary crystals. To visualize the two 
stages, chlorhexidine diacetate solutions were mixed with FITC and RhB accordingly. To 
produce small chlorhexidine primary crystals, both the chlorhexidine diacetate (15mg/ml) and 
CaCl2 solutions (0.33 M) were kept in an ice bath for one hour. The mixing of these solutions 
as described in section 2.3 resulted in immediate precipitation of small chlorhexidine crystals. 
These pre-produced chlorhexidine crystals at 5, 50, 100, 200 and 400 µl (1.63×107 
crystallites/mL) were separately added to 0.33 M room temperature CaCl2, and 15 mg/ml 
chlorhexidine diacetate solutions. After 1 minute, the mixtures were washed with CaCl2 and 
characterized using confocal microscopy. The size effect induced by the chlorhexidine primary 
crystals was determined by analyzing the size distribution of produced chlorhexidine spheres 
using Nano Measure (version 1.2).  




3.2.3 LbL assembly to produce microcapsules 
3.2.3.1 Polymers labelling 
To visualize the microcapsules with confocal microscopy or fluorescence microscopy, the 
polymers (PAH, Parg) used for LbL encapsulation were labelled with dyes (RBITC or FITC).  
Briefly, 100 mg polymers (PAH or Parg) were dissolved in 50 ml 0.1 M borate buffer. The pH 
of the borate buffer was adjusted to 8.5 with NaOH. After that, the dye solutions (RBITC or 
FITC) with a concentration of 1 mg/ml in ethanol were added dropwise into the polymer 
solutions under vigorous magnetic stirring, and kept stirring for one day. Then, to remove the 
unbound dyes, the mixtures were transferred into 25 kDa cut-off dialysis membrane and 
dialysed against deionized H2O for 1 week. The water was changed frequently every day. The 
resulting labelled polymers were then kept in dark at 4 ℃ for further study. 
 
3.2.3.2 Hollow microcapsules and doxycycline encapsulation 
The LbL self-assembly technique was used to produce microcapsules, and the commonly used 
CaCO3 sacrificial templates were employed. The multilayers assembly on CaCO3 cores were 
described in detail in previous studies. But here, subsequent loading of doxycycline into 
capsules, DS was co-precipitated within CaCO3 according to the method for encapsulation of 
large molecules13. DS (20 mg/ml) was added to 0.33 M CaCl2 solution and was then 
immediately mixed with 0.33 M Na2CO3 by vigorous stirring for 20 seconds and then incubated 
for a further 10 seconds. The hybrid CaCO3 particles were washed three times with deionized 
H2O, and were immediately used for microcapsule assembly. PAH and PSS were used for 
synthetic shells, and Parg and DS as biodegradable ones. Due to the DS trapped in the templates, 
the cores were initially negatively charged so PAH or Parg was assembled as the first layer. 
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All the polymer solutions were prepared at 2 mg/ml with NaCl (0.2 M), and after absorbing 
each layer, microcapsules were triple washed with deionized H2O. For fluorescent visualization, 
the second positive layer was replaced with TRITC-PAH or TRITC-Parg. Six layers were 
deposited for all the capsules before dissolving the templates with 0.2 M EDTA solution.  
DS trapped in the hollow cavity of microcapsules was used as attraction for doxycycline 
molecules. This method has been used for encapsulating soluble low molecular weight drugs,98 
which are loaded via electrostatic interaction or as a shell component. Herein, doxycycline       
molecules penetrate the shells and react with DS and form a complex within the microcapsule. 
Microcapsules were counted with a haemocytometer and the concentration adjusted to 6×107 
capsules per ml before mixing with 1 ml of doxycycline solution (10 mg/ml) and shaking for 
8 hours. At the end of this incubation maximum encapsulation was achieved by placing the 
mixture at 60℃ for 10 min to shrink the capsules according to a previously reported 
procedure.184 Then the capsules were washed three times with deionized water and 
supernatants were collected to determine amount of loaded doxycycline.  Besides, to determine 
encapsulated doxycycline amount per gram of microcapsules, equal quantity of microcapsules 
(both empty capsules and doxycycline loaded ones) were freezing dried (ScanVac Cool Safe 
Freeze Drying, Denmark) at   -107 ℃, 0.009 mBar for 2 days. Then each sample was weighed 
(CP2-P microbalance, Sartorius AG Gottingen, Germany) and encapsulated doxycycline 
weight was calculated. 
Phospholipids, DPPC or lecithin, were coated as outmost layers on microcapsules to further 
reduce the permeability and thereby reduce the doxycycline leakage. DPPC (for synthetic 
capsules) and lecithin (for biodegradable capsules) were dissolved in chloroform at 0.5 mg/ml 
and were then evaporated using a rota vap at 42℃, after which a thin layer of phospholipids 
was formed.146, 185  Liposomes were then constructed by adding water (final lipid concentration 
of 1mg/ml) to the lipid film and sonicating for 1 hour at 60℃. The formed lipid vesicles were 
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added to the doxycycline loaded capsules and shaken for 20 min. Then the mixture was washed 
3 times with deionized water to remove excessive lipid, and supernatants were also collected 
for doxycycline concentration measurement. To visualize the lipid coating, Rhodamine B 
labelled lipid (0.2 mg/ml) was mixed with the DPPC or lecithin. Permeability of microcapsules 
was tested with FITC under the confocal microscope. 
To evaluate the influence of AMF on permeability of microcapsules, FITC labelled dextran (70 
kDa), which cannot penetrate the polyelectrolyte shells, were used model molecules.  Firstly, 
200 µl microcapsule suspensions (1×108 capsules) were added into cuvettes and then placed on 
top of electron magnet. The microcapsule suspensions were kept still in the AMF for duration 
of 30, 60, 90, and 120 min. Then the microcapsules were mixed with FITC labelled dextran 
solution and characterized with confocal microscopy. Since the microcapsules were labelled 
with TRITC, block of FITC-dextran outside capsules shells would lead to dark shadow inside 
the microcapsule, while penetration of which would display green fluorescence. Therefore, the 
ratio of microcapsules which were permeable to FITC-dextran was statistically analyzed as a 
function of exposure duration to AMF. 
200 µl microcapsule suspensions (1×108 capsules each) were added into cuvettes. As control, 
microcapsule suspensions were keep still in the cuvette, while for the AMF treated group, 
cuvettes were placed directly on top of the electromagnet. At each time point (from 10 min to 
270 min), the microcapsules in cuvette were precipitated by a magnet and half of the 
supernatants were collected for evaluation of the doxycycline released and equal volume of 
fresh H2O was replaced. Also, one group of microcapsules were exposed to AMF from the 120 
min. All the supernatants for each group at each time point were measured by UV-Vis 
spectrometer at 274 nm according to an established calibration. The cumulative release profile 




3.2.3.3 Solid chlorhexidine microcapsules 
Spherical chlorhexidine particles (15 mg/ml chlorhexidine diacetate and 0.33 M CaCl2) were 
used for LbL self-assembly. PAH (2 mg/ml, with 0.33 M CaCl2) was added to the spherical 
chlorhexidine particles as the first layer and the mixture was shaken (Vortex-Genie 2, Germany) 
for 10 min. Then the mixture was centrifuged (Eppendorf centrifuge 5417C, Germany) at 2000 
rpm and washed with 0.33 M CaCl2 solution (3 times) to remove the excess PAH. The second 
PSS layer (2 mg/ml, with 0.33 M CaCl2) was deposited using the same procedure. After 
assembling 7 layers, the encapsulated chlorhexidine particles with the structure 
Chlorhexidine/(PAH/PSS)3/PAH was produced. To prevent dissolution, all the assembly and 
wash steps were carried out in a solution of 0.33 M CaCl2. The supernatant during each layer 
assembly and after washing was collected for UV measurement to determine chlorhexidine 
loss during the LbL process. To monitor the assembly process, SEM images were taken for the 
spherical chlorhexidine compounds after the assembly of each subsequent layer. FIB SEM 
(Quanta 3D, FEI, E.U./U.S.A.) was also used to characterize the cross-section of the 
chlorhexidine capsule and the shell thickness was measured. The fifth layer of PAH was 
labelled with FITC for fluorescence imaging of the encapsulated chlorhexidine particles. 
 
3.2.4 Spray drying  
Spray-drying solutions were prepared by mixing freezing dried chlorhexidine particles with 
PLA solutions (1 wt.% and 3 wt.% PLA in mixing solvent of chloroform and acetone). The 
mixtures were then sprayed (Sprühflaschen), and the atomized product was collected with foil. 





3.2.5 Electrospinning of PLA fibers 
PLA fibers were fabricated by electrospinning at room temperature, with a working distance 
of 15 cm, pumping rate of 1 ml/h, and a voltage of 18 kV.  PLA was dissolved in a mixed 
solvent of chloroform and acetone (3:1 by volume) at 7 %. All the chlorhexidine particles were 
added at 0.5, 1 and 5 % (wt/wt) to the PLA and mixed using a Rotomix (ESPE RotoMix, USA). 
PLA fibers were collected on foil and characterized using SEM and their mean (SD) diameter 
was analysed using Nano Measure software (version 1.2). Confocal microscopy and FTIR 
(Bruker, Billerica, MA) were also used to confirm the presence of chlorhexidine. 
 
3.2.6 Preparation of chlorhexidine UDMA- HEMA resin discs 
UDMA-HEMA resin was prepared by mixing 64% urethane dimethacrylate (UDMA) 
(Esschem, UK, Lot: 591-22), 36% hydroxyethyl methacrylate (HEMA) (Aldrich, UK), 0.08% 
of N, N-dimethyl-P-toluidine (Acros Organics) and 0.05% dimethylamino ethyl methacrylate 
(Aldrich, UK). The mixture was stirred at 800 rpm for 15 min (VWR Stirrer, USA). Finally, 
camphorquinone (Aldrich, UK) was added at the proportion of 0.1%. The mixture was stirred 
for another 15 min, and then the viscous liquid resin was prepared.  
Freezing dried spherical chlorhexidine particles were weighed and incorporated within the 
resin at 5% by weight. To evenly mix the resin with the chlorhexidine spheres, the mixture was 
placed in an Eppendorf tube and then mixed for 15 s in a Rotomix mixer (120V/60Hz, 2850 
rotations/min) (ESPE RotoMix, USA). A separate set of sample containing chlorhexidine 
diacetate powder was also incorporated in the prepared resin in the same way, with loading 
rates of 5%. The resin mixture was then placed into a Teflon mold (10 mm in diameter ×2 mm 
thick) and cured through a Mylar film with a curing light (Bluedent LED pen, Bulgaria) (430-
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490nm, 600 mW/sq.cm) for 30 s on both sides. Then the discs were next weighed on a 
microbalance (Salter Ander-180A weighing scale, UK), and chlorhexidine amount in each disc 
was calculated. 
For the visualization of chlorhexidine spheres distribution in the resin composites, the spheres 
were labelled by rhodamine B. Spherical chlorhexidine particle were fabricated as described 
above, however before mixing chlorhexidine diacetate solution with CaCl2 solution, minimum 
amount of rhodamine B was added to the chlorhexidine diacetate solution. The produced 
particles were centrifuged and washed in the same way, and freezing dried. The labelled 
spherical chlorhexidine particles were mixed within UDMA-HEMA resin at 5 wt. % and filled 
into Mylar film mold (L 10 mm, W 10 mm, H 1mm), and cured to produce a very thin film. 
The spherical chlorhexidine incorporated resin film was characterized by confocal microscope 
(Leica TS confocal scanning system, Germany).  
UDMA-HEMA resin was prepared by mixing 50% urethane dimethacrylate (UDMA) 
(Esschem, UK, Lot: 591-22), 50% hydroxyethyl methacrylate (HEMA) (Aldrich, UK), 0.08% 
of N, N-dimethyl-P-toluidine (Acros Organics) and 0.05% dimethylamino ethyl methacrylate 
(Aldrich, UK). The mixture was stirred at 800 rpm for 15 min (VWR Stirrer, USA). Finally, 
camphorquinone (Aldrich, UK) was added at the proportion of 0.1%. The mixture was stirred 
for another 15 min, and then the viscous liquid resin was prepared. Freezing dried spherical 
Fe3O4-chlorhexidine spheres were weighed and incorporated within the resin at 5 wt.%. 
Incorporation of the chlorhexidine particles within the resin was carried out by rotating the 
mixture for 15 s in a Rotomix (120V/60Hz, 2850 rotations/min) (ESPE RotoMix, USA). For 
the control group, the resin mixture was then placed into a Teflon mold (10 mm in diameter ×1 
mm thick) and cured through a Mylar film with a curing light (Bluedent LED pen, Bulgaria) 
(430-490nm, 600 mW/sq.cm) for 60 s. For the magnetic field treated groups, the mixed resin 
was placed into Teflon mold which was placed on a MACS magnet. The resin mixtures were 
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kept still on the magnet for 5 min or 10 min, and then cured for 60 s. The discs were next 
weighed on a microbalance (Salter Ander-180A weighing scale, UK), and chlorhexidine 
amount in each disc was calculated. 
The resin discs containing Fe3O4-chlorhexidine spheres were emerged in liquid nitrogen and 
broke to analyse the distribution of spheres. Briefly, cross-section SEM images were taken 
continuously from one side of resin disc to the other side, and then all the images were put 
together to make a panoramic image. The panoramic image was divided into 21 frames with 
length along the x-axis, and each frame presented one single point on the graph.  Number of 
chlorhexidine spheres in each of the frames was counted and summed to get the total number, 
and a point was draw accordingly on the graph. Fe3O4-chlorhexidine spheres distribution in 
the resin discs was plotted in percentage as a function of distance to the magnet. Distribution 
for control resin disc, with 5 min and 10 min magnetic field treatment discs was displayed. 
 
3.2.7 Drug release measurement assays 
The content of chlorhexidine in the compound (0.33M CaCl2 and 15 mg/ml chlorhexidine 
diacetate), was determined by using a UV-Vis spectrometer (Lambda 35, Perkin Elmer, USA). 
Initially, a series of chlorhexidine diacetate solutions with standard concentrations of 0.25, 0.5, 
1, 2, 3, 4, 5, 10, 20, 40 ppm were prepared, and the absorption was measured. The absorption 
peak at 254 nm and the reference concentration had a linear relationship, and the calibration 
curve was established. All concentrations were determined by measuring the absorption of the 
supernatant and calculated accordingly. The number of chlorhexidine spheres in solution was 
counted using a hemocytometer (Neubauer Chamber, UK) and chlorhexidine content in each 
particle was also calculated. 
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Spherical chlorhexidine particles or encapsulated chlorhexidine particles (n=3) were stored in 
2 ml H2O or PBS and agitated (Vortex Genie 2). At specified time points from 5 to 420 mins, 
the samples were centrifuged and supernatants were collected for UV-Vis absorption 
measurement (Lambda 35, Perkin Elmer, USA). After each time interval, the removed 
supernatant was replaced with fresh deionized water or PBS. In addition, the release test for 
chlorhexidine capsules was also carried out in 15.6, 31.3, 62.5, 125, 250 mM NaCl and 
Na2HPO4 solutions to determine the influence of Cl- or PO43-on release kinetics. The 
accumulative release was calculated according to the calibration curve. Following the release 
experiment the chlorhexidine capsules were characterized using confocal microscopy and SEM. 
Release of doxycycline from microcapsules was determined by a fluorescence spectrum assay. 
The doxycycline concentration in solution was calculated according to the emission 
fluorescence intensity at 536 nm. Typically, a series of standard doxycycline solutions (40, 30, 
20, 15, 10, 5, 4, 3, 2, 1, 0.5, 0.25, 0.1, 0.05 ug/ml) were prepared and emission intensity at 536 
nm was measured (excited at 350nm). The calibration curve was used to determine amount of 
doxycycline in supernatants collected during the assembly process and therefore enable 
calculation of the amount of doxycycline retained in each capsule. 
In the release experiments, 12×107of synthetic or biodegradable capsules were prepared in a 1 
ml suspension in either deionized water, PBS or NaCl (0.15M). The suspensions were shaken 
on a vortex for specified intervals, after which it was centrifuged and the supernatant was 
collected for evaluation of the doxycycline released. The removed supernatant was replaced 
with 1 ml of fresh solution and the incubation continued. To demonstrate 100% release, 
doxycycline loaded microcapsules were mixed with 2 M NaOH.186 At this pH, microcapsules 




3.2.8 Cell studies 
3.2.8.1 Myoblasts and fibroblasts 
The lentiviral vectors used to engineer mouse C2C12 myoblast cells  (ATCC® CRL-1772™) 
were pLOX-TwGFP which encodes EGFP from the Ptet and pUCL-MIK which encodes the 
rtTA-2SM2 transactivator187 and the tetRKRAB repressor188 from a bicistrontic cassette189 
under the control of the constitutive SFFV promoter.190 Lentivirus was prepared as previously 
described191 then C2C12 cells were multiply infected with pUCL-MIK before multiple 
infection with pLOX-TwGFP. The resulting cell population was then stimulated with 
doxycycline hydrochloride (1 µg/ml) and after 24 hours the cells with the highest expression 
of EGFP were sorted using a BD FACS Aria II. These cells were plated on a 96 well plate at 1 
cell per well and clones expanded. The selected clone was not fluorescent in the unstimulated 
state but ubiquitously expressed high levels of EGFP upon doxycycline stimulation.  
 
3.2.8.2 Cell viability assays 
The myoblast cells were cultured in the Dulbecco's minimum essential media, containing 10% 
fetal bovine serum (FBS) and 1% penicillin–streptomyosin, at 37 °C and 5% CO2.  The 
standard MTT assay was used to assess the cell viability after treatment with doxycycline 
solution, empty capsules and doxycycline-loaded capsules for 48 hours. Cells were seeded in 
96-well plates with 1×104 cells per well and capsules were added at 10:1 ratio. After 48 hours, 
medium was removed, 20 µl of MTT solution (in PBS) was added to each well and cells were 
cultured for 3.5 hours. Then 150 µl MTT solvent (4 mM HCl, 0.1% Nondet P-40 in isopropanol) 




Toxicity of microcapsules to myoblast cells with and without AMF treatment was evaluated 
by MTT assay. Cells were seeded in 96-well plates at density of 1×104 cells per well, and 
cultured in Dulbecco's minimum essential media, containing 10% fetal bovine serum (FBS) 
and 1% penicillin-streptomyosin. After 24 hours, normal and magnetic microcapsules were 
added to each well, and free doxycycline solution was added as a control (n=5). Doxycycline 
concentration in each well was 4 µg/ml. AMF was placed at the bottom of each well for 30 
min/well after incubating with magnetic or PEI coated magnetic capsules for 1 day, and then 
cultured for another day. Then, the culture mediums were replaced with 0.2 mg/ml MTT 
solution (in DMEM medium) and cultured for 4 hours. After which, 150 µl MTT solvent (4 
mM HCl, 0.1% Nondet P-40 in isopropanol) was added to each well. The plates were read in 
a Multiskan Ascent Plate Reader (Thermo Fisher Scientific, UK) with the filter at 570 nm. 
The cytotoxicity of chlorhexidine containing fibers to fibroblasts was determined using the 
MTT assay. Both fibers with 0.5, 1 and 5 % (wt/wt) chlorhexidine particles, and PLA fibers 
without chlorhexidine, were rinsed with 70% ethanol and sterilized by exposing to UV for 2 h. 
The fibers were then immersed in culture medium at 1 mg/ml and were kept in the incubator 
for 24 h or 48 h. The fibers were next removed and the medium used for cell culture. The 3T3 
cells were seeded in 96-well plates at 1×104 per well, and cultured with fresh medium for 24 h. 
The medium was then removed and replaced with the chlorhexidine fiber release medium, and 
cells were cultured for another 24 h or 48 h. After which, the medium was removed and 20 µl 
of MTT solution was added to each well and cells were cultured for 4 h. Then 150 µl MTT 
solvent (4 mM HCl, 0.1% Nondet P-40 in isopropanol) was added to each well. The plate was 
read in a Multiskan Ascent Plate Reader (Thermo Fisher Scientific, UK) with the filter at 570 
nm. 
Both fibers with 0.5, 1 and 5 % (wt/wt) chlorhexidine particles were cut into 0.8 cm × 1 cm 
mesh, and sterilized using the method described in 2.6. PLA fibers without chlorhexidine 
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particles were used as a control. Prior to cell seeding, the fiber meshes were fixed at the bottom 
of a removable cell culture chamber (Lab-Tek® ІІ, Chamber SlideTM). An Engineered 3T3 cell 
(expressing EGFP) 50 suspension was added to each well at 2×104 cells per well, and then 
cultured for 24 h. The fiber meshes were collected and rinsed with PBS to remove any of the 
dead or detached cells. Confocal microscopy images were acquired with a confocal microscope 
using a 63x/ Oil DIC (WD=0.19mm) objective. All the fiber meshes were spread on glass slides 
and scanned in x–y–z mode. The interval between sections was set as 0.3 µm. All the images 
along the z position were stacked and three-dimensionally displayed using Imaris software 
(Bitplane, version7.7).  
 
3.2.8.3 Targeted delivery and Triggered release 
Mouse C2C12 myoblast cells (ATCC® CRL-1772™) were engineered with lentiviral vectors to 
express EGFP at the present of doxycycline according to the method described in our previous 
study. So the cells could be used as reporters for doxycycline delivery which fluorescence could 
be observed when doxycycline was delivered intracellularly. Here, C2C12 cells were cultured 
in 8-well glass chamber slides (well size 10.7 mm×9.4 mm, ibidi USA Inc) at 1×104 cells per 
well and incubated for one day. Then the doxycycline loaded magnetic microcapsules were 
added to the cells at a 1:1 ratio. To attract the magnetic capsules to the site of interest and 
induce EGFP expression locally, one magnet was placed at the bottom of well. The cells 
together with the magnet were kept in incubator for 24 hours. Cells incubated with magnetic 
capsules but without magnetic field treatment was used as control.  
Intracellular doxycycline delivery and locally induced EGFP expression was imaged with a 
Leica confocal microcopy with 40× oil emersion objective. To visualize the distribution of 
microcapsules and cells with fluorescence, images were taken continuously from one side of 
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the well to the other side in the red, green and transmission channels. Each of the individual 
images were put together to make a panoramic image. 
EGFP expression was quantitatively analyzed using a Fluostar Galaxy plate reader. The cells 
were seeded in 96-well plate at 1×104 cells per well and cultured for one day. Then free 
doxycycline, doxycycline loaded normal and magnetic capsules, PEI coated magnetic capsules 
were added to each well with doxycycline concentration fixed at 4 µg/ml, 2 µg/ml and 0.4 
µg/ml per well (n=5), and cultured for 24 hours. Then the electromagnet was place at the 
bottom of wells with magnetic microcapsules or PEI coated magnetic microcapsules for 10 min 
or 20 min per well. Cells with no AMF exposure were used as comparison. After all the AMF 
treatment, the cells were cultured for another day. To evaluate the EGFP expression, the cells 
were then washed with PBS and lysed for 30 min by 20 µl lysis reagent (0.05% Protease 
Inhibitor Cocktail in CelLytic™) each well. Then, 80 µl PBS was added to each well. EGFP 
fluorescent intensity was measured with excitation wavelength fixed at 480 nm and emission 
fixed at 520 nm. Cells with no free doxycycline or doxycycline loaded microcapsules were 
lysed as the control and 100 µl lysis reagent in PBS was used as the blank. The EGFP 
fluorescent intensity was calculated as follow, EGFP fluorescence intensity = (test well - 
control)/control.  
 
3.2.8.4 EGFP fluorescence intensity assay 
Quantitative analysis of EGFP expression kinetics was performed with a Fluostar Galaxy plate 
reader. Engineered C2C12 cells (1×104 cells per well) in a 96-well plate were treated with free 
doxycycline, doxycycline-loaded synthetic or biodegradable capsules (7 wells for each group). 
After specific intervals (2, 4, 6, 8, 10, 12 days), culture medium was removed, and cells were 
washed with PBS and lysed for 30 min by addition of 20 µl lysis reagent (CelLytic™ M, with 
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0.05% Protease Inhibitor Cocktail added) to each well. Then 80 µl PBS was added, and EGFP 
fluorescence intensity was measured in the reader with excitation and emission wavelengths 
fixed at 480 nm and 520 nm accordingly. Control lysates were prepared using untreated cells 
and the assay blank consisted of lysis reagent and PBS up to 100 µl volume. EGFP intensity 
was calculated according to the following equation, EGFP fluorescence intensity = (intensity 
of test well – intensity of control well) / intensity of control well ×100%. 
 
3.2.9 Antibacterial assay 
The antibacterial activity of doxycycline loaded microcapsules was tested by growth inhibition 
of Escherichia coli (E. coli, DH5a). Bacterial suspensions in LB Broth were cultured at 
37°C/200rpm shaking until they were in the linear phase of growth indicated by an optical 
density between 0.4-0.6 measured using a spectrophotometer (Cecil CE2021) at 400nm. 
Bacterial suspension (0.4 ml) was spread on the surface of dried LB agar plates. The sensitivity 
of the E. coli to inhibition with doxycycline was firstly demonstrated using filters (diameter 7 
mm) treated with doxycycline concentrations from 5 mg/ml to 8 µg/ml and placed on an agar 
plate pre-spread with E. coli. Filters remained on the plate which was incubated at 37°C 
overnight and then diameter of zones of inhibition were measured in mm. Sustained release of 
doxycycline from microcapsules was examined in a transfer experiment in which filters were 
initially loaded with 40 µl of doxycycline solution (0.1 or 1 mg/ml) or 40 µl of microcapsule 
suspension equivalent 1 mg/ml of doxycycline. After incubation for 90 minutes on an agar 
plate pre-spread with E. Coli, filters were transferred to a second pre-spread plate with addition 
of 10 µl sterile water to the filter, the process was repeated every 90 minutes. After 12 hours, 
all the filters were disposed and all the plates were incubated overnight at 37°C. Images were 
taken and the inhibitory zones against E. coli growth were measured using Nano Measurer(1.2). 
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The antibacterial properties of chlorhexidine particles loaded electrospun PLA fibers were 
tested by growth inhibition of Escherichia coli (E. coli, DH5a), using both an agar diffusion 
assay and broth transfer assay. The LB broth base solution was prepared (with 0.5 g NaCl, 10 
g tryptone, 5 g yeast extract per liter). To make the LB agar plates, agar was added to the LB 
broth base solution at 15 g/L. Bacterial suspension in LB broth base solution was cultured at 
37°C/200 rpm shaking, and the density of the suspensions was adjusted to that of a McFarland 
0.5 turbidity, which corresponded to 1.5×108 cells/ml using a spectrophotometer (Cecil 
CE2021, USA) at 625 nm. 0.4 ml of the bacterial suspension was spread on the surface of LB 
agar plates. The sensitivity of the E. coli to inhibition with chlorhexidine was firstly 
demonstrated using filters (diameter 7 mm) treated with chlorhexidine particles or encapsulated 
chlorhexidine particles with chlorhexidine concentrations from 5 mg/ml to 50 µg/ml and placed 
on agar plates pre-spread with E. coli. The fibers were cut into discs (diameter 7 mm, thickness 
0.1 mm) and rinsed with 70% ethanol and H2O, and then placed on LB agar plates which was 
incubated at 37°C for 24 h and then the diameter (SD) (n=3) of zones of inhibition were 
measured in mm.  
The sustained antibacterial effect of the chlorhexidine containing fibers was also examined in 
a transfer experiment. Bacterial suspensions in LB broth base, with McFarland 0.5 turbidity 
were diluted 200 times. Each of the fiber discs (fibers with chlorhexidine particles or 
encapsulated chlorhexidine particles containing 0.5, 1 and 5 % (wt/wt) chlorhexidine, n=3) 
were immersed into the bacterial suspensions (1 ml) and cultured at 37°C/200rpm shaking. 
After each hour, the fiber discs were transferred into fresh bacterial suspensions. After 9 hours, 
all the fiber discs were discarded and all the bacterial suspensions were incubated for another 





3.3.1 Zeta potential and size  
The Malvern Nano ZS zetasizer instrument was used for the size and zeta potential 
measurement (Figure 3.1). The technique allows for clear (or light colored) solutions to be 
characterized in terms of sample particle size, zeta potential and molecular weight, three 
fundamental parameters of nano-sized particles or molecules in a liquid medium. 
For particle size measurement, basically, it is based on the Brownian motion of particles in a 
simple using Dynamic Light Scattering (DLS). When the monochromatic light beam travels 
through the particles suspension, the particles will cause the light to be scattered at different 
intensities, the intensity fluctuation of which is determined by the size of particles. The light 
fluctuation can be detected and analyzed, giving the particle size distribution based on the 
following relationship:  
 
Where r is the radius of particles, kB is Boltzmann’s constant, T is temperature,   is viscosity 
and D is the diffusion constant. 
Zeta potential refers to the charge at the interface of particle surface and the liquid medium, 
and usually is measured in mV. In the electric field, the charged particles will move towards 
















Where   is zeta potential,   is solution viscosity,   is dielectric constant, U is 
electrophoretic mobility,   is speed of particles, V  is voltage and L is the distance between 
electrodes.  
 Figure 3.1 Image of Malvern Nano ZS zetasizer instrument. 
 
3.3.2 UV-Vis spectroscopy  
The Lambda 35 UV-Vis spectroscopy (Perkin Elmer) covering a wavelength range from 175 
to 1500 nm was used for the measurement concentration of chlorhexidine (at 254 nm) and 
doxycycline (at 274nm) in solutions (Figure 3.1). It has to be noted that in the ultraviolet range 
(200 to 400 nm), all the measurements were carried out in the quartz cuvette, which has little 








Basically, when the monochromatic light with specific wavelength pass through the organic 
molecules, they will absorb the energy of light and transit to a higher orbital. The transition of 
molecules normally includes the multiple-bond (π), single bond (σ) and n-caused by lone pairs 
(n). For most of the organic samples, the transition of n or π electrons to π* excited state will 
result absorption region from 200 nm to 700 nm. In addition, the UV-Vis spectroscopy is also 
used to for measuring transition metal ion solutions, for example the gold or iron oxide 
nanoparticles, and DNA or protein samples.  
For the concentration determination, since the absorption intensity of samples (chlorhexidine 
and doxycycline) has a correlation with its concentration, the amount of molecules in solutions 
can be calculated based on the calibrated relationship.  
In addition, for the measurement of bacterial concentration, the optical light spectroscopy 
(Cecil CE2021) was used, and cell concentrations in suspension was determined according to 
the McFarland standard. McFarland standard with different numbers which refer to the 
turbidity of bacterial suspensions, have a correlation with the cell numbers. At McFarland 0.5 
turbidity, the cell density is around 1×108 CFU/ml. and the absorbance is between 0.08 and 0.1 
at 625 nm wavelength.   




3.3.3 Fluorescence spectroscopy 
The fluorescence spectrometer (Perkin Elmer LS55) was used to measure the fluorescence 
intensity and determine concentration of dyes and fluorescence drugs (doxycycline) (Figure 
3.3). Similar to the UV-Vis spectroscopy, the measurement is also based on a linear relationship 
between fluorescence and substance concentration. So a standard calibration is needed to 
measure the release. But to ensure an accurate measurement, the samples should always be 
kept away from the light and concentration for each sample should not too high. With a too 
concentrated solution, it will self-quenching, thus leading to a lower measurement 
concentration. As for quantification of doxycycline concentration, the excitation and emission 
wavelength was set at 350 nm and 536 nm respectively. 
Briefly, a light beam generated by a high energy pulsed Xenon source is used to excite the 
sample molecules, leading to emission of fluorescent light. The excitation light should be 
monochromatic with a specific wavelength, and the emission light is recorded. Also, the 
fluorescence spectrometer can also be measured in an excitation model, which with emission 
light set at specific wavelength and the excitation light is recorded.  
 
Figure 3.3 Image of fluorescence spectrometer. 
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3.3.4 Fourier transform infrared spectroscopy 
The FTIR spectrometer (Pekin Elmer) was used for chemical structure analysis (Figure 3.4). 
Both the chlorhexidine and doxycycline samples were analyzed with the spectral resolution set 
at 4 cm-1 from the range of 4000 cm-1 to 600 cm-1. FTIR is a basic technique for chemical 
structure analysis, functional groups of molecules identification, and detect of certain 
compounds. Either solid or liquid samples could be directly examined.  
Basically, the FTIR consists of an infrared source which emits full spectrum of wavelengths of 
infrared radiation. The infrared radiation then goes into a Michelson interferometer, which 
contains a fixed mirror and a moving mirror, and then is modulated to monochromatic lights. 
It then passes through the samples and be absorbed at different wavelength by different bonds 
and molecular groups. After that, the infrared beam intensity is detected, Fourier transferred, 
and generate a spectrum.  
Different molecules have different bonds and functional groups, so the vibrating of bonds will 
be at different frequencies. Even if the same group in different molecular structures will have 
various vibrating frequency. But we can interpret their chemical bonds and positions by refer 
to the standard spectrums. By comparing the shift of vibrating band and intensity, the chemical 
structure or interaction between functional groups can be interpreted.   
Figure 3.4 Image of FTIR spectrometer. 
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3.3.5 Thermogravimetric analysis  
Thermo-gravimetric analysis (TGA Q50, USA) was used to determine the composition of 
chlorhexidine spheres (Figure3.5). The TGA analysis for all the samples was carried out at 
10°C/min under nitrogen atmosphere, over a temperature range of 50-800°C. And the samples 
were dried and loaded as powder in the pan of TGA machine for analysis.  
TGA is a method to measure the mass change of solid samples over a range of temperature. 
Basically, when the sample is heated, its weight will lose when it starts to decompose or 
evaporate. But sometimes the weight also increases when oxidation happens. The dynamic of 
weight changes is recorded via the microbalance and the temperature is monitored by a 
thermocouple. By referring to the TGA result, we can learn the stability of samples and their 
decomposition temperature. For the metal nanoparticle functionalized chlorhexidine spheres, 
we can even calculate the percentage of the organic and inorganic components.  
 
Figure 3.5 Image of thermo-gravimetric analysis instrument. 
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3.3.6 Fluorescence microscopy  
Fluorescence microscopy (Leica DMI 4000B Epifluorescence microscope) were used for 
characterize samples (microcapsules and cells) with fluorescence. For the microcapsule 
samples, polyelectrolyte shells are normally labelled with dyes (FITC or TRITC). Doxycycline 
is also fluorescent, which can be visualized in the ultraviolet range. For cells imaging, the 
myoblast cells (C2C12) were engineered to express EGFP, therefore, they were imaged directly 
with the fluorescence microscopy to monitor the EGFP expression. 
When the specimen is illuminated with monochromatic light, they will emission light from the 
excited singlet state to the ground state. The microscopy is consisted of light source, dichroic 
mirror, excitation filter and emission filters, both of which are chose corresponding to the 
excitation and emission wavelength of fluorophores. For the Epifluorescence microscopy, each 
time only one fluorophore is imaged, and multicolor samples have to be imaged separately and 
images at different channels then are merged (Figure 3.6). 
Figure 3.6 Fluorescent microscopy schematics. 
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3.3.7 Confocal laser scanning microscopy 
Confocal laser scanning microscopy (CLSM, Leica TS confocal scanning system) was used 
for microcapsules characterization, permeability test, and all the cells imaging. The microscope 
is equipped with 10×, 20×, 40×, 40× oil, 63× oil immersion objectives. For microcapsule 
samples, the suspensions were deposited on thin glass slide and covered with cover glass. Cells 
adhered on electrospum fibers were also transferred on thin glass slides. For cell samples, cells 
were cultured in Ibidi 8-well glass chamber and imaged directly.  
The advantage of confocal microscope over the fluorescence microscope is that high resolution 
images can be taken and a 3-D reconstruction can be achieved. For the traditional fluorescence 
microscope, the light cannot not be focused on a specific area, but whole the sample is excited. 
However, for confocal microscope, focus of light to sight of interest is realized by placing a 
pinhole in front of the detector to eliminate the out-of-focus signal, and only signals very close 
to the focal plane can be detected. The confocal microscope can acquire optical sections as thin 
as 0.5 µm. Therefore, specimen at specific section depth can be easily imaged. To reconstruct 
a 3-D image, we just have to set the start and end depths by adjusting the z-position, number 
of sections, and then take the images continuously. Then the acquired images stack to make 
the 3-D image. Therefore, the 3-D structure of samples, positions between cells compartment 
and capsules can be viewed and analyzed (Figure 3.7).  
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 Figure 3.7 Laser scanning confocal microscopy schematics. 
3.3.8 Scanning electron microscopy  
Scanning electron microscopy (SEM, FEI inspect-F) was used for characterizing chlorhexidine 
samples and microcapsules (Figure 3.8). The samples, either in powder or in suspension, were 
prepared on a glass wafer, and coated with gold or carbon to make the samples conductive. For 
gold or Fe3O4 functionalized chlorhexidine spheres, back-scattered detector was used to 
visualize the distribution of metal elements, so carbon coating was preferred. The voltage used 
for imaging was 10 kV, and spot size was set at 3.5, and working distance was around 10 mm. 
Statistical analysis of particle size based on the SEM images and fiber diameters were carried 
out using Nano Measure (version 1.2).   
The principle of SEM is basically that when a focused electron beam scans on the surface of 
specimen and interact with the surface, signals were detected by detectors, which produce 
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images of sample morphology and composition. The most common detectors used are 
secondary electrons (SE), back-scattered electron (BSE) and photons of characteristic X-rays 
detectors. Secondary electron detector monitors the secondary electrons emitted by the surface 
of samples and can produce images with resolution as high as 1 nanometer. BSE detector 
collects elastic scattering electrons from much deeper surface of samples, and the resolution is 
poorer than the SE images. But elements distribution for the samples can be provided in the 
BSE model. For the characteristic X-rays detector, an inner shell electron from the sample was 
removed and filled by a higher-energy electron, and information is collected. So the 
composition of samples can be identified in this model. To get better images, normally the 
samples should be electrically conductive, therefore, a thin layer of Au, Pt or carbon is sputtered 
on the sample surface. For biology samples, carbon is preferred. And the voltage of electron 
beam ranging from 5 kV to 20 kV is chose depending on the properties of samples, as electon 




Figure 3.8 FEI Inspect F scanning electron microscope photographs: a) microscope general 




3.3.9 Transmission electron microscopy 
Transmission electron microscopy (JEOL 2010) was used for Fe3O4 nanoparticles, Au 
nanoparticles/Nanorods, and microcapsule characterization (Figure 3.9). Samples were 
prepared by put one drop of diluted suspension on the copper grid with carbon film, and dried 
in air. The copper grid was fixed into a holder and placed into vacuum chamber before analyzed 
at acceleration voltage of 200 kV.  
Different from the SEM, the electron beam used in TEM transmit directly through the sample 
and interacting with the it, giving the information of the structure of the sample. So the samples 
should be ultra-thin for electron penetration, and the electron beam is accelerated. The images 
generated based on the information are then magnified and focused, or detected by a sensor 
underneath the sample. The resolution of TEM images is extra high, which makes it possible 
to examine the details of samples such as a single column of atoms.  
 
Figure 3.9 Image of TEM instrument. 
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3.3.10 Ultrasonic unit 
Ultrasound (Piezon Master 400) was used in the study to trigger the release of chlorhexidine 
from HEMA-UDMA resin (Figure 3.10). This ultrasonic unit is frequently used in dentistry for 
the purpose of subgingival calculus removal, periodontal treatment, cavity preparation, root 
canal preparation, cleaning and irrigation and so on. In our experiment, the ultrasound probe 
(27-30 kHz) was contacted with the resin disc surface and sonicated for different durations to 
trigger chlorhexidine release.  
 




3.3.11 Laser irradiation setup 
To irradiate the chlorhexidine capsules a customised laser setup was used (Figure 3.11).192 The 
chlorhexidine capsule suspension was placed on a thin glass slide and the glass slide was 
marked to locate the particles. A 100 mW laser diode (840 nm) was coupled with a simple 
optical microscope (100 × objective, Edmund Scientific, USA), and the focused laser spot was 
tuned by adjusting the operating laser voltage. In addition, the white light source and XYZ 
stages allowed samples to be easily located and focused. The laser beam passed through the 
objective in the Z direction and was focused at the sample to irradiate the specific site. A CCD 
camera was connected to a computer to capture this event. Thus, once aligned and focused, an 
image of sample and a laser spot could be observed on the screen. In the current work, remote 
triggering of the gold functionalized chlorhexidine capsules was carried out using this laser 
setup.  
 
Figure 3.11 Laser irradiation setup (left) and schematics (right).   
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3.3.12 AMF setup 
As an AC electromagnet, a 7 cm long, 2.2 cm diameter linear coil wound on a cylindrical solid 
soft iron core of 1.5cm diameter was obtained from a low voltage electromechanical relay 
switch (manufacturer unknown). It had a DC resistance of 2k, and an impedence of 5k at 
50Hz, indicating an inductance of 14.6 Henrys.  
A power supply was constructed with a 230v to 110v 50Hz mains transformer.  A variable 
voltage was supplied to the electromagnet through a stepped potential divider circuit connected 
across the transformer output consisting of seven 1k 1W resistors in series connected to a 
rotary switch. To avoid damage to the coil from high voltage transients, a resistance of 1k 
was connected in series with the electromagnet, and a 200V surge limiter was placed across its 
terminals. The maximum voltage supplied to the coil was 98V.   
The magnetic field was measured by a Gaussmeter at full voltage. the electromagnet gave an 
AC field of 16.4 milli Tesla (164 Gauss) at the centre of the end of the core. For the experiments, 
the magnet was mounted vertically and the test wells were placed immediately above the end 
of the core. At the spacing of the bottom of the interior of the plastic wells from the core, the 
field was 16.0 milliTesla (160 Gauss). The field at 1 cm directly above the centre of the core 
end fell to one third of level with the probe touching it. At lower voltages, the magnetic field 













4. Chlorhexidine spheres 
4.1 Chlorhexidine spheres and their encapsulation 
4.1.1 Fabrication of chlorhexidine spheres 
4.1.1.1 Chlorhexidine precipitation with salts 
Chlorhexidine cannot readily crystallize,193 so it is commonly used in the form of chlorhexidine 
digluconate, chlorhexidine diacetate and chlorhexidine dihydrochloride. Chlorhexidine 
diacetate has a relatively low solubility (2% in H2O),30 therefore many salts or ions could lead 
to precipitation, enabling the possibility to further modify the formulation and morphology of 
chlorhexidine precipitation.  
Here we used different salts to precipitate chlorhexidine. Briefly, 15 mg/ml chlorhexidine 
diacetate was mixed with solutions of Na2CO3 (Figure 4.1a), Na2HPO4 (Figure 4.1b), NaHCO3 
(Figure 4.1c), Na2SO4 (Figure 4.1d), and not homogeneous precipitations were produced. But 
when chlorhexidine diacetate was mixed with NaBr and KI, some fibrous structure was 
observed as illustrated in Figure 4.4e, f. Especially for the precipitation of 15 mg/ml 
chlorhexidine diacetate solution and 0.66 M NaBr, individual clusters were precipitated. 
According to the enlarged image, a dendritic-like structure was observed, however intact 
spherical particles could not be identified. So we assume that the halogen elements may have 
the potential to help produce homogeneous chlorhexidine particles. Because comparing to the 
precipitation from I-, those precipitated with Br- have a more ordered appearance, so next we 






Figure 4.1 SEM images of chlorhexidine diacetate precipitated with 0.33 M (a) Na2CO3, (b) 
Na2HPO4, (c) NaHCO3, (d) Na2SO4, and 0.66 M (e) NaBr and (f) KI. The inset images are 

















Similarly, 15 mg/ml chlorhexidine diacetate solution was used with different CaCl2 
concentrations to synthesize spherical chlorhexidine particles. As demonstrated in Figure 4.2, 
spherical chlorhexidine particles could be fabricated with low CaCl2 concentration and the 
formation of spheres were dependent on the amount of ions in solutions. When the 
chlorhexidine diacetate concentration was fixed at 15 mg/ml, 2 M CaCl2 this led to irregular 
precipitation (Figure 4.2a). When the concentration was reduced to 1 M a similar clustered 
structure was presented (Figure 4.2b). The 0.5 M CaCl2 solution produced precipitation of 
individual particles, most of which were spherical or semi-spherical with a high porosity 
(Figure 4.2c). The distinct texture revealed the nucleation and growth direction which 
originated from the core. When the CaCl2 concentration was 0.33 M, more regular spheres 
were produced (Figure 4.2d). The interconnected structure was highly porous and 
homogeneous and the mean particle diameter (SD) was 19.9 (3.1) µm. This formulation was 
used for all the following experiments. Further reducing the CaCl2 concentration to 0.25 M and 
0.125 M resulted in the synthesis of particle morphology with a more spherical, compact and 
interconnected structure (Figure 4.2e-f). The CaCl2 concentrations however did not have much 
influence on the chlorhexidine precipitation efficiency, since all solutions used could 
precipitate over 95% chlorhexidine (Table 4.1). The chlorhexidine content in the spheres was 
90 wt. % as determined by measuring the remaining chlorhexidine in the supernatant and the 
weight of the dried spheres. The chlorhexidine content was higher than the other carriers which 
are used for chlorhexidine delivery.71 Chlorhexidine content in each particle was 2.57 ng. The 
minimum inhibitory concentration (MIC) of chlorhexidine reported for E. coli was 2-8 µg/ml 
and for S. epidermidis was 0.5-2 µg/ml.86 Therefore, the concentration of the chlorhexidine 
spheres may be beneficial for sustained antibacterial activity. 
To further confirm the effect of Cl-, chlorhexidine diacetate solution was mixed with other 
equivalent chloride salt solutions (such as NaCl, KCl, ZnCl2, and MgCl2), that similar 
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Figure 4.2 SEM images of chlorhexidine compounds precipitated with: (a) 2 M, (b) 1 M, (c) 
0.5 M, (d) 0.33 M, (e) 0.25 M, and (f) 0.125 M CaCl2. The inset images are individual 
particles at high magnification (×8000). 









CaCl2 concentration            CHX precipitate                 Standard deviation 
                                           efficiency (%)                                (SD) 
2                                           99.1                                          0.02 
1                                           98.9                                          0.11 
0.5                                         98.7                                          0.05 
0.33                                       98.4                                          0.12 
0.25                                      97.4                                          0.01 
0.125                                     95.5                                          0.15 
 
      




Figure 4.3 SEM images of chlorhexidine compounds formed with (a) NaCl, (b) KCl, (c) 
MgCl2 and (d) ZnCl2. 
The spherical chlorhexidine particles made form chlorhexidine diacetate and CaCl2 were 
characterized by Fourier Transform Infrared Spectroscopy (FTIR). Compared to the spectrum 
of chlorhexidine diacetate which was used for particle synthesis, the typical band of C=N for 
chlorhexidine was shifted from 1610 cm-1 to 1621cm-1 (Figure 4.4). The reported position for 
the amine group stretching vibration for chlorhexidine dihydrochloride was 1651cm-1. 194 There 
was a distinct intensity increase at 3118, 3303 and 3190 cm-1, which was assigned to the 
stretching vibration N-H of the groups Alkyl-NH-Aryl and (Alkyl)2NH and the group =NH.28 
The band shift and intensity change was due to the electron density change for the =NH group, 






mechanism for the formation of the radiating interconnected structure is however still unclear, 
but similarly Cu2+ coordinated chlorhexidine complexes were reported and the chelation 
mechanism was well studied.28-29  
 
Figure 4.4 FTIR spectra of chlorhexidine diacetate and spherical chlorhexidine compounds. 
The elemental analysis of chlorhexidine spheres also confirmed the presence of Ca2+ in the 
structure (data not shown). Since the spheres were washed more than 3 times with NaCl 
solution to get rid of the residual Ca2+, we assumed that the Ca2+ was bound in the spherical 
structure instead of physically absorbed on the surface. Moreover, by mixing chlorhexidine 
diacetate solution with 0.33 M Ca(NO3)2, a similar interconnected spherical structure was 
observed (Figure 4.5). This structure was however coarser and the dendrites were thicker. 
Therefore, combining the EDX results with the FTIR spectra, we assume that coordination of 





 Figure 4.5 SEM images of chlorhexidine compounds formed with Ca(NO3)2. 
 
The chloride ions may play a vital role in the formation of the chlorhexidine spheres.  
Chlorhexidine diacetate has a relative low solubility in H2O, and the presence of Cl- in solution 
accelerated the precipitation. When a highly concentrated CaCl2 solution (2 M) was added, 
turbidity was immediately observed, while more time was required to precipitate with the 0.125 
M CaCl2 solution. Chlorhexidine solubility was highly dependent on salt type and 
concentration of the solution, as demonstrated by previous studies.30 Since the addition of 
sodium gluconate into solution would improve chlorhexidine diacetate solubility, while the 
presence of chloride would reduce it.6  
Therefore, we conclude that the formation of spherical chlorhexidine particles with 
homogeneous size distribution is a combined function of chloride anions and the counterpart 
cations (Ca2+ in our case). The chloride anions may help to reduce solubility of chlorhexidine 
and the rate of formation of the interconnected structures, while the cations are responsible for 






The structure of the spherical chlorhexidine particles was further analyzed with powder XRD. 
There was a clear change in the 2 theta positions (missing peaks, peak shifts, peak broadening) 
and the peak intensities, when the chlorhexidine compounds were compared to the 
chlorhexidine diacetate powder (Figure 4.6), indicating a different polymorph and crystallite 
size. The inset SEM image of the chlorhexidine diacetate crystal also confirmed a morphology 
and size which was completely different from the finer, porous interconnected spherical 
chlorhexidine particles. The crystal structural differences in the new compounds were therefore 
in evidence, with crystals growing dendritically from a nucleation site central to the structure. 
 Figure 4.6 XRD of spherical chlorhexidine compounds (lower) and chlorhexidine diacetate 




4.1.1.2 Spherical chlorhexidine particles 
Temperature is a key factor which determines the nucleation and crystal growth. In the present 
study, temperature was explored from 1°C to 25 °C. Figure 4.7 shows the influence of 
temperature on the morphology and size of the chlorhexidine spheres. As the temperature 
increased, the mean diameter (SD) of chlorhexidine spheres also increased from 5.6 (1.5) µm 
(1 °C) to 21 (5.3) µm (25°C). No distinct difference in the particle morphology was observed 
at this temperature range.  There was a correlation (r2 = 0.95) between particle diameter and 
temperature according to Figure 4.8. It is not surprising that higher temperatures would have 
encouraged movement of ions and accelerated the heat transfer favoring increased crystal grow 
rates. The energy required for crystal growth was limited at lower temperatures. The solubility 
of chlorhexidine at lower temperatures may also effect the process/rate of nucleation and the 
kinetics of crystal growth. There is also the potential of particle coalescence (Ostwald ripening) 
in this system, driven by the reduction in interfacial energy when larger particles grow at the 




   
 
   
 
    
 
    
 
    
 




Figure 4.7 SEM images of spherical chlorhexidine particles precipitated with 0.33 M CaCl2 at 
different temperatures. The inset images are individual particles at high magnification (×8000). 
 
Figure 4.8 Mean diameter (SD) of spherical chlorhexidine particles precipitated with 0.33 M 
CaCl2 at different temperatures. 
 
4.1.2 Chlorhexidine spheres encapsulation 
4.1.2.1 LbL encapsulation of chlorhexidine spheres 
The LbL assembly of polyelectrolytes on the surface of crystalline drugs has been extensively 
studied to stabilize the drug and facilitate sustained release.195 Many of these drugs (anticancer) 
are insoluble in H2O, and coating with polymer shells may improve their solubility.196 The 
drugs were either originally charged or tailored with surfactants for polyelectrolyte 
deposition.197 Herein, the chlorhexidine spheres were porous with high surface energy which 
was necessary for sequential assembly of PAH and PSS to yield capsules. Some dissolution of 
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the drug was always accompanied with the LbL process. To reduce this, 0.33 M CaCl2 was 
used during the polyelectrolytes deposition, as Cl- may reduce the solubility of chlorhexidine 
in H2O.30 The SEM images in Figure 4.9, revealed the morphology change after each layer 
deposition on the particle surface. With the first PAH layer, the dendritic surface structure 
could still be identified. As the number of polymer layers increased, the shells became thicker 
until the chlorhexidine spheres were completely covered (Figure 4.9).  
LbL assembly on SiO2 (0.5-5µm) templates provides thin, smooth homogenous layers as 
compared with the rougher coatings on the chlorhexidine spheres.96 There are several 
explanations; firstly, the LbL assembly of PAH and PSS was carried out with 0.33 M CaCl2. 
The presence of divalent ions in the polyelectrolyte solutions had a fundamental effect on the 
conformation of polyelectrolyte molecules. The addition of small amounts of ions may help to 
rearrange the polyelectrolyte chains and form compact layers,198 while higher ion addition 
encourages loop formation.199 The 0.33 M CaCl2 added to PAH and PSS shielded their charge 
and may further cause shrinkage of the polymers. Thus the LbL assembly of polyelectrolytes 
in this state did result in thicker layers compared to LbL assembly without adding salts. A 
similar observation was found for capsule assembly using NaCl solutions.200 Secondly, 
complexation of chlorhexidine with PSS did lead to larger wall thickness. Although the LbL 
assembly process was carried out in CaCl2, the dissolution of chlorhexidine spheres could not 
be avoided. The dissolved chlorhexidine molecules may have diffused through the 
polyelectrolyte shells and formed complexes with the PSS layer, as the sulfonic group of PSS 
could interact with the amine group of chlorhexidine. According to the cross-sectional image 
of the chlorhexidine capsule, the shell thickness (SD) was 1.02 (0.25) µm (Figure 4.9). The 
driving force for polymer absorption is mainly electrostatic interactions, and hydrogen bonding 
and hydrophobic interactions could also be responsible.197 It was also suggested that polymer 
chains had a low diffusion rate and less entropy loss, enabling a high affinity to crystalline drug 
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surfaces.201  The outermost positively charged layer of the chlorhexidine capsule may help to 
attract gram negative bacteria and thus enhance the antibacterial properties. 
 
Figure 4.9 SEM images of spherical chlorhexidine particles coated with 0-7 layers of polymers. 
The inset images are individual particles at high magnification (×8000); Image 8 is the FIB 
SEM image showing the cross-section of the chlorhexidine capsule. 
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The chlorhexidine capsules were further characterized with confocal microscopy when the 
chlorhexidine particle was labelled with RhB and the PAH labelled with FITC. The 
chlorhexidine particles were still intact after encapsulation (Figure 4.10b) and thick polymer 
shells were present (green circles, Figure 4.10a). The overlay images (Figure 4.10c) indicated 
that PAH/PSS had penetrated into the porous chlorhexidine particles, which was in agreement 
with the FIB /SEM results. According to the inset image of fluorescent intensity, that red 
fluorescent intensity was strong, whilst the green fluorescent only appeared at the surface 
(Figure 4.10d). It was a strong evidence of how the PAH and PSS were deposited on the 
chlorhexidine spheres. Chlorhexidine dissolution during LbL was calculated by measuring the 
UV-Vis absorption of the supernatant from each layer. Chlorhexidine did dissolve during the 
LbL assembly process, but only 3wt % was lost after depositing 7 layers. Similarly, confocal 
microscopy was also used to observe the preservation of fluorescein diacetate crystals from 
LbL assembly.202 
Figure 4.10 Confocal images of chlorhexidine capsules. (a) FITC labelled PAH capsule shells 
in green channel, (b) RhB labelled chlorhexidine in red channel, (c) overlap image showing the 
capsule/chlorhexidine relationship, (d) fluorescent intensity across the capsule; the inset 
images are individual capsules at high magnification. 


































    




4.1.2.2 Sustained release of chlorhexidine from LbL capsules 
Release kinetics from the capsules was a result of the solubility of the drug, architecture of the 
polymer multilayers, and the sink condition.195 In the present work, the release of chlorhexidine 
from the uncoated spherical particles or capsules was carried out in both H2O and PBS. The 
cumulative release curves are presented in Figure 8. Without coating, the chlorhexidine 
particles were completely dissolved in H2O within 1 hour, with all the chlorhexidine released. 
In contrast, the PAH/PSS coated chlorhexidine particles showed a burst release (2 hours) 
followed by sustained release, and after 7 hours there was still 15 % chlorhexidine within the 
capsules (Figure 4.11a). The release kinetics for chlorhexidine capsules in PBS was even more 
sustained, since only 2 % chlorhexidine was released from the capsules after 7 hours. There 
was a linear relationship between chlorhexidine release and time (r2=0.99, Figure 4.11b). The 
sustained release effect was provided by the polymer multilayers, and it was even more obvious 
for some other insoluble drugs. For Paclitaxel nanocolloids, for instance, release rates after 8 
hours could be reduced from 80% (1bilayer of PAH / BSA) to 40%, by the addition of a second 
bilayer.107 However, for water soluble drugs, the influence of multilayer coatings was limited;  
with fluorescein crystal capsules with 18 layers resulting in the dissolution rate starting to level 
off within 10 mins.104 Besides the number of layers, the shell architecture also plays a vital role 
in drug release. The polyelectrolytes the authors used were PAH and PSS and they were 
assembled in the presence of 0.33 M CaCl2. Therefore, the multilayer shell was thicker than 
capsules described in the previous literature and less diffusible for small molecules.200 The 
mechanism of how the salt within the multilayer films changed the diffusion coefficient was 
demonstrated by previous study.203 It is thought that loops formed by polyelectrolytes at high 
ionic strength and tightly packed polymer layers were less diffusive to small molecules.203 In 
terms of the release kinetics in PBS, low release rate and linear release kinetics were mainly 
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ascribed to low solubility of chlorhexidine, as solubility of chlorhexidine was highly dependent 
on the salt present in solution.30 The Cl- and PO43- ions in PBS could greatly reduce solubility 
of chlorhexidine and it was more likely to saturate during the chlorhexidine release process. 
The influence of Cl- and PO43- ions on chlorhexidine release kinetics was demonstrated in 
another experiment by carrying out the release test in a series of descending Cl- and PO43- 
solutions (Figure 4.12). A remarkable reduction in chlorhexidine release was observed for 
solutions with Cl- or PO43- concentrations as low as 15.63 mM (Figure 4.12). Compared to the 
Cl-  solutions, the influence of PO43-  was even more obvious (at the same ion concentration), 
as the chlorhexidine release rate in Na2HPO4 was lower than that in NaCl. It was feasible that 
the phosphate ions formed aggregations with the PAH which hindered the diffusion of 
chlorhexidine. Phosphate ions were reported to bind with polyamine in aqueous solutions, via 
a defined hydrogen-bonded network, which was stabilized by electrostatic interactions.146, 204 
Therefore, a zero order chlorhexidine release in PBS was observed in our study. Similarly, 
PAH/PSS coated paclitaxel capsules had more sustained release in PBS and BSA solutions 
than in H2O.105 
Figure 4.11 Chlorhexidine release kinetics in H2O and PBS. (a) Release kinetics of uncoated 
spherical chlorhexidine particles (black line) and chlorhexidine capsules (red line), (b) Release 
kinetics of chlorhexidine capsule in PBS. Values are the mean of 3 groups and vertical bars 
represent the SD. 
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Figure 4.12 Chlorhexidine release kinetics in Cl- and PO43- solutions with different 
concentration. 
 
Theoretically, the microcapsule assembly from polyelectrolytes were porous and permeable 
for molecules with molecule weight less than 5  kDa.96 Chlorhexidine molecules (Mw= 625 
Da) may therefore be likely to diffuse out when stored in H2O, leaving the multilayer shells 
intact.  To illustrate this, the chlorhexidine capsules after the release experiment (H2O storage, 
7 hours) were characterized using SEM (Figure 4.13). The capsules appeared with the center 
collapsed, indicating that most of the chlorhexidine cores were dissolved and released from the 
capsules, leaving voids. The collapsed multilayer capsules remained intact and no obvious 
rupture was observed (Figure 4.13a). Since only 85% of chlorhexidine was released (Figure 
4.11a), the remaining drug (15%) inside the capsules suggests that they were not completely 
hollow, explaining the partially collapsed capsule morphology. PAH/PSS coated ibuprofen and 
PLL/heparin coated paclitaxel capsules similarly did not show complete drug release in 
previous studies.108, 205 The incomplete release of chlorhexidine from the capsules was most 
likely due to the complexation of chlorhexidine with PSS, as turbidity was observed when 
mixing chlorhexidine with the PSS solution. By analyzing the PSS and chlorhexidine mixture 
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with FTIR, the interaction between the sulfonic group of PSS and the amine group of 
chlorhexidine was confirmed (data not shown). The chlorhexidine and PSS mixture showed 
peaks at 1621, 3118, 3303 and 3190 cm-1 which indicated the chlorhexidine composition. The 
sulfonic group of PSS had peaks at 1184 and 1042 cm-1,206 which was also identified at the 
spectrum of PSS-chlorhexidine mixture.  
 
Figure 4.13 SEM images of chlorhexidine capsules after the release test (7 hours in water). (a) 
chlorhexidine capsules at low magnification, and (b) an individual capsule at high 
magnification. 
Confocal images for the labelled chlorhexidine capsules confirmed the intact polymer shells 
(Figure 4.14a) and residual chlorhexidine inside the capsules (Figure 4.14b).  The overlapping 
images illustrated that the residual chlorhexidine appeared trapped within the polymer shells 
(Figures 4.14c, d). This observation was consistent with our hypothesis that residual 
chlorhexidine formed complexation with PSS in the capsule shells. The highly coordinating 
ability of guanidinates of the chlorhexidine molecules could form stable complexes with 
polymers, which was studied in previous research.31 Chlorhexidine based resins or cements 
also show reduced release rates, due to chemical bonding of chlorhexidine to polymers.34, 207 
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In terms of capsules size, there was an average 2 µm swelling after 7 hours water storage, which 
was due to the increased osmotic pressure caused by dissolution of the chlorhexidine core. The 
chlorhexidine capsules have promising antibacterial applications in dentistry. For instance, 
they could be injected into periodontal pockets to treat infections,35 since conventional 
treatment methods such as chlorhexidine containing mouth rinses may not be able to reach 
these deep sites. Injection of chlorhexidine capsules into sites of infection could maintain a 
high local drug concentration and sustained release could also be achieved. Moreover, the LbL 
architecture could easily be changed to realize a more sustained local release and 
biocompatibility, which will be the focus of our future work. 
Figure 4.14 Confocal images of chlorhexidine capsules after the release test. (a) FITC labelled 
PAH revealing the green capsule shells, (b) RhB labelled chlorhexidine showing residual 
chlorhexidine, (c) overlap image showing the capsule/chlorhexidine relationship, (d) 
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fluorescent intensity across the capsule; the inset images are individual capsules at high 
magnification. 
 
4.1.2.3 PLA encapsulation of chlorhexidine spheres by spray 
Since the LbL encapsulation process is quite time consuming and dissolution of chlorhexidine 
always happens, one step encapsulation by spray-drying would be advantageous. Spray-drying 
has a higher drug encapsulating rate than any other methods, since all the dissolved substances 
will precipitate when the solvent evaporates. Therefore, in this part, chlorhexidine particles 
encapsulation was also carried out using the spray-drying method. Freezing dried chlorhexidine 
particles are mixed in PLA solutions (Roto Mix) and sprayed immediately to reduce the 
dissolution of chlorhexidine. The resulted encapsulated particles are presented in Figure 4.15. 
Without any chlorhexidine particles added, the spray dried PLA particles showed a collapsed 
morphology and there were pores on the surface of collapsed PLA particles (Figure 4.15a). 
When chlorhexidine particles were added at a 1:3 ratio to PLA solution, and spray dried, a very 
thin layer of PLA was revealed on surface of chlorhexidine particles. The typical needle-like 
surface structure of chlorhexidine particles could still be identified. Similar to the observation 
of control group, the layer of PLA covered on the surface was also porous (Figure 4.15b). When 
the ratio of chlorhexidine to PLA was reduced to 1:5, a thicker layer of PLA was deposited on 
the chlorhexidine particle surface, and the surface was relatively smoother (Figure 4.15c). The 
chlorhexidine to PLA ratio was tuned because a ratio higher than 1:3 more likely lead to 
aggregations of particles and a too low ratio would result in large amount of empty particles. 
From the view of spray-drying, once of the PLA solution was atomized, small droplets were 
formed in the air and the solvent of the droplet surface was first to evaporate. A fast evaporate 
of solvent from the surface would lead to solidifying of PLA from the solution and porous 
surface morphology. By replacing with a lower boiling point solvent (such as dichloromethane), 
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a more porous surface morphology could be seen (data not shown). With a further evaporation, 
the solvent in the middle of droplets also got dried, resulting a shrinkage in droplet volume and 
collapse of produced PLA particles.  For the solutions containing chlorhexidine particles, when 
atomized, solvent evaporation also started from the surface but for the droplets with particles 
inside, a further collapse was avoided. It explained why much solider particles were observed 
from the SEM images. But there were still collapsed particles presented which might due to 
the formation of empty PLA droplets. An increase of PLA concentration did help to enhance 
the encapsulation of chlorhexidine particles as thicker coating was observed. But it also leaded 
to an increase of aggregation of particles as the viscosity of solution was increased at the same 
time.  
The encapsulation of chlorhexidine particles was also presented by confocal images when the 
chlorhexidine particles were labelled with RhB (Figure 4.16). From the overlapped image, all 
the particles showed red fluorescence. Theoretically, only the PLA particles with chlorhexidine 
encapsulated would demonstrate fluorescence, but the debris also had a red signal which might 
be due to dissolution of chlorhexidine particles during the mixing procedure. As the 
chlorhexidine particles were dispersed in the PLA solution, the dissolved chlorhexidine would 
homogeneously distribute. Once atomized, there was chlorhexidine remaining in the empty 
PLA droplets, which leaded to fluorescent for empty PLA particles. However, the fluorescence 




Figure 4.15 SEM images of spray dried PLA particles. (a) control group without chlorhexidine 
particles added; (b) PLA encapsulated chlorhexidine particles at CHX to PLA ratio of 1:3; (c) 












Figure 4.16 Confocal images of PLA encapsulated chlorhexidine particles. 
 
4.1.2.4 Release kinetics of chlorhexidine from PLA capsules 
Release kinetics of chlorhexidine from the PLA encapsulated capsules was showed in Figure 
4.17. Similar to the release kinetics of LbL encapsulated chlorhexidine particles, the coating of 
PLA layer can significantly reduce the release rate. Without any coating, the chlorhexidine 
particles just dissolved within an hour. But with thin PLA coating, the release rate was much 
slower during the first hour and started to level off then, which after 5 hours there was 58.9% 
chlorhexidine released. When the thickness of PLA coating was increased, more sustained 
release was observed and release curve levelled off after 3 hours. It is assumed that with the 
coating of PLA, chlorhexidine diffusion is hindered and thicker the PLA layer, the harder for 
chlorhexidine to diffused out. Similar to the release principle demonstrated earlier with the LbL 
coating. However, since the PLA layer is hydrophobic, the chlorhexidine release rate was lower 
than that with a LbL coating. Also, the remaining chlorhexidine encapsulated in the particles 
after a few hours’ release test was also higher. It is explainable that since the PLA is 
hydrophobic while the polyelectrolyte layers are hydrophilic, chlorhexidine trapped in the PLA 
polymers will not be likely to diffuse out within a few hours. The release of remaining 
chlorhexidine would be dependent on the degradation of PLA polymers. As demonstrated in 




Figure 4.17 Release kinetics of chlorhexidine from encapsulated particles. 
 
The PLA coated chlorhexidine particles after release test were further characterized with SEM. 
As demonstrated in Figure 4.18, individual solid particles were still identified, however, some 
of the particles collapsed with only porous PLA shells remained. It was more obvious at a 
higher magnification, and for the solid particles, some collapse was also observed. It clearly 
showed that the chlorhexidine particles with a thin PLA coating were more likely released and 
these with thicker coating, more chlorhexidine was remained in the particles. It was also 
confirmed by the confocal images (Figure 4.19) that some of red rings were observed after 
release which indicated released particles and remaining PLA shells, while the other particles 
were still solid with strong fluorescence. Interestingly, all the debris was still fluorescent which 
was in agreement with our hypothesis that the release kinetic of this part of chlorhexidine was 
dependent on PLA degradation.  
































 Figure 4.18 SEM images of PLA encapsulated chlorhexidine particles after release. 
 
Figure 4.19 Confocal images of PLA encapsulated chlorhexidine particles after release. 
 
4.1.2.5 Chlorhexidine particles imbedding in HEMA-UDMA resin 
 
Once the chlorhexidine spheres were incorporated into resin composites or resin-modified 
glass-ionomer cements, antimicrobial properties are enabled, and actually this was extensively 
studied in the last decades by directly incorporating chlorhexidine diacetate crystals 39, 208. Here, 
chlorhexidine particles were incorporated into resin and the cross-section images of the filled 
resin discs are shown in Figure 4.20. As compact and irregular morphology characteristics of 
chlorhexidine diacetate crystals, the resin could not penetrate the crystals and clear boundary 
between drug crystals and resin was observed (Figure 4.20a). However, homogeneous 
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distribution of particles in resin was evidenced and the porous surface morphology of 
chlorhexidine particles allowed resin to penetrate and there was good coherence at the resin 
/particle interface for the UDMA-HEMA resin (Figure 4.20b). And no evidence of dissolve or 
damage of particles was observed, indicating that intact spherical chlorhexidine particles could 
be preserved during the incorporating process.  
 
Figure 4.20 Cross-section of resin discs with chlorhexidine diacetate (a) and spherical 




    
129 
 
4.1.3 Electrospinning PLA fibres with chlorhexidine spheres 
4.1.3.1 Fabrication of chlorhexidine fibres 
 
Chlorhexidine was incorporated into the PLA fibers by electrospinning. The SEM images of 
the fabricated fibers (Figure 4.21) indicate a regular fibrous structure. When the chlorhexidine 
particles were incorporated a beard-in-string structure was demonstrated, in which the spheres 
were connected by two ends, with one fiber end much thicker than the other. For the fibers with 
chlorhexidine particles, a very thin layer of PLA covered the particle surface and the 
interconnected structure could still be seen (Figure 4.21b). In contrast, when the chlorhexidine 
particles were encapsulated and electrospun into fibers, a rougher appearance was observed 
(Figure 4.21c). The mean diameter (SD) of the PLA fibers (control) was 1.35 ± 0.06 µm. When 
the content of the chlorhexidine was increased (from 0.5% to 25%) the diameter of fibers 
decreased, as demonstrated in Figure 4.22. There was no significant difference when the 
chlorhexidine content was below 10%. Further increasing the ratio to 25 % (wt/wt), the 
chlorhexidine particles significantly (p<0.01) reduced the fiber diameter to 0.96 ± 0.06 µm. 
After incorporating CHX, the mechanical properties of the PLA electrospun fibre mat were 
also decreased (Table 4.2). While, the contact angle test showed that wettability of fibers was 
not affected by particle incorporation (123.6±3.7o for control and 121.6±7.2o for 5.0 wt/wt 
CHX fibers). The uncoated and encapsulated chlorhexidine particles within the fibers could be 
clearly seen in the confocal images (Figure 4.23). The black shadow around the chlorhexidine 
particles in the merged images indicates the PLA layer (Figure 4.21 a2). The chlorhexidine 
particles were still intact after electrospinning and FTIR spectra confirmed the presence of 






 Figure 4.21 SEM images of electrospun fiber. (a) PLA fibers as a control; (b) fibers with 
chlorhexidine particles; (c) fibers with encapsulated chlorhexidine particles at a magnification 
of (1) 1000× and (2) 4000×. 
 
Figure 4.22 Mean (SD) diameter of the PLA fibers as a function of chlorhexidine particle 
content. 
 



























Table 4.2 Tensile properties of PLA fibers containing different amount of chlorhexidine. 
Sample name Young’s modulus 
(MPa)* 
Elongation at break (%) Strength (MPa) 
PLA fibre 31.32±5.85 30.43±2.38 1.55±0.14 
PLA fibre-0.5% CHX 25.63±3.06 11.89±1.73 0.70±0.05 
PLA fibre-1.0% CHX 10.47±1.14 13.84±0.41 0.37±0.02 
PLA fibre-5.0% CHX 11.75±1.81 13.40±0.63 0.36±0.02 
* Young’s modulus was calculated by the slope of the stress-strain curve at 1% strain 
 
According to previous research, the embedding of micro particles resulted in defects and 
notches in the fibers, but the diameter of the fibers was increased and mechanical properties 
enhanced 209-210. The addition of chlorhexidine particles in PLA fibers in the current study did 
not lead to obvious defects in the fibers, but it did have significant effect (when CHX loading 
was over 15 % wt/wt) on fiber diameter as a narrowing effect was observed at the distal end, 
adjacent to the particle. The addition of micro particles (calcium carbonate and HA particles 
until a 5 % addition) into electrospun polymer solutions previously increased their viscosity, 
and thus led to an increase of fiber diameters 209-210. However, the average fiber diameter was 
dramatically reduced by adding the chlorhexidine particles, which may be associated with the 
size and volume fraction of the introduced particles, as the diameter of chlorhexidine particles 
was much larger (17.15 ± 1.99 µm) than the electrospun fibers 91. Significant amounts of PLA 
were required to coat and penetrate these larger particles which may have drawn the fibers 
thinner. The shear force generated during electrospinning may be another explanation, which 
is strong enough to lead to deformation of spherical particles into ellipsoidal particles 211. Thus 
the proximal side of the fiber was always thicker than the distal side. These characteristics of 
the fibers also led to a mechanical property decrease (Table 4.2). As for the wettability of fibers, 
it is assumed that all the chlorhexidine particles were covered by a thin layer of PLA, so the 
hydrophilicity of fiber mesh was not affected. The chlorhexidine was also concentrated in the 
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particles instead of distributed freely all over the fibers, which may minimize the effect on 
wettability of fibers. 
 
Figure 4.23 Confocal images of: (a) PLA fibers with chlorhexidine particles; (b) fibers with 
encapsulated chlorhexidine particles (1) in the red channel and (2) merged images with the 
transmitted channel. Chlorhexidine particles were labelled with RhB and one of PAH layers 
was labelled with FITC; the yellow colour indicates the overlap of core and shell. 
 
4.1.3.2 Release kinetics of chlorhexidine from fibres 
The release profile of chlorhexidine from the PLA fibers containing the chlorhexidine particles 
was monitored over 650 hours (Figure 4.24). In H2O the fibers with chlorhexidine particles 
showed a burst release during the first day, with over 60% of the chlorhexidine released, after 
which a sustained release was observed. In contrast, the fibers with encapsulated particles 












much lower release rates compared to that in H2O, and chlorhexidine encapsulation again 
produced a lower but sustained release rate (Figure 4.24b).  
Figure 4.24 Release kinetics of chlorhexidine particle containing fibers in: (a) H2O and (b) PBS. 
The PLA fibers with chlorhexidine particles and encapsulated chlorhexidine particles had a 
chlorhexidine content of 5 % (wt/wt). 
 
The morphology of fibers after the release test in H2O are shown in Figure 4.25 (a-f). For the 
fibers containing chlorhexidine particles, most of the chlorhexidine was released and the 
collapsed spheres were observed (Figure 4.25a). The porous surface of the collapsed sphere 
revealed the original morphology, indicating that the PLA layer had been penetrated. Fibers 
containing encapsulated chlorhexidine particles retained more of their surface coating and 
chlorhexidine content in the collapsed spheres (Figure 4.25d). These observations were 
confirmed by confocal imaging, as in the fibers with chlorhexidine particles virtually no 
chlorhexidine was identified (little signal was detected at the red channel), and voids could be 
seen in the transmitted channel (Figure 4.25 b, c). However, for the fibers with encapsulated 
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(Figure 4.25 e, f). As for fiber release in PBS, most of the chlorhexidine remained in both of 
the fibers and corresponding SEM images and confocal images are not showed. 
 
Figure 4.25 SEM and confocal images of electrospun fibers after the 650 h release test. (a, d) 
SEM images of fibers with chlorhexidine particles and encapsulated chlorhexidine particles; 
(b, e) confocal images of fibers containing chlorhexidine particles and encapsulated 
chlorhexidine particles; (c, f) and shown in the merged transmitted channel.  
 
The encapsulation of chlorhexidine spheres by PLA or polyelectrolytes had a fundamental 
influence on chlorhexidine release kinetics in H2O, although both kinds of fibers displayed a 
burst release at the beginning and sustained release afterwards. In order to avoid dissolution of 
chlorhexidine crystals the electrospun solutions were freshly prepared, and fibers immediately 
spun. The dissolved chlorhexidine in the fibers may have caused the burst release at the 
beginning of the release experiment in water. Comparing the difference in the fibers containing 
 
a b c 
d e f 
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chlorhexidine particles and encapsulated chlorhexidine particles, it is clear that with 
polyelectrolyte shells it was harder for chlorhexidine to diffuse out. Mixing metronidazole with 
polymer solutions and electrospinning gave over 90% metroniodazole release from the fibers 
within the first two days. However, by pre-loading metronidazole in halloysite clay nanotubes 
a sustained release was achieved 90. Various carriers such as mesoporous silica or ZnO 
nanoparticles have been employed to load drugs before electrospinning into fibers to achieve 
sustained release 87, 212-213. Electrospinning the LbL encapsulated drug crystals demonstrated 
another approach, as the LbL shells were already proven to be effective to reduce drug 
dissolution and diffusion 107-108, and their drug loading rate is much higher than other carriers. 
Moreover, the release can be further tuned by adjusting the number of deposited polyelectrolyte 
layers and the type of polyelectrolytes.32 
 
4.1.3.3 Cytotoxicity and cell adhesion on chlorhexidine fibres 
 
Cytotoxicity of the fibers (containing particles) to the fibroblasts is shown in Figure 4.26. The 
fibers containing uncoated and encapsulated chlorhexidine particles with 0.5 % and 1 % (wt/wt) 
chlorhexidine were not toxic to cells over a period of 5 days, as there was no statistical 
difference (p>0.05) in cell viability between the PLA control and the two test groups. When 
the chlorhexidine content in the fibers was increased to 5 % (wt/wt), the fibers containing the 
uncoated chlorhexidine particles reduced the cell viability significantly over 1 day (p< 0.05) 
and more than 2 days (p< 0.01). While the fibers with encapsulated particles (5 % chlorhexidine 
loading ratio) showed better compatibility with cells, with slight cell viability reduction at day 
2 and day 5 (p< 0.05).  
Cell adhesion to the fibers is another indicator of potential cytotoxicity, as demonstrated in 
Figure 4.27. The number of fluorescent cells on the thin fibers directly reflected the influence 
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of chlorhexidine content, with fewer cells on the 5 % (wt/wt) chlorhexidine containing fibers 
than those on the control PLA fibers. The cells appeared less spread out on the fibers and more 
round shaped cells were observed, which may suggest toxicity at 5 % (wt/wt) chlorhexidine 
content. Fibers with less chlorhexidine (0.5 and 1 % wt/wt) in the fibers, encouraged cell 
adherence to the fibers, with typically elongated cell filopodia extensions 90. A similar 
observation was made for fibers with encapsulated chlorhexidine particles (data not shown).  
The toxicity of chlorhexidine to cells is dose and time dependent, and it was reported that 
chlorhexidine concentration over 1 µg/ml was toxic to 3T3 cells.214-215 The chlorhexidine 
content in the fibers with 5 % (wt/wt) encapsulated particles was 50 µg/ml, which showed no 
cytotoxicity after 24 hours. Though, cell viability slightly decreased over the 5 days, it still 
showed much better compatibility over fibers with uncoated particles. We can assume that by 
chlorhexidine particle encapsulation, the release kinetics is better governed, which ensures a 
safer performance. Previous work reported that drug crystals encapsulated by LbL shells could 
reduce toxicity and side effects,105, 216 and this is in agreement with the current study. 
Adherence of cells to the fibers was also evidence of good biocompatibility, as cells could 
adhere, bridge and communicate with the neighbouring cells on the fiber membranes, as 
revealed with SEM and confocal 3D imaging.90, 217 Therefore, the PLA fibers produced here 




 Figure 4.26 Cytotoxicity of chlorhexidine containing fibers with fibroblast cells (3T3). PLA 
fibers containing chlorhexidine particles (black) and encapsulated chlorhexidine particles (red). 
Values are the mean of 5 wells and vertical lines are SD, *p< 0.05 and **p< 0.01 indicate 
statistical differences compared to the control PLA fiber treated cells; ## indicates statistical 
differences between cells treated by fibers with chlorhexidine particles and encapsulated 
chlorhexidine particles (p < 0.01). 
 Figure 4.27 3D images of fibroblast adhesion on PLA fibers containing chlorhexidine particles 
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4.1.3.4 Antimicrobial activity of chlorhexidine fibres 
 
Antibacterial activity of the fibers against E. coli is presented in Figure 4.28. The diameter of 
clear zone is an indication of the inhibitory effect of the chlorhexidine containing fibers, with 
higher chlorhexidine ratio in the fibers leading to large inhibition zones. No inhibition against 
E. coli was observed for the control PLA discs. For fibers with chlorhexidine particles, large 
inhibition zones were observed for all the fiber discs with chlorhexidine ratio at 0.5, 1 and 5 % 
(wt/wt), and higher chlorhexidine loading rates resulting in larger inhibition zones. In contrast, 
the inhibitory zones were only observed at 1 and 5 % (wt/wt) for the fibers with encapsulated 
chlorhexidine particles, which resulted in much smaller inhibitory diameters (p<0.01).  
 Figure 4.28 In vitro inhibition of chlorhexidine containing fibers against E. coli using an agar 
diffusion assay. PLA fibers containing chlorhexidine particles (black) and encapsulated 
chlorhexidine particles (red), and fibers without chlorhexidine were used as a control, **p< 
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The sustained inhibition effect against E. coli was demonstrated by a transfer experiment 
(Figure 4.29). The chlorhexidine burst release (uncoated particles) within one hour inhibited 
proliferation of E. coli in LB broth suspensions over the next 24 hours. For the control 
(untreated bacterial suspensions), the bacteria proliferated and a turbidity around 0.8 was found 
after 24 h (green line). However, 5 % (wt/wt) chlorhexidine in both the fiber containing 
chlorhexidine particles and encapsulated chlorhexidine particles completely inhibited bacterial 
growth even after nine transfers (black line, Figure 4.29 a, b). When the chlorhexidine content 
in the fibers was reduced to 1 % (wt/wt) (red line), no inhibition was observed for the fibers 
with encapsulated particles and the inhibition effect against E. coli depleted quickly after 4 
transfers for fibers containing the chlorhexidine particles. Similar observations were displayed 
for the fibers with 0.5 % (wt/wt) encapsulated chlorhexidine particles (blue line). 
 
Figure 4.29 In vitro inhibition of chlorhexidine containing PLA fibers against E. coli using a 
broth transfer assay. Chlorhexidine loading rate in fibers containing; (a) chlorhexidine particles 
and (b) encapsulated chlorhexidine particles were 0.5 % (blue), 1 % (red), and 5 % (black) 
(wt/wt); PLA fibers without chlorhexidine were used as a control (green) (n=3). 
 






































































Substantial inhibition of the proliferation of bacteria was demonstrated by the agar diffusion 
inhibition assay. Different bacterial strains have different sensitivities to chlorhexidine 
concentration, and the minimum inhibitory concentration (MIC) for E. coli is 2-8 µg/ml 86. At 
lower concentrations, chlorhexidine only interferes with the metabolism of the bacteria 218. As 
demonstrated, fibers with 0.5 % (wt/wt) chlorhexidine particles still indicated inhibition against 
E. coli, and the inhibition diameters were substantially affected by the diffusion manner of 
chlorhexidine in agar. For the fibers containing encapsulated chlorhexidine particles, the 
dissolution and diffusion of chlorhexidine was effectively hindered, and thus the inhibitory 
zone of bacterial growth was significantly smaller than the fibers with chlorhexidine particles. 
Similarly, the sensitivity against E. coli was reduced, as proven by comparing chlorhexidine 
particles and encapsulated chlorhexidine particles at equivalent doses (Figure 4.30). This was 
consistent with the LB broth transfer results that indicated a sustained inhibitory effect against 
E. coli for the fibers containing encapsulated chlorhexidine particles at a high chlorhexidine 
loading ratio (5% wt/wt). However, for 0.5 % or 1 % wt/wt chlorhexidine concentrations, no 
inhibition against E. coli was observed within one hour transfers (Figure 4.29 b). Bacterial 
inhibition may be therefore based on contact between chlorhexidine and the bacterial cell 
membrane, with complete isolation of chlorhexidine particles through encapsulation reducing 
the chance of direct contact between chlorhexidine particles and E. coli, regardless of whether 
it was dissolved or not. For localized treatment of infections, a sustained release of antibacterial 
agents is preferred, and thus controlled release by chlorhexidine encapsulation could be 
beneficial. More interestingly, a combination of uncoated chlorhexidine particles and 
encapsulated chlorhexidine particles in the same fibers may lead to a burst release at the 
beginning and more sustained release in the long term, which is attractive for the treatment of 
bacterial infections 2. However, to validate the performance of chlorhexidine PLA fibers in our 





Figure 4.30 Inhibition of (a) chlorhexidine particles and (b) encapsulated particles against E. 
coli., and (c) comparison of inhibition diameters as a function of chlorhexidine concentration. 
10 µl CHX solutions with different amount of CHX content (50, 25, 10, 5, 2.5, 1, 0.5 µg) were 
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In this part, a new structure of the commonly used antimicrobial drug chlorhexidine diacetate 
was fabricated by co-precipitation with CaCl2. By adjusting the concentration of CaCl2, 
homogeneous and interconnected spherical chlorhexidine particles were produced, with 
chlorhexidine content within the particles as high as 90%. Moreover, the size of chlorhexidine 
spheres could be tailored from 5.6 µm to over 20 µm by controlling the temperature of the 
original solutions. However, with other salts, no of these perfect structures was observed, which 
we can conclude that both the Cl- and Ca2+ ions were responsive for the formation of the 
interconnected structure, as it was confirmed by the FTIR. It is advantageous to have these 
homogeneous drug crystals, first of all, as secondary fillers in dental materials (resin and resin 
composites), the size is a very important factor. Also it opens up possibilities for further 
functionalization of the chlorhexidine particles, which leads to a more controllable and 
responsive release.  
Therefore, the spherical chlorhexidine particles were further encapsulated with different 
polymers, LbL polyelectrolytes, PLA and the HEMA-UDMA resin, using different techniques. 
Firstly, the spherical chlorhexidine particles were encapsulated by LbL self-assembly, which 
oppositely charged PAH and PSS were deposited on their surface, forming multilayer shells. 
The depositing of polymers on the surface changed the surface morphology as layers of flakes 
were observed assembly on their surface until the needle-like structure was completely covered. 
By cutting the encapsulated particles with focus ion beam, the thickness of polyelectrolyte 
shells was around 1.02±0.25 µm. The coating of polymers did stabilize the chlorhexidine 
spheres and lead to a sustained release over 7 hours, while the uncoated ones just dissolved 
within an hour. Though the LbL assembly approach could produce perfect encapsulation, 
which every chlorhexidine particle was encapsulated, and the coating was even and 
controllable by just adjusting the number of layers, it was quite time consuming. A one-step 
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encapsulating approach is desirable, so the spray-drying was carried out. By mixing the 
chlorhexidine particles with PLA solutions and spraying, a layer of PLA was successfully 
coated on the surface, and generally, the thickness of PLA layer could be tuned by tuning the 
chlorhexidine to PLA ratio. With higher chlorhexidine to PLA ratio (1:3), the PLA layer was 
quite thin and increasing the reducing the ratio to 1:5, thicker PLA layer was deposited. As a 
result, chlorhexidine particles with a thick PLA coating demonstrated a more sustained release 
than the thin coated ones, than the uncoated ones. This method was fast and productive, but 
compared to the LbL encapsulated, the resulted particles were not so perfect. Though the 
chlorhexidine to PLA ratio was tuned, the thickness of PLA coating was not even and 
aggregations could not be avoided. Also, due to the fast evaporation of organic solvent, there 
were always pored formed on the PLA layer which leaded to the burst release at the beginning. 
Another shortage was the occupancy of the sprayed particles, that empty PLA clusters were 
always appeared regardless of the chlorhexidine to PLA ratio.  
On the other hand, both the uncoated and LbL encapsulated chlorhexidine particles could be 
electrospun in PLA fibers to enable the fibers with sustained antibacterial properties. The 
incorporation of chlorhexidine particles into fibers greatly improved the drug loading ratio, and 
more sustained release was achieved by pre-encapsulating chlorhexidine particles with 
polyelectrolyte multilayers. Both fibers showed no cytotoxicity to fibroblasts at low 
chlorhexidine loading rate (from 0.5 % to 1 % wt/wt), and by encapsulating the particles, 
biocompatibility was significantly improved at 5 % (wt/wt). Similar results were illustrated by 
3D imaging of cell adhesion on the fibers. Both fibers showed good inhibition against E. coli 
growth in the agar diffusion assay, and sustained antibacterial effect via broth transfer 
experiments (5 % wt/wt). Therefore, the developed PLA fibers containing chlorhexidine 
particles may have promising applications for the localized treatment of infections. By 
incorporating the chlorhexidine particles into fibers, it is easier to hand and place them to 
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specific site which is a big advantage to treat infections. The encapsulated particles in the fibers 
should also allow a tailored drug release, that might be matched to the disease stages, to allow 
a more effective and responsive treatment. 
As a most commonly used antibacterial drug in dentistry, the chlorhexidine particles were 
incorporated into HEMA-UDAM resin discs, which had the potential to be used as restorations. 
The release of chlorhexidine and more detail are demonstrated in section 4.2.  
Overall, the spherical chlorhexidine particles can be encapsulated or embedded into many 
polymer matrixes to achieve a sustained release and antibacterial activity. The process of 
chlorhexidine particles fabrication is simple, and it is also possible to make further 
functionalization to the interconnected structures and achieve stimuli responsive release, which 












4.2 External stimuli responsive chlorhexidine formulation 
4.2.1 NIR light stimulus responsive chlorhexidine release  
4.2.1.1 Gold nanorods synthesise 
 
Based on the seed mediated growth method, the homogeneous gold nanorods used are shown 
in Figure 4.31a. According to the TEM image, the gold nanorods have an average length of 85 
nm and width of 20 nm. UV-vis NIR spectroscopy of the gold nanorods (Figure 4.31b) 
displayed their absorbance peak at 840 nm. The surface plasmon resonance band was largely 
dependent on the shape and ratio of length to width of the gold nanorods, their surface 
properties, as well as the mediums surrounding the particles.126-127 The plasmonic properties of 
gold nanorods make them promising candidates in light responsive drug delivery, since they 
have great photothermal conversion ability and their absorption band in the near infrared range 
is especially preferred for in vivo applications.219  
 
 






4.2.1.2 Effect of Gold nanorods on chlorhexidine crystal growth 
In a previous study, it is reported that chlorhexidine spheres, with homogeneous size and 
morphology, were produced, and proved that the crystal growth of the drug spheres could be 
tuned by temperature and ion concentration. In Medicine and Dentistry24 a more sustained and 
stimuli responsive chlorhexidine delivery system against bacteria is also desirable. This could 
be achieved by combining the chlorhexidine spheres with the gold nanorods. As demonstrated 
in Figure 4.32, gold nanorod functionalized chlorhexidine spheres were synthesized by 
introducing the gold nanorods into the CaCl2 solution. Without gold nanorods, the 
chlorhexidine spheres had a porous interconnected surface morphology, which were comprised 
of small dendrites (Figure 4.32b). In contrast, for the gold nanorods functionalized spheres 
(with 400 µl Nanorods), gold was clearly observed in the backscattered images (Figure 4.32c), 
and at high magnification small gold nanorod clusters were present on the chlorhexidine 
dendrites (Figure 4.32d). The incorporation of gold particles into drug delivery carriers has 
been extensively studied. For instance, hollow gold nanospheres were loaded into PLGA 
microspheres together with paclitaxel, via a double-emulsion solvent evaporation method, and 
the paclitaxel release was modulated by using a NIR light.220 Gold nanorods and doxorubicin 
were incorporated into crosslinked poly(β-amino ester) particles, with the glass transition 
temperature (Tg) close to body temperature. Therefore, transformation of the polymer from a 
glassy to a rubbery state induced by an NIR light produced an instant burst release of 
doxorubicin.221 For both examples drug release benefited from enhanced diffusion through the 
polymer networks. The choice of polymers with either a lower Tg  or high thermal sensitivity, 
such as poly(N-isopropylacrylamide) (PNIPAm),166 is essential for the design of NIR 
responsive drug carriers. The incorporated gold nanorods in the chlorhexidine drug crystals 
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have the potential to generate heat upon NIR light irradiation, and thus deconstruct the 
interconnected drug crystals and induce chlorhexidine release. 
 
 
 Figure 4.32 SEM and BSEM images of gold functionalized chlorhexidine particles. (a) BSEM 
image of chlorhexidine sphere at ×10,000; (b) SEM image shows the surface morphology of 
chlorhexidine sphere at ×40,000; (c) BSEM image of gold-chlorhexidine composites at 
×10,000; (d) SEM image shows the surface morphology of gold-chlorhexidine composites at 
×40,000. 
 
To further understand the role of gold nanorods in chlorhexidine crystal growth, different 
amounts of gold nanorods was dispersed into CaCl2 solutions. Figure 4.33 illustrates the 
influence of gold nanorods on the size of chlorhexidine spheres. Without the addition of gold 







of gold nanorods produced a slight size reduction of 22.9 (4.6) µm. The average chlorhexidine 
sphere diameters gradually decreased on increasing addition of gold nanorods, with a 400 µl 
gold nanorod addition giving a mean (SD) diameter of 14.5 (1.6) µm. There was a correlation 
between the amount of gold nanorods added and the mean chlorhexidine particle diameter 
(r2=0.98, Figure 4.34a). SEM images indicated there was no distinct difference in the 
morphology of chlorhexidine spheres at different gold nanorods addition. The chlorhexidine 
precipitation efficiency (>98%) was also similar for all the samples (data not shown). In terms 
of the particles size distribution, with less gold nanorods added, the size distribution was 
broader (data not shown).  When increasing the amount gold nanorods however, the 
chlorhexidine spheres were more homogeneous. The crystallisation of the chlorhexidine 
spheres involves a rapid nucleation and crystal growth process, so it is likely that the gold 
nanorods in the solution may act as sites for crystallization. This is supported by the data in 
Figure 4.34b where chlorhexidine particle number and size was correlated with the amount of 
gold nanorods added to solution (r2=0.98, Figure 4.34a, r2=0.98, x from 0 to 200, Figure 4.34b). 
The remaining weight of functionalized chlorhexidine spheres also increased as a function of 
increased amount of gold nanorods as indicated by the TGA result (data not shown). Gold 
nanoparticles were previously used as seeds to produce hybrid silica particles,147 and CdSe/ZnS 
quantum dots were also used to grow mesoporous silica shells on their surface.222 Therefore, 
we assume that the amount of gold nanorods in the solution was a key factor to determine the 
chlorhexidine sphere size and number. It was however noted that any excess gold nanorods 
could cluster and be trapped in the crystals, as showed in Figure 4.35. It is a common approach 
to control crystals size by adjusting the seed amount in nanoparticle synthesis. Similarly for 
gold nanoparticle synthesis, the mean particle size can also be tuned, with the mean particle 
size decreased with increased seed concentration, and at low seed and gold precursor ratio, 
large particles and secondary nucleation were observed.123 Interestingly, gold nanorods can 
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also be replaced by other nanoparticles (e.g. Fe3O4 nanoparticles), and the same effect on 
chlorhexidine crystallization has been demonstrated by the authors. The current 
functionalization of chlorhexidine crystals with Gold or Fe3O4 nanoparticles also opens up a 
door for its stimuli responsive release. 
 
Figure 4.33 SEM images of gold-chlorhexidine composites with different amount of gold 
nanorods. (a) no gold nanorods; (b) 5 µl; (c) 50 µl; (d) 100 µl; (e) 200 µl; (f) 400 µl gold 
nanorods (0.45 mg/mL). Inset images are individual particles at high magnification (×8000).  
 
a b c 




Figure 4.34 Effect of gold nanorod addition on the size and number of chlorhexidine particles. 
(a) Mean chlorhexidine particle diameter as a function of gold nanorod amount; and (b) Mean 
chlorhexidine particle numbers as a function of gold nanorod amount. 
 
Figure 4.35 BSEM images of gold-chlorhexidine composites with different amount of Au 
nanorods loaded. (a) no Au nanorods; (b) 5 µl; (c) 50 µl; (d) 100 µl; (e) 200 µl; (f) 400 µl Au 
nanorods.  
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In a parallel experiment, small chlorhexidine spheres were used as primary particles instead of 
gold nanorods to further reveal chlorhexidine crystallization. This was achieved by keeping the 
original chlorhexidine diacetate and CaCl2 solutions in an ice bath and carrying out the 
synthesis to produce primary chlorhexidine particles with a mean (SD) diameter of 5.2 (1.7) 
µm (Figure 4.36a), while chlorhexidine spheres synthesized at room temperature had a mean 
(SD) diameter of 17.2 (1.9) µm (Figure 4.36b). By introducing the chlorhexidine primary 
particles into the CaCl2 solution, growth of a second shell of chlorhexidine crystals were 
successfully achieved. FITC labelled chlorhexidine primary particles were presented as the 
core (green label, Figure 4.36a, c) and the new shells grown from the interface around the 
primary particles were visible when labelled with RhB (red label, Figure 4.36 d, e). At the 
transmitted channel, a clear boundary between the chlorhexidine primary particles and outside 
shell was identified (Figure 4.36f). These observations suggest a seed mediated crystallisation 
of chlorhexidine crystals, which supports the previous hypothesis. Similarly, the mean particle 
diameter of the chlorhexidine spheres decreased as the amount of primary chlorhexidine 
particles increased (date not shown). The chlorhexidine particle size distribution also narrowed 
at increasing primary particle concentration (Figures 4.37). An epitaxial growth on the surface 
of the primary seed crystal may also be likely and is present in other systems where the 





Figure 4.36 Confocal images of core-shell chlorhexidine spheres. (a) chlorhexidine primary 
particles produced in an ice bath (labelled with FITC); (b) large chlorhexidine spheres produced 
at room temperature (labelled with RhB); core-shell chlorhexidine particles produced based on 
the small chlorhexidine primary particles at (c) green channel, (d) red channel and (e) merged 
image; (f) at transmission channel.  
 
 
a b c 
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 Figure 4.37 Effect chlorhexidine seeds amount on the size of chlorhexidine spheres (dash line 
indicates the size of the chlorhexidine seeds).  
 
4.2.1.3 Mechanism of chlorhexidine growth  
Theoretically, the growth of nano/micro particles involved two main stages: rapid nucleation 
to form primary seeds and sustained growth of precursors on the primary seeds.224 The 
formation of homogenous interconnected chlorhexidine spheres was a very rapid process, 
which was dependent on the type and concentration of ions and temperature of the bulk 
solutions, as proposed in our previous study.225  Herein, with gold nanorods or chlorhexidine 
primary particles, the chlorhexidine particle forming process is presented schematically in 
Figure 4.38. At the first stage of synthesis, when chlorhexidine diacetate was mixed with CaCl2, 
monomers were formed immediately following basic coordination chemistry of guanidines.31 
The biguanidines of chlorhexidine have strong coordination capability with ions, such as Cu2+, 
Zn2+ or Ag+.28-29 According to the inset FTIR spectrum (Figure 4.38), the typical chlorhexidine 
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band of C=N was shifted from 1610 cm-1 to 1621cm-1 and N-H stretching vibration of the 
Alkyl-NH-Aryl, (Alkyl)2NH and =NH at 3118, 3303 and 3190 cm-1 was distinctly increased.28 
This is evidence that Ca2+ had coordinated with chlorhexidine. The presence of Cl- may also 
help to accelerate the precipitation of these complexes since the Cl- ion is thought to reduce 
chlorhexidine solubility.30 Interestingly there was a homogenous and copious distribution of 
Ca2+ and Cl- in the chlorhexidine spheres via EDX mapping (Figure 4.39). Therefore, the 
addition of CaCl2 to the chlorhexidine diacetate solution facilitated the formation of 
chlorhexidine nucleation and monomers for crystal growth. The addition of gold nanorods or 
chlorhexidine primary particles in the solution, appears to have encouraged surface 
crystallization to produce more primary crystallites. Research on the growth of mesoporous 
silica shells on gold nanoparticles, indicates the ratio of gold nanoparticles to silica precursors 
was a key factor to determine the gold occupancy and cluster sizes for the synthesized 
composites.148 This could explain why gold was only detected in the backscattered SEM 
images for samples with excess addition of gold nanorods. At more reduced additions of gold 
particles crystallization sites were favoured, while excess gold particles could lead to 
flocculation and clusters observed on the chlorhexidine sphere surfaces. In addition, the 
negatively charged gold nanorods may have a high affinity to positively charged chlorhexidine 
molecules, which encouraged crystallization of chlorhexidine on their surfaces. This is 
advantageous as coating of gold colloids with silica requires a surface modification using a 
silane coupling agent  to make them vitreophilic.145, 147 For the second stage, growth of 
chlorhexidine spheres proceeded via continuous deposition of monomers on the primary 
particles. This process was monitored by labelling the chlorhexidine primary particles and 
chlorhexidine monomers with different dyes and a core-shell structure was displayed (Figure 
4.36). At low temperature, chlorhexidine crystal growth rate was limited, so small (5.2 ± 1.7µm) 
crystals were produced. Once the primary particles were transferred into solutions with 
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monomers, crystal growth continued until the chlorhexidine monomers were depleted. There 
was also evidence of Ostwald Ripening, as the sacrifice of small particles and bridging between 
particles was observed in the SEM images of the chlorhexidine precipitates at different time 
intervals (10, 20, 30, 40, 50 and 60s) (Figure 4.40). 
 
 
Figure 4.38 Schematic illustration of chlorhexidine crystallization. Gold particles (red) and 
small chlorhexidine spheres (green) were used as seeds for chlorhexidine crystals growth; inset 
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 Figure 4.39 EDX mapping of elements distribution on the chlorhexidine sphere.  
 Figure 4.40 SEM images of chlorhexidine crystal growth as a function of time. 
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4.2.1.4 Infrared laser induced release of chlorhexidine  
 
LbL encapsulation of drug crystals is an efficient approach to achieve sustained drug release 
and improve the solubility for some anticancer drugs.108, 196 The advantage of drug colloid 
encapsulation over other delivery methods is the high drug loading rate since the cores consist 
of the drug, and their toxicity can be reduced at the same time compared to the equivalent free 
dose.216 LbL encapsulation of the chlorhexidine composites was necessary to stabilize the 
interconnected structure as the spheres were sensitive and could be dissolved in H2O within a 
few minutes. Successful encapsulation of the chlorhexidine spheres was achieved by carrying 
out the assembly at moderate conditions and in high salt polyelectrolyte solutions. As presented 
in Figure 4.40a, the chlorhexidine sphere cores still remained intact after encapsulating 6 layers 
of polyelectrolytes (shells appear in green). The overlapped images indicated that the 
polyelectrolytes had penetrated into the porous chlorhexidine sphere surface (Figure 4.41a). 
Compared to the conventional LbL capsules, the polymer shells here were much thicker, which 
was due to the deposition of polyelectrolytes at high salt concentration, and also chlorhexidine 
dissolution during the LbL process.200 The shell thickness of the chlorhexidine capsules was 
1.02 µm according to a cross-sectional measurement  in our previous study.225 SEM images 
showed that the chlorhexidine capsules had completely coated the chlorhexidine structure and 




Figure 4.41 Confocal images of gold functionalized chlorhexidine capsules before (a) and after 
laser irradiation (b). One of the PAH layers is labelled with FITC (green) and the chlorhexidine 
particles were labelled with RhB (red). Arrows indicated the remaining polyelectrolyte shells 
and inset images are taken at high magnification. 
 
Gold nanorods have a strong photothermal conversion ability,135 so it was assumed it would be 
possible to trigger the release of functionalized chlorhexidine capsules with NIR light 
irradiation. Using an 840 nm NIR light (up to 100 mW) with our laser setup, the chlorhexidine 
capsules could be ruptured while the others stayed intact (Figure 4.41b). Once targeted by the 
laser beam, the capsule erupted and the exposed chlorhexidine spheres dissolved, as a result 
only polyelectrolyte shells remained as indicated by the arrows in Figure 4.41b. There was 
however still some weak red signal detected within the residual shells, indicating residual 
chlorhexidine. This was due to complexation between the chlorhexidine molecules and the PSS 
layer via an interaction of its amine group and sulfonic group of PSS.  
b
a
green red transmitted overlap
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According to the transmitted channel images, debris around the broken polyelectrolyte shells 
was also observed and confirmed by the SEM images (Figure 4.42a, b). It was not surprising 
that the gold nanorod functionalized chlorhexidine capsules were responsive to NIR light since 
the chlorhexidine crystals were directly grown on top of the nanorods. The energy generated 
by NIR light irradiation was able to disrupt the chlorhexidine crystal structures. In a previous 
study of silica coated gold nanoparticles, the surface temperature of gold particles was 
suggested to be more than 100 ºC upon laser irradiation.226-227  The local heating by using NIR 
light irradiation was therefore a more efficient trigger for drug release than simply heating the 
solution to an equivalent temperature.141 Gold nanoparticles deposited into polyelectrolyte 
capsules previously revealed rupture of the capsules upon laser irradiation,228 even with a  SiO2 
layer deposited on the surface of capsules, which allowed snap intracellular cargo release.139 
Since the chlorhexidine crystal growth is based on the coordination of Ca2+ and biguanidines, 
heat generated by gold nanorods could interrupt the binding and even cause a conformational 
change of chlorhexidine molecules, thus leading to destruction of the crystals.  
 
Figure 4.42 SEM images of gold functionalized chlorhexidine capsules after laser irradiation. 
Untreated capsules were still intact but laser triggered ones were broken with polymer shells 





Local heating of gold nanorods may also accelerate dissolution and diffusion of chlorhexidine 
molecules. According to the in vitro release kinetics (Figure 4.43), chlorhexidine release 
occurred in a stepwise fashion after each cycle of laser treatment. A burst release was observed 
during each laser irradiation cycle. In contrast, the released chlorhexidine content during each 
cycle for the control was lower, although both groups exhibited a sustained release. 
 
 
Figure 4.43 Cumulative release of chlorhexidine from capsules with (red) and without (black) 
NIR light irradiation. Five cycles of NIR light on (30 min, 100 mW) were indicated by grey 
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The proposed chlorhexidine capsules with high drug loading rate and NIR light responsive 
properties have advantages and promising applications in medicine and dentistry. Many current 
products used in dentistry have a limitations due to lack of controlled drug release and 
duration.35 The gold nanorod functionalized chlorhexidine capsules are useful as they may be 
injected into sites such as periodontal pockets. As the periodontitis disease is caused by 
biofilms which are highly resistant to antimicrobial agents, a burst release triggered by NIR 
light is essential to eliminate the pathogens, which cannot be achieved otherwise as the 
minimum bactericidal concentration (MBC) is hardly be reached without any triggers. Any 
bacteria remained may cause a secondary infection, and the non-invasive approach of NIR light 
induced release can open up ways to solve this problem.  Photodynamic therapy using a diode 
laser is used in conjunction with a photosensitizer to decrease or eliminate bacteria229 and it 
may be possible to combine these therapies to increase its efficacy. The in vitro NIR light 
induced chlorhexidine release and their antibacterial activities will be evaluated in our future 
work.  
 
4.2.2 Magnetic field responsive chlorhexidine release 
4.2.2.1 Fe3O4 nanoparticles synthesis 
 
TEM image of synthesized Fe3O4 nanoparticles was showed in Figure 4.44. It can be seen that 
diameter of the nanoparticles was around 20 nm and they were not monodispersed as appeared 
in clusters. These nanoparticles were stored under argon protection to prevent oxidation and 








Figure 4.44 TEM image of Fe3O4 nanoparticles. 
 
4.2.2.2 Fe3O4 nanoparticles functionalization of chlorhexidine spheres 
 
When the Fe3O4 nanoparticles were added, similar results were produced. Without Fe3O4 
nanoparticles added, the mean diameter (SD) for particles was 17.15 (1.99) um, while the Fe3O4 
nanoparticles functionalized chlorhexidine spheres had a mean diameter (SD) of 10.39 (2.61) 
um. According to the images at high magnification (×40000), clusters Fe3O4 nanoparticles 
could be observed (Figure 4.45a). The presence of Fe in the chlorhexidine spheres was further 
confirmed by XRD analysis as shown in Figure 4.44b, c. The peaks of Fe were strong and 






Figure 4.45 SEM image (a) and EDX (b, c) of Fe3O4 nanoparticles functionalized chlorhexidine 
spheres. 
 
4.2.2.3 Magnetic controlled chlorhexidine release from HEMA-UDAM resin 
 
The Fe3O4 nanoparticles functionalized chlorhexidine spheres were freeze dried and the 
powder was incorporated into HEMA-UDMA resin composites. The continuous cross-section 
images of resin discs were joint together to make panoramic images and were presented in 





were intact with resin penetrated into the porous surface of chlorhexidine spheres. No 
dissolution of chlorhexidine spheres was observed as clear boundary of chlorhexidine and resin 
was presented. For the control group resin disc (Figure 4.46a), the chlorhexidine spheres were 
homogeneously distributed inside the resin discs. Whilst, when treated in magnetic field for 5 
min, the magnetic chlorhexidine spheres moved to the end of magnet, which resulted more 
chlorhexidine spheres at the magnet end (Figure 4.46b). The closest two frames in the 
panoramic had significantly more chlorhexidine spheres than the most far away two frames 
which no chlorhexidine spheres were identified. It was even more dramatic when extending 
the magnetic field treatment time to 10 min that most of the magnetic chlorhexidine spheres 







Figure 4.46 Cross-section SEM images of HEMA-UDMA resin with Fe3O4-CHX spheres. (a) 
control without magnetic field treatment; (b) with magnetic field treatment for 5 min; (c) with 
magnetic treatment for 10 min.  
 
 
Figure 4.47 Distribution of Fe3O4-CHX spheres in HEMA-UDMA resin as a function of 
magnetic field treatment. (a) control without magnetic field treatment; (b) with magnetic field 
treatment for 5 min; (c) with magnetic treatment for 10 min. 
 
 

































































According to the numbers of magnetic chlorhexidine spheres counted in each of the frames, 
their distribution was plotted as a function of distance to magnet (Figure 4.47). As for the 
control resin disc, the chlorhexidine spheres were homogeneously distributed so that numbers 
of spheres in each frame were quite even with average of 5 % particles in each frame. Though 
the first frame at the bottom was slightly higher with 8.4 % particles (Figure 4.47a). For the 
resin disc with 5 min magnetic field treatment, half of the magnetic chlorhexidine spheres 
distributed in the first three frames near the magnet with 22.9%, 20.8% and 7.1% for the first, 
second and third frames respectively.  The rest of frames had an 2.5% average chlorhexidine 
spheres distribution (Figure 4.47b). The magnetic effect was most dramatic for the 10 min 
treatment group that 38% and 19.3% of magnetic chlorhexidine spheres was located in the first 
and second frames near the magnet, and the half of the resin disc at the other end of magnetic 
field had almost no chlorhexidine spheres distributed, though one or two particles were rarely 
seen (Figure 4.47c). 
Release kinetics of chlorhexidine from HEMA-UDMA resin discs was showed in Figure 4.48. 
Generally, the release of chlorhexidine had two stages, with a fast release at the beginning 125 
hours and a more sustained release afterwards. For the control group, the release is the most 
sustained, with 4.4 % of chlorhexidine released at the end of 650 hours. With 5 min magnetic 
field treatment, the release was accelerated, and there was 5.9% chlorhexidine release at 650 
hours. The release kinetics for the 10 min treatment group was the most dramatic, that there 







 Figure 4.48 Release kinetics of chlorhexidine from HEMA-UDMA resin as a function of 
magnetic field treatment. (black line) control without magnetic field treatment; (red line) with 
magnetic field treatment for 5 min; (blue line) with magnetic treatment for 10 min. 
 
 
4.2.3 Ultrasound triggered chlorhexidine release from HEMA-UDAM resin 
The release process of the chlorhexidine from spherical particles filled UDMA-HEMA resin 
was much slower than that from chlorhexidine diacetate filled resin (Figure 4.49). Without any 
triggers, chlorhexidine diacetate filled resin discs released 16.2% chlorhexidine (Figure 4.49a, 
black line), in contrast, the chlorhexidine spheres filled resin discs had only 7.7% chlorhexidine 
released (Figure 4.49b, black line) 































The effect of ultrasound on chlorhexidine release kinetics was significant, which the longer 
sonication duration, the higher release rate was observed. By 650 hours, chlorhexidine release 
rate for chlorhexidine diacetate incorporated resin discs were 23.5% (10s), 42.6% (20s), and 
51.2% (30s), while 9.8% (10s), 12.3% (20s), and 14.0% (30s) for chlorhexidine spheres resin 
discs. And chlorhexidine diacetate crystals were more sensitive to ultrasound, which once the 
ultrasound treatment was stopped (at 205h, as indicated by red arrow), the release curve 
levelled off, whilst the spherical chlorhexidine compounds did not show so obvious trend. 
Figure 4.49 Release kinetics of chlorhexidine diacetate (a, c) and chlorhexidine spheres (b, d) 
contained UDMA-HEMA resin discs. Repetitive ultrasound treatment of 0 s (black), 10 s (red), 
20 s (blue) and 30 s (green) and terminated at the 205h (a, b); And without ultrasound treatment 
(black), sonication for 30 s only at the beginning (red), sonication for 30 s twice at the 0h and 
205h (blue), and sonication for 30 s three times at the 0h, 205h and 425h (green) (c, d). Red 
arrows indicated the point of termination of sonication (a, b) and each ultrasound treatment (c, 
d). 










































































































































To further demonstrate the sensitivity to ultrasound and to control the release kinetics of 
chlorhexidine from UDMA-HEMA resin discs, ultrasound was only carried out at some 
specific time intervals (0h, 205h and 425h). The release kinetic of resin discs for each 
ultrasound treatment was illustrated in Figure 3c and d. For the chlorhexidine diacetate resin 
discs (Figure 4.49c), influence of sonication was dramatic that once treated for 30 s at the 
beginning, burst release was observed (indicated by first arrow), and when second treatment 
was applied (at 205h for 30s), more dramatic burst release was showed (indicated by second 
arrow), and the same jump of the release curve at 425 h could be seen when third sonication 
was applied. In comparison, chlorhexidine spheres contained resin discs were less sensitive to 
the sonication (Figure 4.49d), that no significant increase in release was observed for the first 
sonication, though obvious release curve jumps at 205 h and 425 h were also illustrated. These 
results demonstrated the ability to produce a burst or slow controlled/graduated release with 
the chlorhexidine compound within a resin.  
The release profile of chlorhexidine from resin composite was a complicated process, which 
dissolution of drug may be ascribed for burst release only at the beginning, while the sustained 
release profile is dependent on Fickian diffusion 34. This result was consistent with the previous 
studies that chlorhexidine and other antimicrobial agents had relatively higher release rate from 
methacrylate polymers 41, 230, which more than 50% of chlorhexidine could be released, while 
less than 5% was released from glass ionomer cements over 30 days 207, 231. Similarly, increased 
chlorhexidine release rate was observed when hydrophilic components were increased and drug 
release had a correlation with the H2O sorption 41.  
Chlorhexidine release was also enhanced by ultrasound treatment for both the chlorhexidine 
diacetate and chlorhexidine spheres incorporated resin composites. With longer sonication 
(from 10s to 30s for each intervals), more chlorhexidine was released. And it was more obvious 
for the chlorhexidine diacetate crystals incorporated resin discs. It is feasible that micro 
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streaming induced by ultrasound was the main reason, which cavitation effect of ultrasound 
will be beneficial for fluid exchange which promotes the chance for chlorhexidine to diffuse 
out 232. As aqueous channel/pathway is needed for chlorhexidine to leak out from resin 
composites, the influence of sonication on this process may be dramatic. In addition, thermal 
effect generated by sonication should also be taken into consideration. As indicated that 
influence of ultrasound on gentamicin release was equal to that caused by increasing 3℃ 115.  
We could assume that heat generated during sonication helped dissolution of chlorhexidine 
compounds in the resin composites. Besides, the size of incorporated chlorhexidine compounds 
also had influence on release kinetics as bigger chlorhexidine crystals were more sensitive to 
ultrasound triggers than the homogeneous spheres, more dramatic jumps on release curve were 
observed corresponding to each of the ultrasound treatment. 
Cross-section of chlorhexidine diacetate and spherical chlorhexidine compounds doped resin 
discs after 650 hours release were observed by SEM. As chlorhexidine was dissolved and   
released from the resin, voids could be observed. For the chlorhexidine diacetate incorporated 
resin, the dissolution of chlorhexidine started from crystal boundaries. The remaining 
chlorhexidine crystals were isolated in the cavity and small debris appeared (Figure 4.50a, no 
ultrasonication). In contrast, for the chlorhexidine spheres, the dissolution of chlorhexidine was 
started from the middle of particles, which voids were observed only at the central of particles 
and the particle/resin interface remained as intact as before. This was more obvious when 
comparing the discs with different ultrasound treatment duration. Longer ultrasound treatment 
lead to more chlorhexidine release and larger voids left in the middle of original particles 






Figure 4.50 Cross-section of resin discs with chlorhexidine diacetate (a) and spherical 
chlorhexidine particle (b) after release test.  
 
Confocal images of labelled chlorhexidine particles inside UDMA-HEMA film also revealed 
the similar chlorhexidine dissolve process (Figure 4.51). When the spherical particles were 
labelled with RhB, their distribution in the resin film could be observed, which at the red 
channel typical radiate needle structure was clearly seen. And before release, they were intact 
and had distinct edges. However, dissolution and release of chlorhexidine resulted in dark 
center in original particles, indicating that there was no chlorhexidine was there, though the 
interfaces of particles/resin remained distinct. The results further confirmed that dissolve of 
chlorhexidine was started at original particles center, and there was still large amount of 
chlorhexidine remained in the resin composite. 
 
 




Figure 4.51 Confocal images of UDMA- HEMA resin film containing spherical chlorhexidine 
particles before (a) and after release (b). 
 
4.2.4 Conclusion 
In this section, chlorhexidine particles with multiple responsiveness were produced. When the 
chlorhexidine particles were functionalized with gold nanorods, a NIR light responsive 
property was achieved. By introducing gold nanorods into chlorhexidine solutions it was 
possible to control the amount and size of chlorhexidine spheres. Formation of gold 
functionalized chlorhexidine crystals was demonstrated in a gold nanorod assisted 
crystallisation and Ostwald Ripening mechanism. This process was also demonstrated by using 
chlorhexidine primary particles control chlorhexidine crystallisation, which a core-shell 
structure was demonstrated. Encapsulation of the gold nanorod functionalized chlorhexidine 
crystals using LbL polyelectrolyte multilayers allowed a sustained release and stimuli 
responsive release when NIR light irradiation was used.  
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When replacing the gold nanorods with Fe3O4 nanoparticles, similar size reducing effect was 
observed. The advantage to have Fe3O4 nanoparticle incorporated into the chlorhexidine 
spheres was that the drug particles could be attracted with an external magnetic field, and 
moved to the site of interest. So the magnetic chlorhexidine particles were imbedded into 
HEMA-UDMA resin and attracted by magnetic field for different durations before light curing. 
The distribution of magnetic chlorhexidine particles was successfully manipulated with 
magnetic field that with longer treatment more chlorhexidine particles were distributed at the 
surface of resin discs, and thus leaded to a higher release rate.  
In addition, the chlorhexidine particles incorporated in the resin could be triggered with 
ultrasound. Compared to resin discs with chlorhexidine diacetate crystals imbedded directly, 
the resin with chlorhexidine particles showed a lower release rate, and upon ultrasound 
treatment, a more controllable burst release was demonstrated, which was beneficial for a safer 
performance in dentistry. 
Overall, it is promising to have a chlorhexidine release on demand, either with ultrasound, NIR 
light or magnetic field, because bacterial infection treatment is always a tough and complicated 
process. Generally, a burst release is always needed at the beginning to kill most of the bacteria 
at infection site and then a sustained activity to inhibit any potential growth. So if any secondary 
infection occurs, it is likely to achieve another burst release with external triggers to get rid of 
the bacteria. Combined with magnetic responsive properties, it is even more attractive as we 
can easily increase the local drug concentration by targeting delivery with magnetic field. For 
the biofilm treatment, a very high local drug concentration is needed, chlorhexidine particles 
have the potential to be navigated to biofilms and transport through their barriers and triggered 




5. Doxycycline delivery 
5.1 Local and sustained delivery of doxycycline 
5.1.1 Doxycycline encapsulation  
Small molecule drugs can be incorporated into microcapsules through electrostatic interactions 
following a post loading approach.99, 233 Doxycycline as a small molecular drug (structure 
showed in Figure 5.1a), in our study, was encapsulated by precipitating with DS (Figure 5.2). 
Typically, two types of capsule were assembled, synthetic capsules consisting of PAH/PSS 
layers and biodegradable ones composed of Parg/DS, both of which had DS in the interior for 
doxycycline loading (Figure 5.3a and d). Upon incubation, doxycycline penetrated the 
microcapsule layers forming a less soluble complex with DS in the core, as well as being 
trapped within the layers. The synthetic capsules became smaller in size and had a more 
protuberant structure after doxycycline loading (Figure 5.3 b), indicating that doxycycline-DS 
complex was formed in the core. Whilst, the biodegradable capsules did not undergo such 
notable morphological change, but according to the increased capsule shell thickness (Figure 
5.3 e), we could assume that more doxycycline was absorbed in the microcapsule walls. The 
principle of the complex forming was based on the ion paring ability of dextran sulphate, as 
indicated by the FTIR spectrum (Figure 5.1b), which was also used to promote minocycline 
loading efficiency in PLGA nanoparticles.4 Similar phenomenon was observed when 
ciprofloxacin was deposited into capsules, with a black shadow seen in the capsule interior 
under TEM and an increase in average capsule height by 500 nm.234 According to measurement 
of supernatants from encapsulation, doxycycline loaded in synthetic and biodegradable 
capsules was determined to be 5.4 pg and 4.8 pg per capsule, respectively. Doxycycline amount 
per gram of capsules was determined to be around 9.74 wt.% according to the net weight 
increase compared to the empty microcapsules. The results were confirmed by fluorescence 
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imaging, synthetic capsules with doxycycline had more blue fluorescence in the core, while 
blue fluorescence in biodegradable capsules was within the rings of microcapsule shells (Figure 
5.4) in both instances doxycycline is complexed with DS.                                                                  
 
 
Figure 5.1 Doxycycline and FTIR spectrum. Molecule structure of doxycycline (a), FTIR 
spectrum of doxycycline (blue), dextran sulfate sodium salt (black) and doxycycline-DS 
complex (red) (b).  
 
 
Figure 5.2 SEM and fluorescence image of doxycycline-DS complex (a, b). 
 
 
    












 Figure 5.3 SEM images of synthetic capsules (a-c) and biodegradable capsules (d-f), before 
being loaded with doxycycline (a, d), after loading with doxycycline (b, e), and coated with a 
lipid layer on the surface (c, f) (scale bar of 20 μm). The inset images are individual capsules 
at high magnification (×40000) (scale bar of 3 μm). 
 
 Figure 5.4 Fluorescence images of doxycycline-loaded synthetic capsules (a) and 
biodegradable capsules (b). 
 
      
      





Figure 5.5 Permeability of DPPC coated synthetic capsules to FITC (outmost lipid layer was 
labelled with Rhodamine B). 
 
Since the microcapsule shells are permeable, extra layers are often assembled to enable longer 
drug retention. Such layers are either more hydrophobic or have a denser meshwork. The 
phospholipids DPPC and lecithin were used as an outer layer for synthetic and biodegradable 
capsules respectively. As could be seen by changes in zeta potential (data not shown), the 
outmost DPPC coating altered the negative charge of PSS to slightly positive, which confirmed 
addition of the lipid layer on the surface. In addition, confocal images of capsules show red 
circles when the lipid was labelled with Rhodamine B. In the permeability test, the outer lipid 
layer also effectively hindered penetration of FITC through capsules. Whilst an incomplete 
lipid layer on the microcapsule surface only rendered them partially permeable to FITC (Figure 
5.5). These results provide evidence that microcapsule permeability was reduced by the lipid 
coating. SEM images of lipid coated capsules (Figure 2c and f) shows that DPPC, or lecithin 
coating smoothed the capsule surface (inset image), which was evidenced as a more compact 
outer shell was formed. Similar morphological changes were previously observed when 
biotinylated lipid was assembled on the surface of PAH/PSS capsules resulting in an 
uncollapsed structure.235 According to measurement of supernatants, doxycycline loaded in 
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DPPC-coated synthetic and lecithin-coated biodegradable capsules was 5.3 pg and 5.4 pg per 
capsule, respectively.  
 
5.1.2 Release kinetics of doxycycline 
Release kinetics of a drug from LbL assembled microcapsules is primarily dependent on 
physio-chemical properties of the polymeric shells200 and the binding characteristics between 
the drug molecules and capsules.233, 236 In our study, doxycycline was trapped by forming a 
complex with DS, and the release of payload was affected by both factors. Due to the porous 
structure of polymeric shells, doxycycline was able to diffuse through, but the capsules shell 
thickness, polyelectrolyte molecular weight and ionic strength of the medium all affect the 
diffusion rate.200 Changes in the ionic strength of solution alter the strength of electrostatic 
interactions within the microcapsule shell structure and in the binding between doxycycline 
and DS. By shaking in water, 0.15M NaCl or PBS, doxycycline release from all microcapsules 
was monitored, and the rate of doxycycline release from all microcapsules was PBS>0.15M 
NaCl>water (Figure 5.6). In low ionic strength solution, a tightly packed microcapsule 
structure is observed, but when the polymeric structure is transferred to high ionic strength 
solution, the charge of polymers is shielded and the rearranged microcapsule structure is more 
permeable to small molecules.203 With regards to doxycycline and DS binding, in water, there 
would be a stronger binding between the two molecules, due to charge interaction of negatively 
charged DS and amino groups of doxycycline, but PBS and NaCl might accelerate the 
dissociation of the DS-doxycycline complex via charge decoupling in salt solution. What 
facilitates release of free doxycycline from the capsule interior. And in general, the release of 
doxycycline from microcapsules was bi-phasic; a primary burst release within the first 40 
minutes and a slower secondary release after 40 minutes (Table 5.1). The first phase is relevant 
to detaching of more loosely bound doxycycline and second phase is salt induced dissolution 
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of complex between DS and doxycycline. In case of pure water the effect of different stage is 
less notable. By mixing the microcapsules with 2 M NaOH, all microcapsules disassembled186 
and all the encapsulated doxycycline was released immediately. After being centrifuged, 
doxycycline capsules without NaOH had yellow pellet at the bottom of tube (means 
doxycycline was still encapsulated in capsules). However, with 2 M NaOH added, there was 
no pellet but the dissolution was yellow. By measure the solution, 100% release rate was 
identified.  
The release kinetics were however slower when microcapsules were coated with a lipid layer 
as shown in Figure 3c and 3d. The retention of doxycycline with the lipid coated capsules can 
be attributed to lipophilic nature of doxycycline237 and to the hydrophobic barrier formed at the 
outmost capsule surface by phospholipids which would be less permeable aqueous solutions. 
A phospholipid outer layer seal was previously employed in the encapsulation of the small 
molecule drug doxorubicin.185 The difference in the release kinetics for lipid coated synthetic 
and biodegradable capsules may be due to the fact that lecithin, a natural phospholipid, is a 
heterogeneous molecule with a range of molecular weights which may prohibit the formation 




Figure 5.6 Kinetics of doxycycline release from microcapsules. Release profile of doxycycline 
from synthetic capsules (a), biodegradable capsules (b), synthetic capsules with DPPC coating 
(c) and biodegradable capsules with lecithin coating (d) in water, 0.15 M NaCl, and PBS. 
Values are the mean of 3 groups and vertical bars represent the SD. 
Table 5.3 Rate of doxycycline release rates from microcapsules in different solutions. Phase 1 
release is the kinetic in the first 40 minutes whilst phase 2 release relates to the kinetic during 
the subsequent 235 minutes. 
 
Doxycycline release rate 
(ug/min) 
In H2O                          In NaCl                    In PBS 
Phase1   Phase2      Phase1   Phase2      Phase1   Phase2 
Syn capsules                                        0.229    0.067         0.700    0.019       1.595    0.032 
DPPC coated syn capsules                  0.263    0.016         0.428    0.029       1.045    0.043 
Bio capsules                                        0.305     0.043        0.769    0.021       1.794    0.039 
Lecithin coated bio capsules               0.313     0.019        0.599    0.029       1.476    0.059 
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5.1.3 Local and sustained activity of doxycycline in Engineered C2C12 cells 
Viability of cells treated with doxycycline solution, synthetic and biodegradable capsules (w/o 
doxycycline encapsulated) is shown in Figure 5.7. Compared to the control group, cells treated 
with doxycycline solution (2.5 µg/ml) had a viability of 89% after 48 hours incubation. With 
both synthetic and biodegradable capsules, over 80% cell viability was observed at the same 
time point. In addition, no significant difference was observed between empty and doxycycline 
loaded capsules which was consistent with previous studies of capsule cytotoxicity in vitro and 
in vivo.20, 238-239 
 
Figure 5.7 Cell viability of engineered C2C12 cells incubated with doxycycline solution, 
synthetic and biodegradable capsules with and without (w/o) doxycycline. Values are the mean 
of six values and vertical bars represent the SD. 
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When reporter cells were treated with doxycycline solution or encapsulated doxycycline the 
different cell delivery routes impacts on the kinetics of EGFP expression from the tetracycline 
responsive promoter (Ptet). The promoter is activated by rtTA-2SM2 in the presence of 
doxycycline and is actively switched off upon removal of doxycycline through binding of the 
repressor tetRKRAB.  This tet-on system has shown high gene regulation efficiency in our 
previous study,50 and this was confirmed here. Confocal images were taken to assess whether 
doxycycline loaded capsules were internalized by myoblast cells and subsequently induce 
EGFP expression in C2C12 cells via the tet-on system. Synthetic capsules were incubated with 
cells for 2 days at a ratio of 10 capsules per cell, and the same amount of free doxycycline was 
used as control. As illustrated in Figure 5.8, EGFP expression was successfully switched on by 
doxycycline solution with homogenous fluorescence in every cell (Figure 5.8A). However, 
when delivered as cargo by microcapsules, doxycycline was released after cell uptake of 
capsules, so cells without internalized capsules had no fluorescence as indicated by red circles 
in Figure 5.8B. The results highlighted that doxycycline delivery from microcapsules can be 
targeted to specific cells via capsule internalization which then function in situ. 
To evaluate the efficiency of doxycycline delivered by capsules, cells were classified into four 
categories (Green/red, green, red and none – see methods for details) and the number of cells 
in each category was counted within the panoramic confocal image, and was presented as a 
percentage in Figure 5.9. The capsule uptake ratio by cells was about 70%, and doxycycline 
capsules induced EGFP expression was as high as 61.8% (shown as green and red in the 
histogram), but there were a small proportion of these cells with red microcapsules that were 
devoid of EGFP expression (8.9%). When no capsules were engulfed 18% of cells were not 
green as expected, but 11% were fluorescent. There are potential explanations for this 
observation, firstly, capsules were not visible in these cells (hidden under the nucleus); 
secondly, after cell division a daughter cell could contain EGFP but not a microcapsule from 
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the parent cell; alternatively, doxycycline could leak from extracellular microcapsules located 
nearby or in other cells. A similar phenomenon was observed when EGFP was delivered as 
cargo in capsules to A549 cells, when cells with no engulfed capsules had EGFP in the 
cytosol.144 As for the non-fluorescent cells that had internalized microcapsules, the absence of 
fluorescence may be due to capsules being devoid of doxycycline or containing an amount of 
doxycycline below the threshold to induce EGFP expression, though the baseline for 
doxycycline to switch on gene expression is known to be very low (1 pg/ml).50 Previous studies 
have tried to chemically modify doxycycline to achieve spatial and temporal gene expression 
regulation,54, 240 in which doxycycline was inactivated in a ‘cage’ so that transcription was only 
promoted after photo-activation. But, delivery by versatile microcapsule carriers is a preferable 
approach as minimum modification to molecular structure is introduced and side products of 
chemical reactions are not generated. 
Figure 5.8 Images of doxycycline induced EGFP expression. Cells treated with a solution of 
doxycycline (A) and doxycycline-loaded synthetic capsules (B) (capsules to cells ratio 10:1, 
incubate time 48 hours, red circles indicate cells that have no internalized capsules or EGFP 







Figure 5.9 Correlation of microcapsule delivery and EGFP expression in C2C12 cells. After 
incubation with doxycycline-loaded synthetic microcapsules that were labelled red due to use 
of TRITC labelled PAH cells exposed to doxycycline express EGFP. The distribution of cells 
in the four categories (Red/green: cells with microcapsules and expressing EGFP; Green: cells 
expressing EGFP but have no capsules; Red: cells with microcapsules have no EGFP 
expression; None: neither red or green) was determined by microscopic examination with 
results expressed as a percentage of all cells (total number 459). 
 
To demonstrate the sustained effect of doxycycline delivered by microcapsules, the kinetics of 
EGFP expression was monitored by fluorescence intensity change in long-term experiments. 
Four types of capsules, synthetic (PAH/PSS) and biodegradable (DS/Parg) were compared with 
their lipid coated counterparts. EGFP fluorescence intensity at specific time intervals was 
measured for each type of capsule. Cells treated with free doxycycline had the maximum 
fluorescence intensity at day 2 and declined to baseline values after 10 days (Figure 5.10a). For 
 






















all the capsule-treated cells, the fluorescence intensity increased and peaked on the fourth day, 
then fluorescence decreased gradually, and there were significant differences compared with 
the free doxycycline treated cells after the sixth day (p< 0.05). Doxycycline molecules are 
lipophilic enabling them to rapidly enter cells and induce gene expression, while microcapsules 
enter cells following membrane adherence, phagocytosis and macropinocytosis mechanisms, 
and are finally targeted to phagolysosomes95, 238 doxycycline released from microcapsules in 
these compartments can still penetrate lipid membranes but clearly the kinetics of nuclear 
delivery are slower than the free doxycycline. For the synthetic capsules, DPPC coating 
resulted in elevated and prolonged EGFP expression compared with the uncoated 
microcapsules (p<0.01) (Figure 5.10b). Whilst for the biodegradable capsules, the lecithin 
coating only improved expression from day 4 to day 8 (p< 0.01) (Figure 5.10c).  
The fluorescence intensity kinetics indicated that all doxycycline loaded capsules had a 
sustained effect in vitro, which was optimal with DPPC coated synthetic capsules. The EGFP 
fluorescence peak intensity was higher for lipid coated capsules than the uncoated ones. It is 
feasible that the DPPC lipid not only promoted microcapsule retention of lipophilic 
doxycycline but may also promote cell uptake of capsules.185, 241 If this is the case then higher 
levels of EGFP expression observed with DPPC coated capsules could, in part be attributed to 
a higher total doxycycline dose delivered to cells. For the lecithin coated biodegradable 
capsules, though, the in vitro release kinetics of coated microcapsules is more sustained than 
the uncoated ones, the EGFP kinetics are similar. It is feasible that digestion of outmost lecithin 
layer could limit lipid retention and result in a similar intracellular doxycycline release rate as 






 Figure 5.10 Kinetics of EGFP expression following delivery of free or encapsulated 
doxycycline. Cells were cultured in 96-well plates with 1×104 cells in each well and the 
following day were incubated with free doxycycline (a), doxycycline-loaded synthetic and 
DPPC coated synthetic capsules (b), and doxycycline-loaded biodegradable and Lecithin 
coated biodegradable capsules (c) at a ratio of 10 microcapsules per cell (n=7), medium was 
changed every two days, and after 2, 4, 6, 8, 10 and 12days cells were lysed and fluorescence 
intensity was measured with excitation at 488nm, emission at 520nm. Values are the mean of 
5 wells and vertical lines are SD, *p< 0.05, **p< 0.01, compared with free doxycycline treated 
cells; #p< 0.05, ##p < 0.01, compared between lipid coated and uncoated capsule treated cells. 
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The observations were further explored in a parallel experiment that monitored EGFP 
expression by confocal microscopy. As shown in Figure 5.11, the same amount of doxycycline, 
delivered by capsules could extend the duration of EGFP expression. For cells treated with free 
doxycycline, EGFP fluorescence began to decline after six days, and by the eighth day, dark 
nuclei appeared and only the cytoplasm was fluorescent. The decline of EGFP continued until 
to the twelfth day when no fluorescence was observed. For uncoated synthetic and 
biodegradable capsules, EGFP expression was maintained for twelve days, after which dark 
nuclei also appeared, and the decline in EGFP expression continued to day 34. EGFP 
expression was prolonged to eighteen days for the DPPC coated synthetic capsules, indicating 
that sustained release from engulfed capsules at levels sufficient to induce EGFP expression. 
As for the lecithin coated biodegradable capsules, the lipid layer did not dramatically enhance 
the duration of EGFP expression, which was similar to the duration of uncoated biodegradable 
microcapsules. Although a biodegradable or synthetic microcapsule structure can have a big 
influence on release of contents this is of less importance for the release of low molecular 
weight drugs which can pass through the microcapsule structure even in the intact state. 
However, release of low molecular weight doxycycline will be sensitive to permeability 
changes in microcapsules associated with degradation and digestion of the lipid layer. In our 
studies with myoblast cells, though some ‘intact’ biodegradable capsules were observed inside 
cells after 34 days, the degradation of the lecithin layer might have occurred much earlier.  As 
shown in previous research, 6-carboxyfluorescein could penetrate DPPC/DMPA lipid capsules 
immediately after partial hydrolysis by the enzyme phospholipase A2, while untreated capsules 
were impermeable. High-resolution surface force microscopy further revealed the increased 
capsule surface roughness after enzyme treatment.242 The combination of the versatility of LbL 
microcapsules and the sensitivity of the Tet-on system have enabled us to accurately monitor 
the delivery of doxycycline in a cellular system. From our previous investigations it should be 
188 
 
possible to include doxycycline into capsules engineered with nanoparticles or enzymes within 
the shells, so that release of doxycycline could be regulated in response to lasers, magnetism 
or in an endogenously responsive manner.19, 243 Magnetism could also be used to target 


































 Figure 5.11 Comparison of EGFP expression kinetics following delivery of free and 
encapsulated doxycycline to engineered C2C12 cells. Cells were incubated with free 
doxycycline (a), doxycycline-loaded (b) and DPPC coated (c) synthetic capsules, and 
doxycycline loaded (d) and lecithin coated (e) biodegradable capsules at a ratio of 10:1 as 
indicated. The free doxycycline concentration in culture medium was 2 µg/ml, and medium 
was changed every two days. Images were captured using Leica confocal microscope with 40× 
oil emersion objective. Microcapsules are labelled with TRITC and are red in images of 
microcapsule treated cells (scale bar of 75 μm). 
 
5.1.4 Antimicrobial activity of doxycycline capsules 
The activity of doxycycline in the C2C12 cell assay opened the possibility for delivering 
antimicrobial effects with LbL microcapsules. Since persistent infections are challenging to 
treat that overuse of antibiotics will lead to resistant bacteria,2 a deposit of sustained antibiotic 
release may be an attractive treatment approach for local infections. The sensitivity of E. coli 
growth to inhibition with doxycycline was initially demonstrated in a dose response experiment 
in which the relationship between diameter of clear zone and doxycycline concentration was 
pictured (Figure 5.12a) and plotted (Figure 5.12b). Clear zones in this assay show that higher 
doxycycline concentrations have greater inhibitory effect and the assay is sensitive to 
doxycycline concentrations as low as 40 µg/ml. The inhibitory zone against E. coli was 
dependent on the concentration of doxycycline, with more doxycycline diffused into the agar 
larger clear zones were formed. In the transfer experiment, free doxycycline (1 mg/ml) was 
devoid of any antimicrobial activity after 6 hours, whilst inhibitory activity for the 0.1 mg/ml 
solution was lost after 3 hours (Figure 5.12c). In contrast, doxycycline loaded microcapsules 
had more sustained antimicrobial effect, clear zones were still visible for all the microcapsules 
day2 day6 day10 day14 day18 day22 day26 day30  
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after 7.5 hours and for synthetic microcapsules with a DPPC outer layer activity persisted 
beyond 10.5 hours (Figure 5.12c). The kinetics of inhibition are plotted in Figure 5.12d, and 
clearly illustrate the sustained antimicrobial effect of doxycycline loaded microcapsules with a 
gradual decline in activity compared to the more rapid decline seen with doxycycline solutions. 
It is likely that diffusion of encapsulated doxycycline was more sustained because more liquid 
exchange was needed to detach doxycycline from microcapsule shells and the DS-doxycycline 
complex. Microcapsules may be particularly suited to topical application here their size permits 
them to reside around root hair cells244 and also in situations where prolonged local delivery of 
antibiotic is beneficial such as post-operative and dental applications. 























































Figure 5.12 Antimicrobial activity of doxycycline with an agar diffusion assay against E. coli. 
The sensitivity of E. coli growth to inhibition by doxycycline is shown by a dose response 
experiment pictured in (a) and the diameter of the growth inhibition zones for this experiment 
is plotted in (b). Pictures of plates following the sustained activity of doxycycline solutions (1 
and 0.1 mg/ml) and microcapsules in the transfer assay are shown in (c) and the change in 
diameter of the growth inhibition zones are plotted against time in (d) with water (black), 
doxycycline solutions of 0.1 mg/ml (blue) and 1 mg/ml (red), along with microcapsules - 

































































The results of this section illustrate that low-molecular-weight doxycycline could be 
encapsulated in LbL microcapsules via attraction to DS in the microcapsule core, and specific 
and sustained activity of doxycycline is observed in a gene expression system via the Ptet 
promoter and in an anti-bacterial diffusion assay. Slower release and sustained activity is 
enhanced by coating capsules with a lipid layer, which retards the leakage of doxycycline and 
may promote cell uptake as well. However, a lecithin coating was less effective for sustained 
release in vitro perhaps due to degradation by intracellular lipases. Sustained delivery of 
doxycycline with engineered microcapsules could provide an improved formulation for 






5.2 Alternating magnetic field (AMF) triggered release of 
doxycycline  
5.2.1 Magnetic capsules with doxycycline 
Negative charged iron oxide nanoparticles with average size of 13.0 nm were deposited as one 
layer of multilayered microcapsules, which resulted in a rough appearance according to the 
SEM images (Figure 5.13a). The electronic interaction was commonly used for 
functionalization of microcapsules with nanoparticles, though a directly growth and deposition 
of Fe3O4 nanoparticles on LbL multilayered shells was also reported.245-246 The inclusion of 
magnetic nanoparticles into microcapsules is beneficial for either targeted delivery of cargos 
of interest or a further external responsive release. Herein, the doxycycline molecules were 
loaded into the magnetic capsules via a post interaction with DS in the core.4 Compared to the 
empty capsules which displayed a flat morphology, the doxycycline loaded ones had a more 
protuberant appearance, indicating that doxycycline-DS complex was formed (Figure 5.13b). 
In addition, physically trapped doxycycline molecules between the shells may be another 
reason which changed the rigidity of capsules as shell thickness was increased. According to 









Figure 5.13 SEM images of magnetic microcapsule (a) before and (b) after loading with 
doxycycline. Inset images are individual capsules at high magnification. 
 
5.2.2 Capsules permeability change by AMF 
It is known that microcapsules are not permeable to molecules with molecule weight larger 
than 5 kDa,247 so here we used FITC labelled dextran (70 kDa) as model dye to monitor the 
permeability changes induced by AMF, and the microcapsules were labelled with TRITC. 
When microcapsules were mixed with FITC-dextran, theoretically, the dyes would be isolated 
by the capsules walls, resulting dark in the capsule cavity. According to the confocal images, 
the control capsules without AMF treatment has complete isolation for FITC-dextran (Figure 
5.14a), and with longer incubation (until 60 min), only one or two capsules were filled with 
green fluorescence. When the microcapsules were exposed to the AMF for 20 min, the number 
of dye penetrated capsules increased to 13.5%, and with longer AMF exposure, more capsules 
were permeable to FITC-dextran, from 18.1% at 30 min to 52.8% at 360 min (Figure 5.14b, c). 
However, most of the microcapsules were still intact after 60 min’s AMF treatment. The 




microcapsules showed no visible cracks or pores as shown in Figure 1a. After AMF stimulus, 
the microcapsules were still intact overall, but some cracks and holes on the capsules walls 
could be observed, which may be corresponding to the percentage of capsules which were 
permeable to FITC-dextran (Figure 5.14d). Besides, microcapsules also underwent slight 
shrinkage during AMF stimulus, as some free-standing capsules were displayed.  
The increased permeability induced by AMF was ascribed to the agitation of Fe3O4 
nanoparticles within the polymer shells. The nanoparticles twisted and vibrated in the 
corresponding frequency as the AMF, leading to the distortion of the polyelectrolyte 
multilayers and promoting the diffusion of FITC-dextran molecules into capsules. Different 
from the AMF used in the other studies, the frequency of which was as high as 300 kHz,23 the 
AMF used in our study was only 50Hz, so it was more likely to disturb the polymer shell 
mechanically and the energy generated was also limited. It has been reported that AMF with 
frequency higher than 300 Hz did lead to negligible permeability increase regardless the 
exposure time.178 The high frequency AMF is more likely to destroy the microcapsules 
thermally since the local heat generated by it was incredibly high. According to Hu et. al, a 10 
min exposure of magnetic capsules to 50-100 kHz AMF did result in numerous nanocavities 
up to 100 nm on surface of microcapsules, and 15 min stimulus directly ruptured the 
capsules.174 Some of the pores and small cracks were also observed in our study (Figure 5.14d, 
indicated by arrows). It was feasible that big aggregation of Fe3O4 nanoparticles in capsule 
shells would tried to align in the magnetic field, which caused large stresses to the capsule 
shells and thus resulted pores and cracks. Therefore, using of low frequency AMF may be a 





Figure 5.14 Permeability of microcapsule to dextran-FITC (70 kDa). (a) without and (b) with 
AMF treatment for 360 min, and (c) the percentage of microcapsules which were permeable to 
FITC-Dextran (70 kDa) as a function of AMF exposure time; (d) SEM image of microcapsules 
after AMF treatment for 360 min. Arrows indicate the defect of microcapsules caused by AMF. 
 
5.2.3 AMF triggered release of doxycycline  
As a small molecular weight drug, doxycycline is easy to diffuse from the microcapsules, and 
in our previous study, it has been proved that doxycycline release could be divided into two 
stages, dissociation of doxycycline-DS complex and doxycycline diffusion from the capsule 
walls.248 Therefore, factors such as ionic strength and polyelectrolyte shell composition would 
influence the release profile. In the case here, the AMF had a dominating effect on capsule wall 
permeability, and thus promoted the doxycycline diffusion. According to the release kinetics, 
 








































AMF did obviously accelerate doxycycline release from microcapsules, which 3% more 
payload doxycycline was release over 4.5 hours compared to the control group (Figure 5.15). 
To further evaluate the effect of AMF, another group of doxycycline loaded microcapsules 
were exposed at the 120 h, and an immediate increase in doxycycline release was displayed. 
As demonstrated earlier in with the FITC-dextran, AMF could facilitate the diffusion of big 
molecules into microcapsules. Since the molecule weight of doxycycline was much smaller, it 
was easy to diffusion even without any external triggers, so no dramatic burst release was 
observed. The result was in agreement with a similar AMF assistant doxorubicin release. 
According to their study, the doxorubicin release profile was divided into two stages, a slow 
and steady release stage was maintained when microcapsule structure was still integrity, while 
a burst release was occurred until the microcapsules were ruptured by the AMF.174  
 
Figure 5.15 Release kinetics of doxycycline from magnetic capsules with (blue line and black 
line) and without (red line) being exposed to AMF.  
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5.2.4 Local delivery of doxycycline by magnet 
Cell viability after incubated with free doxycycline, normal and magnetic microcapsules was 
presented in Figure 5.16. With 4 µg/ml free doxycycline, it showed slight toxicity, while 
microcapsules loaded with equivalent amount of doxycycline showed excellent 
biocompatibility. Either the normal or magnetic microcapsules were already proved to be 
biocompatible in vitro until the capsule to cell ratio was as high as 100 to 1.249 Compared to 
free doxycycline, the encapsulated drug would enter the cells via a routine which started with 
phagocytosis and micropinocytosis and finally reached the lysosomes.238 The carriers would 
protect the drug during the whole process and thus reduced its toxicity. However, the free 
doxycycline could diffuse quickly into cells and nucleus, and lead to cytotoxicity. It was 
evidenced by cells incubated with doxorubicin which the free drug molecules displayed 
significant red fluorescence in the nucleus within 30 min, whilst micelles with doxorubicin 
were only found in the cytoplasm up to 4 hours.18 When the cells with magnetic microcapsules 
internalized were exposed to AMF, no evidence of toxicity was displayed for cells treated for 
10 min and 30 min. However, when extending the AMF exposure time to 60 min, slight 
decrease in cell viability was displayed (87.3%, p<0.05), and further elongating it to 90 min 
and 120 min, cell viability was significantly reduced to 81.2% and 75.0% respectively (p<0.01).  
It is strongly evidenced that the low frequency AMF used in our study was friendly to cells, 
even after exposing for 60 min. Interestingly, as demonstrated in previous studies that a high 
frequency AMF (300 kHz) was used, the temperature of microcapsule bulk solution could 
reach 90 °C within 10 min exposure, which may be dangerous for intracellular drug delivery.23 
That is why the thermal effect was utilized for tuber ablation in which tumor cells were killed 
by the heat generated by external magnetic field. The local hyperthermia induced by high 
frequency AMF was able to significantly enhance the performance of doxorubicin to kill 4T1 
cells when it was delivered by magnetic PLGA microspheres.164 However, for drug delivery to 
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healthy cells and tissue, the local hyperthermia will be toxic, therefore, the low frequency AMF 
demonstrated in our study will be beneficial.  
 
Figure 5.16 Cytotoxicity of C2C12 cells (a) after treated with free doxycycline, doxycycline 
loaded normal and magnetic capsules, and PEI coated magnetic capsules; (b) with AMF 
exposure for different duration. Doxycycline concentration in each well was 4 ug/ml. *p<0.05, 
**p<0.01 compared to control group cells, n=5. 
 
Magnetically targeted drug delivery and gene transfection were of great interest to design high 
efficient carriers,250 and in fact, there are already magnetically in vivo targeted dene transfection 
demonstrated using liposomes.251 To further demonstrate to potential of microcapsules for 
targeted doxycycline delivery, the tet-on system was utilized to engineer the myoblast cells 
which acted as reporters of intracellular doxycycline activity. Basically, as showed in Figure 
5.17a, this tet-on system was based on the tetracycline responsive promoter (Ptet), which can 
be activated by rtTA-2SM2 and repressed by tetRKRAB. The magnetic microcapsules were 
added to cells chambers with a magnet placed at the bottom, so the doxycycline loaded capsules 














































were engulfed and released their cargos locally, and further intracellular activated the EGFP 
expression. The results were demonstrated by monitoring the microcapsules distribution and 
EGFP expression in the whole chamber. As illustrated in Figure 5.17b, the control group with 
no static magnet placed at the bottom of chamber had a random and homogeneous distribution 
of microcapsules and thus cells with green fluorescence. Since the tet-on system had shown 
excellent EGFP regulation capability in our previous study,248 it was certain here that the green 
cells located in the whole chamber were activated by microcapsules internalization. So if the 
magnetic microcapsules were attracted to the specific site, the EGFP expression could be 
activated locally. As displayed in Figure 5.17c, red microcapsules were only appeared at the 
site of magnet, and accordingly, only the cells at where there were microcapsules located had 
green fluorescence while cells at the rest of chamber were completely dark. We can conclude 
that local delivery and EGFP expression activation was achieved by exert of magnetic field, 
and no free doxycycline was located elsewhere away from the magnet, as the threshold for 
doxycycline to switch on EGFP expression is very low (1 pg/ml).50 It is an important 
observation that the magnetic microcapsule could be navigated with magnetic field and release 
their cargo locally while avoiding the unnecessary exposure of doxycycline to the other cells. 
It will be advantages for antibiotics delivery as the local drug concentration could be effectively 
increased without improving a systematic administration. In addition, the selectively switch on 
of EGFP expression also showed a potential for gene therapies as the expression of the gene of 










Figure 5.17 Magnetic control of GFP expression with magnetic microcapsules. (a)Schematic 
illustration of magnetic targeted delivery and vector used for C2C12 engineering; (b) control 
group without magnet targeting; (c) cells with magnet placed under the chamber. 
Microcapsules in red channel were labelled with TRITC and cells with doxycycline delivered 
had EGFP expression. 
 
 




Microcapsules were attracted by magnetic field, switching on EGFP expression locally
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5.2.5 Intracellular AMF-induced doxycycline release and EGFP expression 
To further demonstrate the possibility of intracellularly promoting the EGFP expression via an 
external AMF, the engineered myoblast cells with microcapsule internalized were exposed to 
AMF and lysed to examine the EGFP fluorescence intensity. Both the normal and magnetic 
microcapsules with different capsule to cell ratio were tested, and the PEI coating was to 
promote the cell internalization. According to Figure 5.18, cells with free doxycycline had 
significantly higher EGFP expression compared to equivalent doxycycline delivered by normal 
microcapsules at all ratios (p<0.05). This was due to the fast diffusion of free doxycycline into 
cells, while once encapsulated by microcapsules it was engulfed via an endocytosis pathway. 
However, the internalization of magnetic capsules was enhanced and the EGFP expression was 
significantly promoted at both 10:1 and 5:1 capsule to cell ratio (p<0.01). According to a 
similar observation in our previous study that magnetic capsules could promote luciferase 
delivery and increase cell transfection efficiency, it was because magnetic microcapsules had 
a higher sedimentation rate than the normal capsules, which was beneficial for the interaction 
of cells and microcapsules.249 At capsule to cell ratio of 1:1, there was no difference between 
these two types of capsules. In comparison, with PEI coated as the outmost layer, the 
doxycycline induced EGFP expression was further enhanced at all ratios (p<0.01). It was 
explainable that the strong positive charge of PEI enabled a rapid interaction between capsules 
and cells. Besides, the proton sponge effect of PEI could also promote the transition of 
doxycycline molecules from endosome to cytosol, which was also proved to be effective for 
plasmid DNA and siRNA delivery with microcapsules.13, 253 
Under the AMF, the intracellular doxycycline delivery was further enhanced, as an increase of 
EGFP expression was demonstrated (Figure 5.18, red and blue column). With an extension of 
AMF exposure from 10 min to 20 min, the EGFP fluorescence intensity also displayed an 
increasing tendency at all ratios. For magnetic microcapsules group, there was significant 
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difference between cells with and without AMF treatment at both 10:1 and 5:1 capsule to cell 
ratio (p<0.01), and for the PEI coated magnetic capsules, the promoted EGFP expression by 
AMF was also remarkable at the ratio of 5:1 (p<0.05). These results were consistent with the 
in vitro doxycycline release profile, indicating that the release of cargo intracellularly was also 
achievable via an external AMF. Increasing the AMF treatment time to 30 min did lead to 
higher EGFP expression intensity, however, it decreased when further extending the exposure 
time to 60 min and 90 min (Figure 5.18d). We can hypothesize that the applying of AMF did 
facilitate a fast diffusion of doxycycline from microcapsules and liberation from endosomes, 
but too longer AMF exposure man not be beneficial as it will damage the cells and reduce cell 
viability. It was clearly evidenced by confocal images that fluorescent doxorubicin was 
sequestered inside intracellular endosomes and no cancer cell death was induced, but until 
when AMF was exerted, the cell viability was dramatically reduced.254 However, different from 
the use of high frequent AMF, the hyperthermia effect of which could directly lead to in vitro 
cytotoxicity and in vivo tumor growth inhibition,164 the low frequent AMF used here had a 
much gentler effect and a safe performance for drug delivery could be ensured.  
The demonstration of navigated delivery of doxycycline with magnetic microcapsules, and 
subsequent AMF intracellular triggered release highlighted a perspective in in vivo drug 
delivery. Though, some studies have showed the possibility for targeted drug delivery and 
remote AMF triggered release in vivo using other carriers,164, 255-256 the microcapsules still show 
great advantages due to their versatility, and the intravascular delivery of microcapsules is also 
possible.257 Further studies will be carried out to seal the microcapsules to ensure a precise on-






Figure 5.18 EGFP fluorescence intensity of cells treated with free doxycycline, doxycycline 
loaded normal and magnetic synthetic capsules. Doxycycline concentration in each well was 4 
ug/ml (a), 2 ug/ml (b) and 0.4 ug/ml (c). Cells were exposed to AMF for 10 min and 20 min 
each well (a-c), and 30 min, 60 min and 90 min for (d). After which, cells were lysed and tested. 
* p<0.05, ** p<0.01, compared to normal capsules, # p<0.05, ## p<0.001, compared between 
no AMF treated and AMF treated cells, n=5. 
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A low frequent AMF in this section was proved to be effective to trigger doxycycline release 
from microcapsules without destroying their architecture or damaging the cells with 30 min 
exposure, and further up-regulate the EGFP expression via the tet-on system. The low frequent 
AMF enhanced the permeability of microcapsules as a function of exposure duration and 
induced more doxycycline release. Doxycycline delivered by magnetic microcapsules enable 
a specific site delivery and local function with static magnetic, while non-targeted sites 
remained unaffected. In addition, the local function was further promoted by the AMF. The 
targeted delivery of doxycycline and remote AMF enhanced activity open up exciting 





6. Conclusions and future work 
 
6.1 General conclusions 
 
Delivery of antibacterial agents with carriers is not a new concept that many systems were 
utilized ranging from micro/nano-particles (polymeric particles, nanogels, micelles, liposomes), 
electrospinning fibers to polymer films. These kinds of carriers did greatly improve the delivery 
efficiency and prolong the activity of antibacterial agents, and enhance their performance 
against bacteria. This work was intended to make a step further to enable a sustained and 
external responsive antibacterial agent delivery. Two different type of antibacterial drug, 
chlorhexidine and doxycycline, were delivered with layer-by-layer assembly microcapsules, 
spray PLA particles, HEMA-UDMA polymer matrix and electrospinning fibers to achieve a 
sustained effect. On the other hand, to facilitate an external trigger (NIR light and alternating 
magnetic field) responsive release, either the drug formulation or the carrier were 
functionalized with components, such as gold nanorods or magnetite nanoparticles. 
In the chlorhexidine chapter, a new formulation of chlorhexidine was produced taking 
advantage of the coordinating ability of chlorhexidine molecules. It was easy to precipitate 
chlorhexidine by mixing with a range of salts, however, the formation of homogeneous 
particles was dependent on the type and concentration of ions in the solutions. Combining 15 
mg/ml chlorhexidine diacetate solution with 0.33 M CaCl2 solution, spherical drug crystals 
with an interconnected structure were produced. The forming of this structure was due to the 
interaction of Ca2+ and Cl- with guanidine groups. Moreover, the size of chlorhexidine particles 
could be tuned from a few micrometers to over 20 micrometers by temperature. The advantage 
of this chlorhexidine formulation is the possibility of further modification. Used as templates, 
polyelectrolyte multilayers were deposited on the surface, which stabilized the drug crystals 
and prolonged the release kinetics. The solid chlorhexidine capsules with an average shell 
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thickness of 1.02 µm showed a high drug retention since chlorhexidine could interact with PSS 
layers. On the other hand, the encapsulation of chlorhexidine drug crystals was simplified with 
the spray-drying technique, which by mixing the chlorhexidine particles with PLA solutions 
and spraying, layer of PLA was deposited on the particle surface. The thickness of PLA shell 
depended on the concentration of PLA solution, and thus affected chlorhexidine release 
kinetics. The chlorhexidine spheres were also advantageous over the commercially used 
chlorhexidine diacetate, since a more sustained and controllable chlorhexidine release was 
demonstrated when both of them were incorporated into the HEMA-UDMA resin.  
More importantly, the formulation of chlorhexidine was possible to be directly functionalized 
with metal nanoparticles. With gold nanorods pre-added into the CaCl2 solution, the nanorods 
were incorporated into the interconnected structure. The presence of gold nanorods did affect 
the crystalline of chlorhexidine that with more nanorods in the system, chlorhexidine particles 
with a smaller size would be produced but the number of chlorhexidine particles were increased. 
The nanorods were likely to act as crystallization sites for chlorhexidine which was illustrated 
by using chlorhexidine seeds (5.2 µm) as primary particles for chlorhexidine growth and a 
core-shell structure was observed. Similarly, when gold nanorods were replaced with Fe3O4 
nanoparticles, size of resulted chlorhexidine particles was also reduced. It can be concluded 
that introducing of nanoparticles into the chlorhexidine system led to a surface crystallization 
and thus achieved a multi-functionalization, which opened possibilities for an external 
manipulated release. When the gold functionalized chlorhexidine particles were focused by 
NIR light, local heating of drug crystals led to rupture of solid chlorhexidine capsules and 
chlorhexidine release, and step-wise chlorhexidine release was demonstrated with NIR light 
illumination. This strategy offered a novel way to control the release of chlorhexidine upon 
demand. Also, the magnetite nanoparticles functionalized chlorhexidine particles could be 
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attracted by magnetic field, and distribution of drug crystals in resin was manipulated, leading 
to different release kinetics.  
The chlorhexidine particles were further incorporated into the electrospun PLA fibers, 
producing antibacterial fiber meshes. With chlorhexidine particles incorporated, the size of 
PLA fibers reduced, as well as the mechanical properties. Due to the high surface area, fibers 
with uncoated chlorhexidine particles showed a burst release in H2O, but when the particles 
were LbL encapsulated, the burst release could be reduced, improving the biocompatibility at 
the same time. It was beneficial to have a moderate chlorhexidine release to ensure safe 
performance. Both PLA fibers with uncoated and encapsulated chlorhexidine particles 
demonstrated good antibacterial activity sustained effect against E. coli.  
For doxycycline delivery, the low molecular weight drug was encapsulated into LbL 
microcapsules by interaction with the DS in the capsule cavity. Since the microcapsules were 
porous and diffusible for small molecule drugs, the doxycycline encapsulated capsules were 
sealed with a lipid layer, facilitating a more sustained release kinetics than the non-lipid coated 
capsules. Doxycycline delivered by microcapsules has the potential to enhance the treatment 
for intracellular infections. So myoblast cells engineered with tetracycline regulated gene 
expression system were used to demonstrate the intracellular doxycycline release. By 
encapsulation, doxycycline was delivered to cells via capsule internalization, which only the 
cells with capsules engulfed expressed EGFP while gene expression in the other cells was 
silenced. The sustained doxycycline release in cells was monitored via EGFP fluorescence. 
Cells with doxycycline loaded synthetic capsules and biodegradable capsules showed longer 
EGFP expression than the free doxycycline, and it was further extended by coating with a 
DPPC on the synthetic capsules. However, lecithin coated biodegradable capsules did not 
prolong the EGFP expression since the intracellular degradation. Doxycycline delivered by 
microcapsules also showed a more sustained antibacterial activity against E. coli. 
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The release of doxycycline from microcapsules was further tuned by an external alternating 
magnetic field when magnetite nanoparticles were assembled in the capsule shells. Upon AMF 
exposure, the magnetic nanoparticle rotated within the shells, leading to permeability 
improvement. As demonstrated with FITC labelled dextran (70 kDa), more capsules were 
permeable with an increase of AMF exposure duration. Doxycycline release was also enhanced 
by AMF in vitro. When the doxycycline loaded magnetic capsules were internalized by cells, 
the intracellular release was also possible to enhanced, up-regulating the EGFP expression. 
Moreover, with magnetic capsules, the doxycycline could be delivered to specific site and 
switched on the EGFP expression locally with a static magnet. It was an exciting observation 
since targeted delivery of antibiotics could greatly improve the efficiency and reduce side effect 
to normally cells or tissues. And a local triggered release by AMF may further enhance its 
activity, which is attractive for infections treatment.  
 
6.2 Future work 
 
This thesis has initiated new formulation of antibacterial agents and demonstrated possibilities 
to burst the release with various triggers such as NIR light, magnetic field, and ultrasound. The 
results are promising for treat of infections in reality, but more experiments are needed to be 
carried out to evaluate their safety and activity against bacteria in vitro and in vivo. Also some 
improvement for the formulations demonstrated in the thesis needed to be achieved.  
1) Crystal structure of chlorhexidine spheres and the formation mechanism. Though the 
crystallization of chlorhexidine particles were controlled by ions, temperature and 
nanoparticles existing in the system, and primarily the chemical interactions between 
chlorhexidine molecules and ions was revealed by FTIR, the mechanism of how this 
interconnected structure formed was not fully understood. With the help of further XRD 
210 
 
analysis, simulation, or other techniques, this spherical crystal structure might be better 
understood. 
2) Chlorhexidine particles encapsulation. The spherical chlorhexidine particles were 
encapsulated with both LbL polyelectrolyte multilayers and PLA shell. However, either of 
these two methods solved the problem of chlorhexidine burst release at the beginning. For LbL 
encapsulation, multilayer architecture could be optimized and biodegradable polymers need be 
used for encapsulation to meet the potential applications in vivo. For the spray-dried 
chlorhexidine particles, same exploring of the usage of polymers for encapsulation is also 
needed to solve the problem of porous morphology of coating, as well as temperature, solvents, 
concentrations. If possible, the spray-drying equipment might be updated that the parameters 
such as temperature, flow of gas would be better controlled to produce higher quality particles. 
3) Safety evaluation and antibacterial assay for chlorhexidine product. The chlorhexidine 
particles were successfully encapsulated with different polymers or embedded into polymer 
matrixes, and when the particles were functionalized, an external responsive release was 
demonstrated. However, no experiments were carried out to assess their biocompatibility or 
their antibacterial activity. As there are already some commercial chlorhexidine products 
available, it is important to address the safety and antibacterial activity, and advantage of 
products we fabricated. For example, there is no studies that even reported magnetic control 
the distribute of drug crystals. This strategy is so attractive to treat the infection and biofilm in 
periodontal pockets. So it is beneficial to evaluate their biocompatibility, optimize the drug 
loading amount, explore the possibility to attract the chlorhexidine particle in vivo, and to see 
their antibacterial activity.  
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4) In vivo antibacterial activity for chlorhexidine fibers. The uncoated and encapsulated 
chlorhexidine particles containing PLA fibers showed good biocompatibility and in vitro 
antibacterial activity. Further in vivo experiments could be carried out. 
5) More controllable doxycycline release from microcapsules.  In chapter 5, doxycycline was 
successfully encapsulated by forming complex with DS, and release was reduced by lipid 
coating, and a AMF triggered release was demonstrated when the microcapsules were magnetic. 
But, as the doxycycline molecules are so small that they are diffusing from the microcapsules 
all the time even without any triggers. It will be beneficial to have the microcapsule completely 
sealed to trap them inside, so that an on-demand release could be achieved. Strategies such as 
depositing a layer of silica on capsule surface are likely to achieve this goal. 
6) Intracellularly antibacterial of doxycycline loaded microcapsules. When the doxycycline 
encapsulated microcapsules were internalized by cells, a sustained intracellular release was 
demonstrated via monitoring the EGFP expression and AMF also could increase the release in 
cells. It was exciting observations that the sustained doxycycline activity might also be 
promising to treat intracellular infections. So in the future, some intracellular infection models 
could be established and the doxycycline loaded microcapsule might be used to kill the bacteria 
inside cells. 
7) Generally, any other drugs or antibacterial agent formulations could be fabricated with the 
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